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Chapter 1 
General introduction 

Introduction 
1.1. Human heart transplantation 
Since the beginning of this century experimental heart transplantations in animal 
studies were performed.' These studies were started in Rotterdam in the seventies 
to compare heterotopic and orthotopic heart transplantations, and to study the 
process of chronic rejection. ~4 
The history of the first human heart transplantation started in South-Africa and it was 
carried out by Barnard in 1967" Several cardiac surgeons around the world initiated 
new transplantation programmes. However, the problems with patient and donor 
organ selection as well as with immunosuppression, severe rejection and infection 
were common. This meant in 1968, only 22% of all transplants survived after the first 
year.6 Consequently, many centres stopped their programmes. 
Heart transplantation, as a routine treatment for organ failure, only became possible 
with the development in 1973 of the endomyocardial biopsy technique for monitoring 
acute rejection? and in 1975 by the further discovery of cyclosporin A. 8 In the early 
eighties cyclosporin A was successfully introduced as an immunosuppressive 
medicine post clinical heart transplantation.' Cyclosporin A acts by binding to 
calmodulin and thereby inhibits the transcription of the IL-2 and IFN-y gene." With 
the development of these new processes, a 50% survival rate after 5 years was 
achieved in 1982." 
The first Dutch patient received a human cardiac allograft in June 1984 in 
Rotterdam. Up to January 1993, 200 patients with end-stage heart disease received 
a cardiac allotransplant with a 92% patient survival rate after 1 year, and 84% 
survival rate after 5 years." 
Because the donor heart is derived from a genetically nonidentical (non-self) donor, 
an immune response directed to the foreign graft will occur. Therefore, life-long 
immunosuppression is necessary to prevent the immune system from rejecting the 
allograft. Of all the foreign antigens that can be recognized by the immune system of 
the organ recipient the 'major histocompatibility complex' is the most important. 
1.2. Organ allograft rejection 
The major problem after organ transplantation is graft rejection. Allograft rejection 
falls into 4 categories and can be identified by the time-frame in which it develops 
after transplantation. 
Hyperacute rejection 
Hyperacute rejection occurs very rapidly within the first 24 hours after transplantation 
and can occur in patients with pre-existing humoral antibodies against donor cells. 
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Patients who already have circulating antibodies against the allograft due to ABO-
incompatibility between recipient and donor, prior blood transfusions, pregnancies or 
previous transplants are at risk for immediate graft loss through hyperacute 
rejection.'3 In the graft, preformed antibodies fix complement which causes 
endothelial cell damage resulting in leakage of cells, fluids and platelet aggregation 
leading to blocking of the microvasculature by thrombosis and ultimately depriving 
the graft of blood. 
This immediate graft loss through hyperacute rejection can be avoided by performing 
cross-match studies before transplantation. Serum from the patient is screened first 
against a panel of cells with different HLA-types to determine the level of panel 
reactive antibodies and then just before transplantation against donor cells for the 
presence of donor-specific cytotoxic anti-HLA antibodies."·15 Only patients without 
anti-donor HLA antibodies will be transplanted. 
In the University Hospital Rotterdam-Dijkzigt hyperacute rejection did not occur in 
any of the 200 heart transplant recipients." 
Accelerated acute rejection 
Accelerated acute rejection or delayed hyperacute rejection takes place within the 
first five days after transplantation. In these patients the cross-match stUdies are 
negative preoperatively. Accelerated allograft rejection, when compared to acute 
rejection, is a more severe rejection form with earlier onset, higher fever, and a more 
prolonged period of rejection." This type of rejection is described as frequently 
reversible by some 16 and completely irreversible by others. 17 It is evident that the 
process of accelerated rejection has not yet been clearly defined. Whether it involves 
separate cellular or humoral factors, or both, remains to be elucidated. 
Three out of the 200 cardiac transplant recipients from the transplant centre in 
Rotterdam suffered from this type of rejection resulting in graft dysfunction." 
Acute rejection 
After the first week of transplantation, most (75%) of the heart transplant patients 
experienced at least one acute rejection episode."'" In kidney transplant recipients 
the diagnosis of rejection can be made on clinical grounds (rising creatinine, oliguria, 
fever, and graft tenderness), and confirmed by core needle biopsy.20 In contrast, 
acute rejection in heart transplant recipients can only be monitored by cardiac 
biopsies taken from the right ventricle via the right jugular vein. Biopsies are 
performed weekly during the first 6 weeks, thereafter twice monthly up to 3 months, 
monthly up to 6 months, every 2 months for the rest of the first year, and continuing 
at intervals of every 4 months thereafter." Grading of rejection is histologically 
determined in endomyocardial biopsies (EM B) according to the criteria of Billingham 
et al. 21 Scoring indices register the infiltration of mononuclear cells and signs of 
myocyte damage or even necrosis. In severe acute rejection edema, haemorrhage 
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and vasculitis are usually present. 
Acute rejection episodes are treated by pulsed high doses of methylprednisolone, or 
by polyclonal rabbit-antithymocyte globulin, and in cases of ongoing or frequently 
recurring rejection episodes by monoclonal antibodies against the T-cell receptor 
(OKT3).19 
Chronic rejection 
The long-term success of organ transplantation is limited by the development of 
chronic rejection. Chronic rejection is primarily an occlusive disease of the donor 
vessels in an allograft, which leads to ischemia and subsequently to organ 
destruction. 
The pathology of chronic cardiac rejection may occur quite early postoperatively, 
often within the first 3 months and in other patients within 3 to 5 years." In human 
cardiac allografts, it is characterized by a process of accelerated coronary artery 
disease, and is also called graft vascular disease (GVD). GVD can be visualized by 
angiography or ultrasound techniques. 
In common (non-transplant) atherosclerosis eccentric narrowing of the vessels 
occurs, in which non symmetric deposits of occlusive plaque develop in the larger 
vessels.23 GVD is characterized by a symmetric occlusion along the entire length of 
vessels." This type of occlusion often continues into smaller vessels within the 
myocardium itself." GVD seldom affects the veins of the transplanted heart; lesions 
are primarily restricted to the large and small coronary arteries and the aorta, which 
is attached to the donor heart." 
The exact pathogenesis of GVD is unclear. However, arterial lesions develop in the 
donor vessels and are absent in the recipient vessels, which suggests that GVD 
results from an immune-mediated process, initiated at and located within the donor 
vasculature. 
In the transplant centre of the University Hospital Rotterdam-Dijkzigt, heart transplant 
recipients are routinely checked for GVD by angiography at one year after 
transplantation. GVD is defined as all or any vascular wall irregularities including 
minimal wall changes. One year after transplantation 26% of the patients 
transplanted in Rotterdam had signs of GVD in their angiograms, increasing to 80% 
10 years after transplantation. Therefore, it can be concluded that GVD is an 
inevitable complication affecting almost all heart transplant recipients. 
No correlation between the occurrence of GVD and a wide range of factors (such as 
gender, age, ischemic heart disease before transplantation, hypertension, serum 
cholesterol and triglycerides, use of calcium antagonists, and cytomegalovirus 
infection or disease) has been determined." Since the vascular lesions only develop 
in donor vessels and remain absent in recipient vessels an allogeneic immune 
process is possibly involved in the pathogenesis of GVD. During the searches carried 
out in the transplant centre of Rotterdam, no immunological parameters (the 
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instances of acute rejection episodes, preoperative reactive antibodies against a 
panel of lymphocytes and number of HLA mismatches) were detected in relation to 
GVD." 
Currently, no treatment for chronic rejection exists and retransplantation is the only 
solution. 
1.3. Major histocompatibility complex and T-cell receptor 
Major histocompatibility complex 
The genetic loci involved in rejection of an allograft form a region known as major 
histocompatibility complex (MHC). One way to overcome rejection of the graft is 
matching for these histocompatibility antigens. The human MHC, known as the 
human leucocyte antigen (HLA) system is a set of genes coding for highly 
polymorphic cell surface structures. It is located on the short arm of chromosome 6.27 
Three sets of MHC genes are identified. The class I and class II genes are involved 
in triggering T-Iymphocytes, while class III genes are related to the components of 
the alternative complement activation pathway, and are located between the HLA 
class I and II genes. The extreme polymorphism of the HLA-system results in a vast 
number of HLA-types. MHC class I genes are expressed in all nucleated cells, 
whereas class II genes are only found on cells which are involved in antigen 
presentation (dendritic cells, macrophages, monocytes, B-cells, activated T-cells and 
endothelial cells). 
MHC class I molecules present foreign and self peptides to CDS' T-cells. The class I 
region encodes HLA-A, HLA-B, HLA-C and five not completely characterized loci 
(HLA-E, -F, -G, -H, -J)." Class I antigens are composed of a highly polymorphic 
heavy chain (a-chain) and a noncovalently associated nonpolymorphic ~2-
microglobulin. Epitopes involved in alloantigen recognition are located on the a-
chain, which is organised in three globular domains (a1, a2, a3). The a1 and a2 
domains are the most polymorphic domains of the class I gene.29 Peptides of S to 10 
amino-acids are bound on the groove formed by these two domains. Several 
polymorphic residues are located in the part of the molecule that constitute this 
groove, resulting in the ability to bind different peptides. 
Class II genes, encoded by HLA-DR, HLA-DO and HLA-DP, are heterodimers 
consisting of a heavy a-chain and a light ~-chain, each encoded by a separate gene 
A and B, respectively. Both chains have two extracellular domains: a1 and a2, ~1 
and ~2. Class II polymorphism is concentrated in the peptide binding groove formed 
by the ~-chains in DR molecules and by the a1 and ~1 domains in DO and DP 
molecules. In contrast to class I molecules, the groove of class II molecules is open 
at both ends, resulting in longer peptide binding (12-25 amino-acids) that extends out 
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of the cleft.30 
T-cell receptor 
T-cells recognize antigens bound to MHC molecules using a specific receptor: the T-
cell antigen receptor (TCR). There are two types of TCR: TCR-a~ and TCR-yD. 
Approximately all T-cells express the TCR-a~ together with the CD4 or CD8 
molecule, while only a few T-cells express the TCR-YD together with the CD8 
molecule. The latter type of T-cells have a non-MHC restricted repertoire,31 while the 
TCR-a~-complex recognizes antigen in association with MHC. Both types of TCR 
are associated with the CD3-complex. 
The TCR-a~ compromises a disulphide-linked heterodimer of an a and ~ chain. The 
diversity of the T-cell repertoire is created by the rearrangement of the gene. Both 
chains have a constant C region. In addition, the a-chain is encoded by V (variable) 
and J Uoining) gene segments, and the ~-chain by V, D (diversity) and J segments." 
Within the V gene there are three areas of relatively greater variability present 
(complementarity-determining region (CDR) 1, CDR2 and CDR3).32 These 
hypervariable regions make contact with the antigen. In this process the CDR1 and 
CDR2 regions interact with the MHC-molecule on the antigen-presenting cell, while 
the CDR3 region bind to the peptide presented in the MHC molecule. 
In addition to the 'first signal' of specific T-cell recognition of an antigen by the TCR, 
other cell surface structures play an important role in the activation process of the T-
cell. These have been termed the 'second signals' (e.g. LFA1-ICAM1, CD2-LFA3, 
CD28-B7). Without these costimulatory signals, T-cells cannot respond to the 
presented antigen. Further to these signals, also cytokines have a major function in 
T-cell activation. 
1.4. Antigen-presentation pathways 
Recipient T-cells can recognise foreign donor MHC antigens by two different 
pathways, either directly as intact molecules or indirectly as peptides after antigen 
processing. 
Direct antigen-presentation pathway 
Recipient T-cells can directly engage and respond to intact allogeneic (donor) MHC 
molecules, either in combination with an allo-peptide or a self-peptide, on the surface 
of donor antigen-presenting cells (APCs). Direct T-cell activation is possible via two 
kinds of APCs: many tissues have their own APCs (e.g. Langerhans' cells in the skin, 
Kupffer cells in the liver), but also endothelial cells of vascularized grafts appear to 
have APC-function, especially if activated. 33 The normal T-cell repertoire contains a 
17 
Chapter 1 
very high precursor frequency of T-cells capable of responding to allogeneic HLA 
molecules. 34 
Indirect antigen-presentation pathway 
T-cells can recognise nominal or recall antigens as processed peptides presented by 
self MHC molecules (MHC restriction). For recognition of allogeneic MHC via the 
indirect presentation pathway, donor MHC molecules are processed and presented 
by recipient MHC molecules on recipient APCs. Indirect presentation depends on the 
APCs in the recipient's draining lymph nodes and spleen. Dendritic cells and 
monocytes have the capability to stimulate indirect responses."·36 Also activated B-
cells and T-cells can have APC function."·38 
Pathways of antigen processing 
The MHC molecules present peptides to T-cells. Therefore, the antigens have to be 
segmented into peptides. Two types of responses can be mounted against 
pathogens that have invaded an organism. 39 Antigens derived from pathogens that 
have access to the cytosolic compartment of cells (e.g. viruses) are usually identified 
by the immune system via HLA class I molecules. Because these antigens are 
synthesized within the APC, it is also called the endogenous pathway. This pathway 
includes cytosolic proteins as well as membrane or secreted proteins. Whereas 
antigens that reside extracellularly (e.g. bacteria) are presented by MHC class II 
molecules. These antigens are internalized by the APC from the extracellular 
medium: the exogenous pathway. 
MHC class I molecules bind peptides of S to 11 amino-acids long within the 
endoplasmic reticulum (ER). The peptides are generated by the proteasome and are 
translocated from the cytosol into the ER by TAP (transporters associated with 
antigen processing) molecules that are located in the ER-membrane. The peptide-
MHC class I-complex travels through the Golgi-complex directly to the cell surface for 
presentation to CDS· T-cells.40 
MHC class II molecules acquire peptides derived from antigens that are internalized 
in the endocytic pathway" MHC class II heterodimers assemble in the ER with the 
invariant chain (Ii). At the trans-Golgi network the complex is targeted to the MHC 
class II compartments (MIIC) in the endocytic pathway. There the invariant chain is 
proteolytically removed and the antigenic peptides can bind to the class II molecules. 
Peptide loaded MHC class II complexes are then transported to the plasma 
membrane for presentation to CD4· T-cells. 
In vitro data showed that also HLA class II molecules on APCs can present peptides 
derived from HLA class 142.43 and class 1144 ,45 alloantigens. 
Alloantigen recognition pathways after human transplantation 
Most studies on the role of the direct and indirect presentation pathway in allograft 
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rejection have been performed in rodents. Only a few groups have investigated the 
presentation routes in human transplant recipients. 
Shearers' group demonstrated in renal transplant recipients with stable graft function, 
that the direct pathway was not different from that of healthy volunteers. Those 
stable transplant patients showed, however, no response to alloantigens presented 
via the indirect pathway. The presence of reactivity via the indirect pathway was 
found to correlate with acute or chronic rejection in non-stable patients."·47 In 
addition, it has been suggested that the indirect pathway is more sensitive to 
immunosuppression than the direct route of alloantigen presentation.47.48 
The group of Suciu-Foca studied the indirect immune response of kidney, heart and 
liver transplant recipients. They suggested that the indirect response to peptides of 
donor HLA antigens occur only to a limited number of HLA peptides and this is 
correlated with acute and chronic rejection.49.54 
1.5. Cytokines after clinical heart transplantation 
CD4+ T-Iymphocytes are the regulatory cells of the immune response. Much of their 
function is mediated through cytokines, whose expression and secretion are induced 
as a result of the engagement of the T-cell with an APC. 
Type of cytokine producing T-helper cells 
Mosmann55 showed that murine CD4+ T-cell clones can be separated based on the 
cytokines they produce in response to antigen. Early in the primary CD4 T-cell 
response a random assortment of cytokines (T-helper (Th) 0 cytokines) are 
produced. After prolonged stimulation, the CD4+ T-cell population can be divided in a 
Th1 or Th2 population. Also CD8+ T-cell population can be divided into Th1 and Th2 
producing cells. 56.57 The Th1-like cells produce interleukin (IL)-2, interferon (IFN)-y 
and tumour necrosis factor (TNF)-~, while the Th2 pattern consists of IL-4, IL-5, IL-6 
and IL-10 production. Th1 cells induce enhanced activity in macrophages, activation 
of cytotoxic T-Iymphocytes (CTLs) and natural killer (NK) cells (cellular immunity), 
whereas Th2 cells make products that act on the B-cell which than differentiate it into 
an antibody-producing cell (humoral immunity). Both Th cell subsets tend to 
counteract and cross-regulate each other's activity. Therefore a popular hypothesis 
states that preferential induction of allograft-specific Th2 cytokines would inhibit Th1-
regulated rejection responses. 
In vivo T-cells are exposed to many different influences as they undergo primary 
activation, clonal expansion, effector cell differentiation, and reactivation by antigen. 
The cytokine expression pattern can be influenced by the outcome of interaction with 
APCs during priming, which can be affected by TCR affinity and avidity, peptide/MHC 
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density, costimulatory signals, the duration and frequency of interaction, the activities 
of bystander cells, cytokines, endocrine hormones, and other soluble mediators. 58 
Therefore, the Th1fTh2 paradigm in man is not so strong, and it is not surprising that 
T-cells isolated from different tissue sites can display a diversity in cytokine profiles. 
Monitoring of cytokines in peripheral blood after clinical heart transplantation 
Jordan et al. 59 showed no correlation of IL-2 and TNF-a levels in serum of peripheral 
blood with the histological grade of allograft rejection. In agreement, Fyfe et al.60 also 
demonstrated no relation with the level of IL-2, IL-4, IL-6 and TNF-a and the 
presence or absence of acute rejection both in serum from peripheral blood and from 
coronary sinus blood. 
Despite these disappointing results, in 1996 another group tested levels of IL-2, IL-4, 
IL-6, IL-10, IFN-y, and TNF-a in serum from peripheral blood from human cardiac 
allograft recipients." These serum cytokine levels sometimes showed peaks that 
appeared to be correlated with acute rejection or occasionally to infection, but these 
relationships were not consistent. In contrast, in the same year, Chang" 
demonstrated again that monitoring cytokine levels of IL-1, IL-2 and TNF-a in serum 
is not useful in predicting cardiac transplant rejection. 
Lagoo et al." showed after rejection treatment a decrease in IL-1D, IL-6, and TNF-a 
expression in resting peripheral blood mononuclear cells (PBMC), and a decrease in 
IL-4 and IL-10 gene expression in phytohaemagglutinin (PHA) and 
lipopolysaccharide (LPS) stimulated PBMC. They suggested that this decline was 
due to changes in the proportion of lymphocytes and monocytes in peripheral blood 
in concert with a steroid-induced down regulation by cytokine gene transcription. 
Only one group reported a clear positive relation between cytokine levels in 
peripheral blood and acute rejection. Kimball et al. 64 suggested that high IL-6 and IL-
a levels, and not IL-1, IL-2 and TNF-a levels, are effective markers of acute rejection 
following human heart transplantation. 
Intragraft monitoring of cytokines after clinical heart transplantation 
Intragraft monitoring of cytokines gives better insight in the rejection process. 
After clinical heart transplantation, Cunningham65 demonstrated in endomyocardial 
biopsies (EMBs) that only the presence of IL-2 mRNA expression related to acute 
rejection, while IL-1~, IL-4, TNF-a, and TNF-~ did not. Baan et al.66 had also clearly 
demonstrated the importance of upregulation of the IL-2 gene in acute graft rejection, 
but also reported that IL-4 and IL-6 could playa role. Contrary to Cunningham et al. 
and Baan et aI., Zhao et al.67•68 found however no relation between IL-2, IL-4, IL-5, IL-
1, TNF-a, and IFN-y gene expression and acute rejection, but noted an increased IL-
6 and TGF-~ gene expression with rejection. 
Both Baan et al.66 and Azzawi et al.69 found no relation with IL-10 and acute rejection. 
However, Grant et al. 70 suggested that IL-10 and possibly IL-4 may suppress graft 
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rejection, whereas IL-2 may promote rejection. 
The cytokine protein can be detected with the use of monoclonal antibodies and 
immunohistochemical techniques. 71 In this way, the presence of IL-2 and IFN-y 
located in lymphocytes of EMBs from cardiac allograft recipients was shown to be 
indicative of acute rejection, whereas IL-6 was rarely detected," 
1.6. Cytotoxic T-Iymphocytes after clinical transplantation 
The cytokines produced by T-helper cells play an important regulatory role in 
determining the activation state of the cytotoxic T-Iymphocytes (CTLs). 
To destroy allogeneic target cells, the target cell is recognized by T-cells using their 
specific TCR and other receptor-ligand interactions (e.g. CDS-HLA class I, CD4-HLA 
class II, CD2-LFA3, LFA1-ICAM1). In cytotoxic reactions the attacking cells direct 
their granules towards the target cell. The granules of the CTLs contain periorins and 
granzymes, which can punch holes in the outer membrane of the target cell. CTLs 
can also signal to the target cell to start a programme of self-destruction resulting in 
fragmentation of the DNA in a process called apoptosis. 
During stable engraftment, Mathew et al. 73 and Van Twuyver et al. 74 demonstrated 
donor-specific CTL non-responsiveness in the peripheral circulation of long term liver 
allograft recipients, while this is not common after kidney transplantation. 74 
Hu et al. 75 showed 4 to 6 months after heart transplantation a decrease in donor-
specific circulating CTLs. Steinmann et al. 76 found the same reduction within the first 
3 months after kidney transplantation. The reduction of CTLs was seen in patients 
with acute rejection episodes as well as in patients without rejection. Vaessen et al. 77 
could not detect a correlation with CTLs in peripheral blood and rejection, while the 
number of committed donor-specific CTLs propagated from EMB-cultures correlated 
well with acute rejection. 
From literature, it is clear that CTLs can destroy allografts," however CTLs can also 
be obtained from stable, well functioning allografts. 79.80 Therefore, the difference in 
quality between CTLs derived from non-rejecting and rejecting grafts may playa 
major role in the rejection process. 
CDS and CD4 molecules on the T-Iymphocyte are accessory molecules that stabilize 
TCR-antigen interaction by binding to the non-polymorphic region of HLA class I and 
class II, respectively.81.82 CTLs that are dependent on CDS or CD4 molecules are 
known as low avidity cells. In the presence of CDS or CD4 monoclonal antibodies 
these CTLs are not able to lyse their target cells, whereas CTLs with high avidity 
remain effective in this area. 
The number of high avidity CTLs directed to donor HLA class I antigens is higher in 
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patients with acute rejection than those who had never experienced rejection,83 this 
number even increases during a rejection period." The importance of HLA class II 
directed Clls has also been demonstrated in relation to human cardiac allograft 
rejection.'5 In addition to high avidity CDS' Clls, CD4' Clls can mediate heart 
allograft rejection when they have high avidity for HlA class II donor antigens." 
References 
1, Carrel A, Guthrie CC. The transplantation of veins and organs. Am Med 1905;10:1101. 
2. Jongsma C. The problem of the heart transplantation mode!. Thesis. Rotterdam (The 
Netherlands), Erasmus University, 1978. 
3. Bos E. Models in orthotopic canine cardiac allotransplantation. Thesis. Rotterdam (The 
Netherlands), Erasmus University, 1979. 
4. Penn OKCM. Chronic rejection after orthotopic cardiac transplantation. Thesis. Rotterdam 
(The Netherlands), Erasmus University, 1979. 
5. Barnard eN. The operation. A human cardiac transplant: an interim report of a successful 
operation performed at Groote Schuur Hospital, Cape Town. S Afr Med J 1967;41 :1271. 
6. Pennock JL, Oyer PE, Reitz, et al. Cardiac transplantation in perspective for the future. 
Survival, complications, rehabilitation, and cost. J Thoracic Surgery 1982;83:168. 
7. Caves PK, Billingham ME, Stinson EB, et al. Serial transvenous biopsy of the transplanted 
human heart. Lancet 1974;1:821. 
8. Borel JF, Feurer C, Gubler HU, Stahelin H. Biological effects of cyclosporin A: new 
antilymphocytic agent. Agents Action 1976;6:468. 
9. Oyer PE, Stinson EB, Jamieson SA, et al. Cyclosporin A in cardiac allografting: a preliminary 
experience. Transplant Proc 1983;15: 1247. 
10. Schreiber SL, Crabtree. The mechanism of action of cyclosporin A and FKS06. Immunol 
Today 1992:13;136. 
11. Jamieson SW, Stinson EB, Shumway NE. Cardiac transplantation. In: Morris PJ, ed. Tissue 
Transplantation. Edingburgh: Churchill Livingstone, 1982:147. 
12. Balk AHMM. Clinical aspects of heart transplantation. Thesis. Rotterdam (The Netherlands), 
Erasmus University, 1993. 
13. Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldborg O. Hyperacute rejection of kidney 
allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 
1966;2:662. 
14. Stiller CR, Sinclair NR, Abrahams S, Ulan RA, Fung M, Wallace AC. Lymphocyte-dependent 
antibody and renal graft rejection. Lancet 1975;1:953. 
15. Ross J, Dickerson T, Perkins HA. Two techniques to make the Iymphocytotoxic cross match 
more sensitive: prolonged incubation and the antiglobuline test. 
16. Anderson CB, Newton WT. Accelerated human renal allograft rejection. Arch Surg 
1975:110;1230. 
17. Lucas ZJ, Coplon N, Kempson R, et al. Early renal transplant failure associated with 
subliminal sensitization. Transplantation 1970: 1 0;522. 
18. Balk AHMM, Simoons ML, Jutte NHPM, Brouwer ML, Meeter K, Mochtar B, Weimar W. 
Sequential OKT3 and cyclosporin after heart transplantation. A randomized study with single 
and cyclic OKT3. Clin Transplant 1991 ;5:301. 
19. Balk AHMM, Meeter K, Simoons ML, et al. Polyclonal versus monoclonal rejection 
prophylaxis after heart transplantation. A randomized study. Transplant Int 1992;5:S476. 
20. Van Gelder T, Zietse R, Mulder AH, et al. A double-blind, placebo-controlled study of 
monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute 
rejection after kidney transplantation. Transplantation 1995;60:248. 
22 
Introduction 
21. Billingham ME, Cary NRB, Hammond ME, et al. A working formulation for the standardization 
of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. J 
Heart Transplant 1990:9;587. 
22. Billingham ME. Pathology and etiology of chronic rejection of the heart. CUn Transplant 
1994;8:289. 
23. Ross R. Atherosclerosis: Current understanding of mechanisms and future strategies in 
therapy. Transplant Proe 1993;25:2041. 
24. H~yry P, Isoniemi H, Yilmaz S, et at Chronic allograft rejection. Immunol Rev 1993;134:33. 
25. Billingham ME. Cardiac transplant atherosclerosis. Transplant Proc 1987;4: 19. 
26. Balk AHMM, Simoons ML, Van der Linden MJMM, et al. Coronary artery disease after heart 
transplantation: timing of coronary arteriography. J Heart Lung Transplant 1993;12:89. 
27. Breuning MH, Van den Berg-Loonen PM, Bernini LF, et al. Localization of HLA on the short 
arm of chromosome 6. Human Genet 1977;37:131. 
28. Corzo 0, Salazar M, Granja CB, Yunis EJ. Advances in HLA genetics. Exp Clin 
Immunogenet 1995;12:156. 
29. Bjorkman PJ, Shaper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. The foreign 
antigen binding site and T cell recognition regions of class I histocompatibity antigens. Nature 
1987;329:512. 
30. Brown JH, Jardetzky TS, Gorga JC, et al. Three-dimensional structure of the human class II 
histocompatibility complex antigen HLA-DR1. Nature 1993;364:33. 
31. Haas W, Pereira P, Tonegawa S. Gamma/delta cells. Annu Rev Immuno] 1993;11:637. 
32. Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature 
1988;334:395. 
33. Page C, Thompson C, Yacoub M, Rose M. Human endothelial stimulation of allogeneic T 
cells via a CTL-A4 independent pathway. Transplant ImmunoI1994;2:342. 
34. Sharrock CEM, Man S, Wanachiwanawin W, Batchelor JR. Analysis of the T cell repertoire in 
man. Transplantation 1987;43:699. 
35. Adams PW, Lee HS, Waldman WJ, Sedmak DO, Orosz CG. Alloantigenicity of human 
endothelial cells. III. Quantitated indirect presentation of endothelial alloantigens to human 
helper T lymphocytes. Transplantation 1994;58:476. 
36. Kalhs P, White JS, Gervassi A, Storb R, Bean MA. In vitro recall of proliferative and cytolytic 
responses to minor histocompatibility antigens by dendritic cell enriched canine peripheral 
blood mononuclear cells. Transplantation 1995;59:112. 
37. Parker DC. T cell-dependent B cell activation. Annu Rev Immunol 1993;11 :331. 
38. Croft M. Activation of naive, memory and effector T cells. Curr Opin Immunol 1994;6:431. 
39. Harding Cv. Pathways of antigen processing. Curr Opin Immunol 1991 ;3:3. 
40. Koopmann JO, Hammerling GJ, Momburg F. Generation, intracellular transport and loading 
of peptides associated with MHC class I molecules. Curr Opin ImmunoI1997;9:80. 
41. Pieters J. MHC class II restricted antigen presentation. Curr Opin ImmunoI1997;9:89. 
42. Chen BP, Madrigal A, Parham P. Cytotoxic T cell recognition of an endogenous class I HLA 
peptide presented by a class II HLA molecule. J Exp Med 1990;172:779. 
43. Essaket S, Fabron J, De Preval C, Thomsen M. Corecognition of HLA-A1 and HLA-DPw3 by 
a human CD4+ alloreactive T lymphocyte clone. J Exp Med 1990;172:387. 
44. De Koster HS, Anderson DC, Termijtelen A. T cells sensitized to synthetic HLA-DR3 peptide 
give evidence of continuous presentation of denaturated HLA-DR3 molecules by HLA-DP. J 
Exp Med 1989;169:1191. 
45. Liu Z, Braunstein NS, Suciu-Foca N. T cell recognition of allopeptides in context to syngeneic 
MHC. J ImmunoI1992;148:35. 
46. Sehuliek RD, Weir MS, Miller MW, Cohen OJ, Serams, Shearer GM. Longitudinal study of in 
vitro CD4+ T helper cell function in recently transplanted renal allograft patients undergoing 
tapering of their immunosuppressive drugs. Transplantation 1993;56:590. 
47. Muluk SC, Clerici M, Via CS, Weir MR, Kimmel PL, Shearer GM. Correlation of in vitro CD4+ 
T helper cell function with clinical graft status in immunosuppressed kidney transplant 
23 
Chapter 1 
recipients. Transplantation 1991 ;52:284. 
48. Clericr M, Shearer GM. Differential sensitivity of human T helper cell pathways by in vitro 
exposure to cyclosporin A. J Immunol 1990; 144:2480. 
49. Liu Z, Colavai AI, Tugulea S, et al. Mapping of dominant HLA-DR determinants recognized 
via the indirect pathway. Transplant Proc 1997;29: 1 014. 
50. Liu Z, Harris PE, Colavai AI, Reed EF, Maffei A, Suciu-Foca N. Indirect recognition of donor 
MHC class II antigens in human transplantation. CUn fmmunollmmunopath 1996;78:228. 
51. Liu Z, Colavai AI, Tugulea S, et al. Indirect recognition of donor HLA-OR peptides in organ 
allograft rejection. J Clin Invest 1996;98:1150. 
52. Molajoni ER, Ginti P, Orlandi A, et al. Mechanisms of liver allograft rejection: the indirect 
recognition pathway. HUman ImmunoI1997;53:57. 
53. Suciu-Foca N, Liu Z, Colovai AI, et al. Indirect T-cell recognition in human allograft rejection. 
Transplant Proc 1997;29:1012. 
54. Suciu Foca N, Liu Z, Colovai AI, et al. Role of indirect allorecognition in chronic rejection of 
human allografts. Transplant Proc 1996:28;404. 
55. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman Rl. Two types of murine 
helper T-cell clone. I. Definition according to profiles of Iymphokine activities and secreted 
proteins. J Immunol 1986; 136:2348. 
56. Sad S, Mosmann TR. Interleukin (lL) 4, in the absence of antigen stimulation, induces an 
anergy-like state in differentiated CD8+ TC1 cells: Loss of IL-2 synthesis and autonomous 
proliferation but retention of cytotoxicity and synthesis of other cytokines. J Exp Med 
1995;182:1505. 
57. Erard F, Wild MT, Garcia-Sanz JA, Le Gros G. Switch of CD8 T cells to non cytolytic CD8-
CD4- cells that make Th2 cytokines and help B cells. Science 1993;260:1802. 
58. Fitzpatrick DR, Kelso A Independent regulation of cytokine genes in T cells. The paradox in 
the paradigm. Transplantation 1998;65: 1. 
59. Jordan SC, Czer L, Toyoda M, et al. Serum cytokine levels in heart allograft recipients: 
correlation with findings on endomyocardia! biopsies. J Heart Kung Transplant 1993;12:333. 
60. Fyfe A, Daly P, Gallican L, Pirc L, Feindel C, Cardella C. Coronary sinus sampling of 
cytokines after heart transplantation: evidence for macrophage activation and interleukin-4 
production within the graft. J Am Coil Cardiol 1993;21 :171. 
61. Grant SC, Lamb WR, Brooks NH, Brenchy PE, Hutchinson IV. Serum cytokines in human 
heart transplant recipients. Is there a relationship to rejection? Transplantation 1996;62:480. 
62. Chang OM, Ding YA, Kuo SY, Chang ML, Wei J. Cytokines and cell surface markers in 
predicting of cardiac allograft rejection. Immunollnvest 1996;25:13. 
63. Lagoo AS, George JF, Naftel DC, et aJ. Semiquantitative measurement of cytokine 
messenger RNA in endomyocardium and peripheral blood mononuclear cells from human 
heart transplant recipients. J Heart Lung Transplant 1996; 15:206. 
64. Kimball PM, Radovancevic S, Isom T, Spickard A, Frazier OH. The paradox of cytokine 
monitoring-predictor of immunologic activity as well as immunologic silence following cardiac 
transplantation. Transplantation 1996;61 :909. 
65. Cunningham DA, Dunn MJ, Yacoub MH, Rose Ml. Local production of cytokines in the 
human cardiac alJograft. A sequential study. Transplantation 1994;57: 1333. 
66. Baan CC, Van Emmerik NEM, Balk AHMM, et al. Cytokine mRNA expression in 
endomyocardial biopsies during acute rejection from human heart transplants. CUn Exp 
ImmunoI1994;97:293. 
67. Zhao XM, Yeoh TK, Hiebert M, Frist WH, Miller GG. The expression of acidic fibroblast 
growth factor (heparin-binding growth factor-1) and cytokine genes in human cardiac 
allografts and T cells. Transplantation 1993;56:1177. 
68. Zhao XM, Frist WH, Yeoh TK, Miller GG. Expression of cytokine genes in human cardiac 
allografts: correlation of IL-6 and transforming growth factor- P (TGF-P) with histological 
rejection. Clin Exp Immuno! 1993;93:448. 
69. Azzawi M, Has!eton PS, Grant SC, Stewart JP, Hutchinson IV. Interleukin-10 in human heart 
24 
Introduction 
transplantation: an in situ hybridization study. The Manchester Cytokine Group. J Heart Lung 
Transplant 1995;14:519. 
70. Grant SC, Guy SP, Lamb WR, Brooks NH, Brenchley PE, Hutchinson IV Expression of 
cytokine messenger RNA after heart transplantation: relationship with rejection and serum 
cytokines. Transplantation 1996;62:910. 
71. Van Hoffen E, Van Wichen 0, Stuij I, et al. In situ expression of cytokines in human heart 
allografts. Am J PathoI1996;149: 1991. 
72. Ruan XM, Qiao JH, Trento A, Czer LSC, Blanche C, Fishbein MG. Cytokine gene expression 
and endothelial cell and lymphocyte activation in hUman cardiac allograft rejection: an 
immunohistochemical study of endomyocardial biopsy samples. J Heart Lung Transplant 
1992;11:1110. 
73. Mathew JM, Marsh JW, Susskind B, Mohanakumar T. Analysis of T cel! responses in liver 
allograft recipients. Evidence for deletion of donor~specific cytotoxic T cells in the peripheral 
circulation. J Glin Invest 1993;91:900. 
74. Van Twuyver E, De Hoop J, Ten Berge RJ, et al. Comparison of T~cell responses in patients 
with a long-term surviving renal allograft versus a long-term surviving liver allograft. It's a 
different world. Transplantation 1996;61: 1392. 
75. Hu H, Robertus M, De Jonge N, et aJ. Reduction of donor-specific cytotoxic T lymphocyte 
precursors in peripheral blood of allografted heart recipients. Transplantation 1994;58:1263. 
76. Steinmann J, Kaden J, May G, Schroder K, Herwartz C, MOlier-Ruchholtz W. Failure of in 
vitro T-cell assays to predict clinical outcome after human kidney transplantation. J Clin Lab 
Anal 1994;8: 157. 
77. Vaessen LMB, Baan CG, Ouwehand AJ, et al. Acute rejection in heart transplant patients is 
associated with the presence of committed donor-specific CTL in the graft but not in the 
blood. elin Exp ImmunoI1992;88:213. 
78. Bradley JA, Mason OW, Morris PJ. Evidence that rat renal allografts are rejected by cytotoxiC 
T cells and not by nonspecific effectors. Transplantation 1985;39:169. 
79. Duquesnoy RJ, Trager JDK, Zeevi A. Propagation and characterization of lymphocytes from 
transplant biopsies. Crit Rev Immunol 1991 ;10:455. 
80. Suitters AJ, Rose ML, Dominquez MJ, Yacoub MH. Selection for donor-specific cytotoxic T 
lymphocytes within the allografted human heart. Transplantation 1990;49: 11 05. 
81. MacDonald HR, Glasebrook AL, 8ron C, Kelso A, Cerottini JG. Clonal heterogeneity in the 
functional requirement for Jyt-2/3 molecules on cytolytic T lymphocytes (CTL): possible 
implications for the affinity of CTL antigen receptors. Immunol Rev 1982;68:89. 
82. Biddison WE, Rao PE, Talle MA, Goldstein G, Shaw S. Possible involvement of the T 4 
molecule in T cell recognition of class If HLA antigens. Evidence for studies of CTL-target cell 
binding. J Exp Med 1982; 159:783. 
83. Ouwehand AJ, Baan GC, Roelen DL, et al. The detection of cytotOXiC T cells with high affinity 
receptors for donor antigens in the transplanted heart as prognostic factor for graft rejection. 
Transplantation 1993;56:1223. 
84. Van Emmerik NEM, Vaessen LMB, AHMM Balk, 80S E, Claas FHJ, Weimar W. Progressive 
accumulation of GTL with high avidity for donor antigens during the development of acute 
cardiac rejection. Transplantation 1996;62:529. 
85. Ouwehand AJ, Vaessen LMB, Baan CC, et aJ. Alloreactlve lymphoid infiltrates in hUman heart 
transplants. Loss of class II-directed cytotoxicity more than 3 months after transplantation. 
Hum Immunol 1991 ;30:50. 
86. Van Emmerik NEM, Loonen EHM, Vaessen LMB, et al. The avidity, not the mere presence, 
of primed cytotoxic T-Iymphocytes for donor human leukocyte antigens determines their 
clinical relevance after transplantation. J Heart Lung Transplant 1997; 16:240. 
25 

Chapter 2 
Aim of the study 

Aim of the study 
The main aim of the studies described in this thesis is the monitoring of T-cell 
reactivity in relation to acute rejection and graft vascular disease (GVO) after heart 
transplantation. These rejection processes are investigated both in peripheral blood 
leukocytes and in graft-infiltrating lymphocytes. 
2.1. Peripheral blood monitoring after clinical transplantation 
In addition to testing of the direct and indirect presentation pathways (chapter 1.4) 
and the inventory of cytokine production (chapter 1.5), various other in vitro 
techniques with peripheral blood have been investigated for a possible role in 
monitoring graft rejection. 
Variable results were obtained with the mixed lymphocyte culture (MLC). Langhoff et 
al. ' suggested a primary role for MLC matching in the outcome of kidney graft 
survival. This was supported by the observation that the MLC correlated well with 
DR-matching. Additionally, evidence was presented for a role of the MLC to detect 
donor-specific hyporesponsiveness. Ghobrial et aI.' showed that in some renal 
allograft recipients, a state of donor-specific hyporesponsiveness develops, and this 
state may be associated with a beUer graft outcome (less acute rejection episodes) 
at one year. The same was demonstrated for liver, lung and kidney transplant 
patients. 3 These hyporeactive patients also experienced a lower incidence of chronic 
rejection'·s In contrast to these observations, no correlation between the MLC and 
graft outcome in patients receiving a renal allograft was found by Cullen et al. 6 and 
Jeffery et al. 7 
Limiting dilution assays have also been used in peripheral blood monitoring to 
correlate the frequency of helper T-Iymphocyte precursors (HTLp) and cytotoxic T-
lymphocyte precursors (CTLp) with clinical relevant parameters. A significantly 
reduced proportion of HTLp in the peripheral blood mononuclear cell population from 
immunosuppressed allograft recipients was demonstrated by Cattell et aI.' However, 
it was still possible to measure the frequency of donor-reactive helper cells in the 
blood cells of renal and cardiac transplant patients. 
The frequency of donor-specific HTLp increased during episodes of acute rejection 
after heart transplantation.' Zanker et al. 1O showed that after kidney transplantation 
functional deletion of circulating donor-reactive T-cells can occur at the level of 
HTLp, but also at the level of CTLp, or both. Reader et al." found an increase of 
CTLp frequencies during acute cardiac allograft rejection, which CQuid not be 
confirmed by others. 12 
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2.2. Monitoring of graft-infiltrating lymphocytes in relation to acute 
rejection and graft vascular disease after clinical heart transplantation 
Although macrophages, B-Iymphocytes, neutrophils, eosinophils and natural killer 
cells have been identified in rejecting grafts,13,,. it is generally accepted that T-
lymphocytes are the primary mediators of graft rejection," T-Iymphocytes that 
infiltrate the allograft, are primed to donor antigens and undergo expansion and 
functional differentiation, Studying their characteristics may be helpful in 
understanding the development of acute rejection and GVD, 
Immunohistochemical studies of lymphoid infiltrates, have shown that CD3' 
lymphocytes are the predominant cell type, Both CD4' and CDS' cells are generally 
present Infiltrating T-cells express IL-2 receptors and HLA-DR antigens,16 
An elegant approach in studying the functional characteristics of the graft-infiltrating 
lymphocytes (GIL) is to isolate these cells from the graft, The in vitro propagation of 
lymphocytes from human transplant biopsies is based upon the concept that the 
allograft is infiltrated by activated T-Iymphocytes that proliferate in the presence of 
exogenous IL-2H Activation of T-cells occurs as a result of recipient allorecognition 
of donor antigens which lead to the expression of IL-2 receptors on the activated T-
cells, Subsequently, IL-2 is required for clonal expansion, 
From all heart recipients transplanted in the University Hospital Rotterdam-Dijkzigt, 
peripheral blood cells and endomyocardial biopsies (EMBs) were collected, while 
spleen cells were extracted from the original heart donor. The EMBs were cultured in 
IL-2 containing medium, When GIL-cultures were obtained, their phenotype was 
determined and a cell mediated Iympholysis assay was performed to measure their 
cytotoxic capacity against donor antigens, After this analysis the remaining cells 
were stored at -140°C, 
Successful cell growth from EMBs was cross-checked with the histologic rejection 
grade and time-lapse after transplantation, Cell growth was observed to be more 
frequent during an acute rejection episode than in rejection-free periods,18,19 In 
addition, in vivo activated, committed donor-specific CTLs were propagated from 
expanded GIL-cultures and their presence was linked to acute rejection, while in 
peripheral blood no committed CTLs were found," Based on these results, the 
importance of investigating GIL-cultures is demonstrated, During further 
investigations, the phenotype of the cultures appeared to correlate with acute 
rejection: more CD4' T-Iymphocytes were cultured from rejection-EMBs than from 
those which remained free from rejection,19 
During the first 3 months after transplantation, an increased number of cultures from 
patients who experienced one or more rejection episodes had cytotoxic reactivity 
recorded against both donor HLA class I and class II antigens versus patients who 
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did not have signs of rejection,18,19 The frequency of committed CTLs increased 
significantly towards rejection and recovered to a base level after rejection treatment. 
In contrast, no significant difference was found in the number of precursor CTLs." 
The avidity of the CTLs for antigen proved to be an important characteristic in 
relation to acute rejection, The cytotoxic capacity of CTLs with low avidity for 
alloantigens can be inhibited with CDS or CD4 monoclonal antibodies, while high 
avidity CTLs are not affected, In patients with rejection, the number of high avidity 
CTLs (CDS and CD4 resistant) was higher than in patients who had never 
experienced rejection,"'" Before rejection episodes, only a small fraction of the 
CTLs had high avidity for donor antigens, while this fraction increased gradually and 
became dominant during rejection, After successful rejection treatment a decrease to 
base levels was observed," 
The characteristics of the GIL-cultures were also investigated in relation to the onset 
of GVD, The incidence of acute rejection, the period between transplantation and the 
first rejection episode as well as the successful cell growth from EMBs were not 
different between patients with and without signs of GVD,24 During the first year after 
transplantation patients with signs of GVD had a higher percentage of CDS' T-cells 
and a lower percentage of CD4' T-cells in their GIL-cultures,25 Although, the 
cytotoxic reactivity of the cultures against donor HLA class I or class II antigens was 
comparable between the patient groups, 
2.3. Objectives of the study 
The theme of this thesis is intragraft (chapter 3 and 4) and peripheral blood (chapter 
5) immunological monitoring in relation to both acute rejection (chapter 3 and 5) and 
GVD (chapter 4 and 5) in an endeavour to understand and to interpret the 
immunological mechanisms and processes during both acute rejection and GVD, In 
addition, to establish a pattern and identify key characteristics in acute rejection and 
the development of GVD, 
The results described in chapter 2,2 suggest that allograft-infiltrating lymphocytes 
playa key role in acute rejection as well as in the development of GVD, Therefore 
both rejection processes were studied in graft-infiltrating lymphocytes (chapter 3 and 
4), 
Chapter 3 describes some characteristics of lymphocytes that infiltrate the rejecting 
cardiac allograft, The cell growth and phenotype of the GIL-cultures propagated from 
EMBs taken during an acute rejection episode and during a rejection-free period are 
investigated (chapter 3,1), which extends previous observations by Ouwehand et 
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al. 18,19 Thereafter, the local production of cytokines by T-helper 1 and T-helper 2 cells 
within the lymphocyte cultures derived from rejection EMBs and non-rejection EMBs 
is described (chapter 3.4), Special attention is given to the concordance (chapter 3.2) 
and kinetics (chapter 3.3) of cytokine gene expression and protein production. 
Chapter 4.1 demonstrates patterns of cell growth and phenotypic characteristics of 
GIL-cultures derived from patients with and without GVD in different periods after 
heart transplantation, which extends previous studies of Groeneveld et al. 24 and Jutte 
etal." 
Chapter 4.2 studies whether there is a relationship between levels of T-helper 1 and 
T-helper 2 cytokines produced by the infiltrating lymphocytes and the process of the 
onset of GVD. In chapter 4.3 the cytotoxic capacity of the GIL-cultures to donor HLA 
class I and class II antigens and their relation to GVD is also described. The second 
part of this chapter discusses the relevance of CDS' and CD4' CTLs during the 
development of GVD using the frequency and avidity of committed CTL for donor 
HLA class I and class II antigens. 
Because the EMB-procedure is an invasive method and propagating GIL-cultures is 
time consurning, also relations with peripheral blood monitoring and acute rejection 
and the development of GVD are investigated (chapter 5), 
Only two groups (chapter 1.4) have studied alloantigen recognition pathways after 
human transplantation, The importance of the direct and indirect pathway remains 
unclear. Accordingly, chapter 5.1 reports the response of peripheral blood cells to 
antigens presented via the direct and the indirect pathway, Both presentation 
pathways are not only related to acute rejection and GVD, but also periods of 
immunological quiescence are investigated. 
An increased frequency of circulating HTL' and CTL" was related to acute rejection 
after heart transplantation, Their role in the development of GVD is unknown, 
Therefore in chapter 5.2 donor-specific HTL and CTL frequencies are measured in 
peripheral blood and related to GVD. 
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Abstract 
Acute rejection (AR) is mediated, at least in part, by cellular processes. Therefore, 
we cultured graft-infiltrating lymphocytes (GIL) from endomyocardial biopsies (EMB) 
taken during the first year after transplantation, determined their phenotypic 
composition, and correlated it to AR. We observed more often GIL growth from EMB 
with AR than from non-rejection EMB (P=O.02). CD4' cells were always more 
numerous than CD8' cells, and no difference in phenotypic composition was found 
between AR and non-rejection EMB. 
In conclusion, AR is correlated with cell growth of EMB and not with the phenotypic 
composition. 
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Introduction 
In several studies, we and others have shown that alloactivated graft-infiltrating 
lymphocytes (GIL) can be expanded in vitro from endomyocardial biopsies (EMS) in 
IL-2-containing medium.'·' This culture system is thought to promote growth from in 
vivo activated GIL only.' We also have suggested that the outgrowth of GIL from 
EMS and their phenotypic composition corresponded with histological findings of 
acute rejection (AR).' In the present study, we applied the same method of culturing 
GIL, and studied per patient the proportion of EMS from which GIL could be obtained 
and determined their phenotype in the first 3 months after heart transplantation 
(HTx), in an attempt to show whether our previous findings in groups of patients 
could be applied to individual cardiac transplant recipients. We compared these 
parameters for episodes with and without AR. 
Patients and methods 
We studied 60 cardiac allograft recipients, who were transplanted between March 1991 and 
September 1993. EMS were taken at regular intervals after HTx and examined histologically. 
According to the criteria of the International Society of Heart and Lung Transplantation,3 AR was 
defined as cel! infiltrate with myocyte necrosis and anti-rejection therapy was prescribed. 
Culture method and phenotypic analysis 
We received EMB from 49 out of 60 patients taken in the first 3 postoperative months to obtain GIL. 
GIL were cultured from EMS in IL-2 containing medium as described before. 1 GIL were analyzed by 
two-.colour flow cytometry on a FACScan for the expression of cell surface markers. Initial screening 
was performed with the combinations WT31 FITC-CD3 PE, CD4 FITC-CDB PE, and CD16 FITC-CD56 
PE. When CD3+WT31- cells were found, the GIL cultures were stained for T-cells bearing T-cell 
receptor (TCR)-y5. WT31 (TCR-al1) and TCR-y5 were obtained from Becton Dickinson (San Jose, 
CA, USA) and the other monoclonal antibodies from lmmunotech (Marseilie, France). 
Statistics 
We determined from all individual patients the fraction of EMB in the first 3 postoperative months 
showing signs of AR, the GIL growth from EMB, and their phenotypic composition. The Mann-Whitney 
U test was used to evaluate the differences between the patient groups. 
Results 
Most acute rejections occur in the first 3 months after HTx' Therefore, we analyzed 
the relationship between AR and outgrowth of GIL from EMS and the percentage of 
phenotypic composition in this period. 
More outgrowth of GIL from EMS was seen when AR was diagnosed (Table 1). 
The same quantities of TCR-aB, TCR-y5, CD16, CD3, CD4 and CD8 were found in 
the GIL derived from rejection and non-rejection EMS (Table 1). Significantly more 
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CD4' than CDS' T-Iymphocytes were obtained from EMS with and without AR 
(P=0.001). 
Table 1 Graft~infiltrating lymphocyte (GIL) outgrowth from endomyocardiaJ biopsies (EMS) and 
their phenotypic composition of non~rejection and rejection EMB taken from 49 
patients in the first 3 months after heart transplantation (HTx). 
non-rejection rejection P-value 
(mean %)9 (mean %)B 
eel! growth 42 61 0.02 
TCR-a~ 90 94 0.14 
TCR-y~ 2 0.74 
CD3 92 94 0.37 
CD16 B 4 0.14 
CD4 57' 59' 0.57 
CDB 32' 35' 0.64 
BMean value of all individual patients 
b,cMean percentage CD4 versus CDa in cultures derived from non-rejection (P<O.001)a and rejection 
(P=O.001)' EMB. 
Discussion 
The positive correlation between cell growth from EMS and AR is in agreement with 
our previous study which described the results per EMS taken from cardiac allograft 
recipients,' and can be explained by the higher frequencies of cells infiltrating the 
rejecting allograft compared to non-rejecting grafts. In the previous stUdy' and this 
report, we found CD4 to be the predominant phenotype in most cultures. In contrast, 
in individual patients we could not confirm that cultures derived from EMS with signs 
of AR were associated with a higher proportion of CD4-dominated cultures.' 
However, we analyzed the phenotypic composition per patient in a fixed period after 
transplantation (0-3 months) and not individual GIL cultures. Another difference 
between the earlier report and the present results is that we investigated rejection 
and non-rejection EMS per individual patient and not EMS derived from groups of 
patients with and without rejection episodes. 
From the described study, we conclude that AR is positively related to GIL growth 
from EMS, and there is no relation to the phenotypic composition of the GIL and AR. 
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Introduction 
Cytokines playa central role in the induction of alloreactive effector cells. Several 
groups have studied the production of cytokines, their receptors, and the 
corresponding mRNA in peripheral blood or directly in the transplanted organ 
(reviewed by Dallman).' Analysis of mRNA gene expression and the production of 
cytokines from in vitro-propagated graft-infiltrating lymphocytes (GIL) may give 
information how cytokine secretion within the transplanted heart is regulated. 
Materials and methods 
GIL cultures propagated from human endomyocardial biopsies were established in medium containing 
interleukin~2 {lL-2).2 Before testing, the cells were washed and 5x104 cells/well were incubated in IL-2-
free medium during 24 hours. Thereafter, 5x104 irradiated (60 Gy) and washed Epstein-Barr virus 
(EBVHransformed B-cells (B-LCL) of donor origin or a third-party were added. 
After 4 hours of cOGulturing, eel! pellets were snap-frozen for mRNA analysis by reverse transcriptase 
peR. 3 Sequence-specific primers were used for amplification of the human cytokine genes (Table 1). 
r1-Actin served as positive control for successful RNA extraction. 
In parallel, 8-LCL were cocultured for 20 hours and the concentration of IL-2, IFN-y, and IL-4 in the 
supernatants were determined by ELISA (IL-2: detection range 15 to 1000 pg/ml, IFN-y: range 80 to 
5000 pg/ml and IL-4: range 10 to 450 pg/ml). 
Table 1 Oligonucleotides used to amplify target cDNA. Product sizes predicted, and the 
sequences of the internal oligonuleotides used for Southern blot analysis of the 
products. 
Target 
IL-2 sense 
IL-2 anti-sense 
IL-2 probe 
IFN-y sense 
IFN-y anti-sense 
IFN-y probe 
IL-4 sense 
IL-4 anti-sense 
IL-4 probe 
p-actin sense 
~-actin anti-sense 
p-actin probe 
Sequence 
5' ATG TAC AGG ATG CAA CTC CTG TCT T 3' 
5' GTC AGT GTT GAG ATG ATG CTT TGA C 3' 
5' TTC TTC TAG ACA CTG AAG ATG TTT CAG TTC 3' 
5' TCT GCA TCG TTT TGG GTT CT 3' 
5' CAG CTT TTC GAA GTC ATC TC 3' 
5' TCT GGT CAT CTT TAA AGT TTT TAA AM GTT 3' 
5' ATG GGT CTC ACC TCC CAA CTG 3' 
5' TCA GCT CGA ACA CTT TGA ATA TTT CTC TCT CAT 3' 
5' GTC CTT CTC ATG GTG GCT GTA GAA CTG CCG 3' 
5' ATC TGG CAC CAC ACC TTC TAC AAT GAG CTG CG 3' 
5' CGT CAT ACT CCT GCT TGC TGA TCC ACA TCT GC 3' 
5' GGC TGG GGT GTT GAA GGT CTC AM CAT GAT 3' 
Product 
size (bp) 
458 
301 
462 
838 
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Results and discussion 
Unstimulated GIL cultures and stimulator 8-LCL alone neither expressed IL-2 or IL-4 
mRNA nor produced these cytokines. In contrast, IFN-y mRNA was present in these 
controls, although no protein was detected. 
Table 2 summarizes the results obtained from stimulated GIL cultures. When IL-2 
and IL-4 mRNA were expressed in cells after 4 hours of stimulation, we always found 
the corresponding cytokine protein in supernatants after 20 hours of stimulation. In 
case of IFN-y, the mRNA was always present; however, subsequent protein 
production was only found after donor stimulation. Quantitative PCR may 
demonstrate that the IFN-y mRNA expression after donor stimulation is higher than 
after third-party stimulation or unstimulated control cells alone. A clear donor-specific 
reaction was only seen for IL-2 mRNA expression and the protein production of IL-2 
and IFN-y. In a larger group of GIL cultures, we described the donor specificity of 
cytokine production and the predominance of Th1 cytokines after donor stimulation.' 
In conclusion, the present study showed a clear concordance between mRNA 
transcription of IL-2 and IL-4 after 4 hours of stimulation and protein production 20 
hours after stimulation. 
Table 2 
mRNA@ 
expression 
protein@ 
production 
mRNA expression and production of cytokines by seven graft-infiltrating lymphocyte 
(GIL) cultures, obtained from endomyocardial biopsies of six cardiac transplant 
recipients, after stimulation with donor 8-cell lines (B-LCL) or with third-party 8-LCL. 
IL-2 IFN-y IL-4 
donor 31d party donor 3rd party donor 31d party 
7/7 3/7' 7/7 7/7 2/7# 1/7 
7/7 3/7' 7/7 3/7' 2/7' 1/7 
@The GIL cultures were scored for the presence of mRNA expression Of protein production. 
·P=O.08: donor response compared with third-party response (chi-square test with Yates correction). 
#P=O.03; Th1 (IL-2 and IFN-y) response compared with Th2 (IL-4) response for both mRNA expression 
and protein production (chi-square test with Yates correction). 
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Abstract 
During cardiac rejection we studied the kinetics of IL-2 and IL-4 mRNA and 
subsequent protein production by in vivo primed graft-infiltrating lymphocytes (GIL), 
using semi-quantitative RT-PCR and ELISA. Following in vitro stimulation with either 
donor or third-party antigens, mRNA expression of IL-2 and IL-4 were already 
detectable 1-2 h after stimulation, while their protein production could be measured 
from 4 h onwards at least until 48 h. At both the mRNA and protein level, we 
measured a donor-specific signal for IL-2 and for IL-4 production (P=0.02), while the 
relative donor-specific IL-2 mRNA level was significantly higher than the relative IL-4 
mRNA level (P=0.002). These observations suggest that after in vitro challenge with 
donor antigens, GIL obtained from rejecting cardiac allografts predominantly produce 
IL-2 mRNA and protein. 
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Introduction 
After clinical heart transplantation, acute rejection usually occurs within the first three 
months and is characterized by high levels of inflammation in the graft. ' ·' The 
immune mechanisms responsible for cellular allograft rejection are dependent on the 
activities of primed allospecific T-Iymphocytes. Interaction of these 
immunocompetent CD4' T helper cells (Th) and CDS' cytotoxic T-Iymphocytes (Tc) 
with donor antigens results in activation of the transcription of cytokine messenger 
RNAs (mRNA) followed by the subsequent cytokine protein release. These soluble 
mediators regulate the immune response against the transplanted graft. 
Human T-cells, although not so tightly restricted as described for mouse T-cells, can 
be divided into functionally different subsets on basis of their cytokine production 
pattern. ThO cells produce cytokines such as IL-2 and IL-4, while Th1fTc1 cells 
secrete IL-2, IFN-y, TNF-11 and Th2fTc2 cells produce IL-4, IL-5, IL-6, IL-10.'·5 
Allograft rejection is associated with an upregulation of several cytokines within the 
graft implying that ThO cells or a mixture of both Th1fTc1 and Th2fTc2 cells have 
infiltrated the allograft.',7 The production of cytokines within the graft can be analysed 
directly in biopsies on the transcriptional level and on the protein level using 
techniques such as RT-PCR and immunohistochemistry. 
It was shown that, in man, cardiac allograft rejection is associated with intragraft 
production of IL-2 and IFN-y at both the transcriptional and protein leveL"1O In 
contrast, for the Th2 cytokines ILA and IL-10 the data are less clear. Also at the 
transcriptional level, we and others found that both during acute cardiac allograft 
rejection and during immunological quiescence ILA and IL-10 mRNA expression can 
be found within the graft.'" This suggests that while these cytokines may be present 
during allograft rejection, they actually may be involved in the down-regulation of the 
allogeneic immune response. Indeed, a role for IL-4 in the process of spontaneously 
resolving rejection and even in tolerance has already been reported after clinical liver 
and renal transplantation."·12 
Although it is thus clear that both IL-2 and IL-4 are important determinants of 
outcome of the immune process in human transplants, the kinetics of Th1 and Th2 
cytokine production by graft-infiltrating lymphocytes (GIL) at the mRNA and at the 
protein level in the graft are unknown. The capacity of in vivo primed GIL to produce 
cytokines can be determined after in vitro challenge with donor antigens.13 In order to 
study the regulation of cytokine production by GIL, it is essential to measure cytokine 
mRNA expression, since cytokine production is predominantly controlled at the 
transcriptional leveL '4 An important advantage of our in vitro system is that mRNA 
expression by in vivo primed GIL can be compared directly with the cytokine protein 
production. Therefore, we have analysed the kinetic pattern of IL-2 and IL-4 mRNA 
synthesis by in vivo primed GIL, grown from rejection biopsies, after in vitro 
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stimulation with donor and third-party antigens using semi-quantitative RT-PCR 
analysis. These findings are compared directly with levels of these cytokines 
measured in cell culture supernatants by ELISA. 
Materials and methods 
Patients 
Endomyocardial biopsies were obtained from three heart transplant recipients during their first acute 
clinical rejection episode (14~84 days post-transplant). Maintenance immunosuppressive therapy 
consisted of cyclosporin A and low-dose steroids. No additional therapy was given. Rejection was 
histologically diagnosed according to the criteria of the International Society for Heart and Lung 
Transplantation. 3 For the diagnosis of clinical significant rejection, the coexistence of myocyte 
damage and mononuclear infiltrates was required (grade 3A). In that case, anti-rejection therapy was 
instituted. 
GIL cullure method 
GIL cultures were grown from endomyocardial biopsies in 96~wells U~bottom tissue~culture plates 
(Costar, Cambridge, MA, USA) as described before. 15 GIL were expanded in culture medium (RPMr~ 
1640 Dutch Modification Gibco, Paisley, UK) supplemented with 10% pooled human heat~inactivated 
serum, 4 mM L~glutamine, 100 IU penicillin and 100 I-Ig/ml streptomycin) in the presence of 30 Ulml 
exogenous rL~2 (rectin~free Iymphocult T~LF, Biotest AG, Dreieich, Germany) and 105 irradiated (30 
Gy autologous peripheral blood mononuclear cells. GIL cultures were grown at 37 "C in a humidified 
CO2 incubator for two to three weeks. Half of the medium was refreshed every two to three days. 
Phenotypic analysis of GIL cultures 
Surface antigens were analysed by two~color flow cytometry after staining with monoclonal antibodies 
directed against CD3 (anti~leu 4) as pan mature T~cell marker, WT31 as a marker for the a/f1~chain 
and 11F2 as a marker for v/o~chain of the T~cell receptor. CD4 (anti~leu 3) and COB (anti~!eu 2) were 
used as T-cell subset markers. CD16 (anti~leu 11) was used as a marker for natural killer cells. The 
antibodies were directly conjugated to fluorescein or phycoerythrin (Becton and Dickinson, Maintain 
View, CA, USA). GIL cultures were analysed using a flow cytometer (FACscan, Becton and 
Dickinson). 
Allogeneic stimulator cells 
B Iymphoblastoid cel! lines (B~LCL) originated from the infection of donor and third~party spleen cells 
with EBV obtained from the marmoset cell line B95~8.16 
Study design 
Before testing, GIL were washed and 5x104 cells/well were incubated in tL-2 free culture medium for 
24 h. Thereafter, 5x104 irradiated (60 Gy) and washed B-LCL of donor or third-party control origin 
were added. Third-party control B-LCL shared human leucocyte antigens neither with the donor nor 
with the recipient. At each time-point, the GIL were stimulated in duplo. After stimulation, these cell 
pellets and supernatants were pooled. Supernatants (180 1-11) and cell pellets (105 GIL + 105 irradiated 
stimulator cells) were harvested between 1 and 72 h of co~culture and stored at ~80°C before 
analysis of cytokine production. Washed unstimulated GIL and irradiated stimulator B-LCL alone 
served as control. 
Total RNA preparation 
Total RNA was isolated from the stimulated GIL and their controls by a modification of the 
Chomczynski and Sacchi method as described before. 9.17.18 Briefly, cells were homogenized in 500 1-11 
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4 M guanidinium-isothiocyanate in the presence of 20 1-19 poly A (Boehringer Mannheim, Germany). 
The solution was extracted once with phenol, phenof-chloroform-isoamylalcohol (25:24: 1) and 
chloroform-isoamyJalcohol (24:1), respectively. Total RNA was precipitated with 600 111 2-propanol 
and 35 IJI 3 M sodium acetate (pH 5.2) at -20"C for 18 hours. Precipitates were peneted at 10.000xg 
at 4°C and washed once with 500 1-11 ice-cold 80% ethanol. Air-dried pellets were resuspended in 50 
1-11 diethyJpyrocarbonate-treated H20. Total RNA was denaturated for 5 min at ao°c and then chilled 
on ice. 
cDNA synthesis 
First strand eDNA synthesis was performed from 25 1-11 of the isolated RNA with 0.25 1-19 
hexanucleotides (Promega Corporation, Madison, WI, USA) and transcribed with 500 U Moloney 
murine leukemia virus (MMLV) reverse transcriptase (Gibco-SRL, Gaithersburg, MD, USA) at 42°C 
for 90 min in a total volume of 50 j.J1. The reaction mixture contained 10 j.J1 5x MMLV-RT buffer (250 
mM Tris-HCI pH B.3, 15 mM MgCI" 375 mM KCI), 2.5 ~I dNTP (10 mM), 200 U of RNAsin (Promega) 
and 5 ~I (0.1 M) DTT. 
PCR amplification and Southern blot analysis 
Sequence-specific primers were used for amplification of the human cytokine genes (Table 1). PCR 
primers detecting transcripts for the human house keeping gene keratin, which is expressed by 
haematopoietic cells,19 were used as an internal control to monitor mRNA extraction and cDNA 
amplification (Table 1). For qualitative analysis, 5 j.J1 cDNA sample was added to 95 j.J1 PCR mixture 
containing 10 mM Tris-HCI pH B.3, 50 mM KCI, 1.5 mM MgCI" 0.2 mM of each dATP, dCTP, dTTP, 
dGTP, 2 U Taq DNA polymerase (Promega) and 50 pmol of 5' and 3' sequence-specific primers. 
Each reaction mixture was overlaid with 50 j.J1 mineral oil (Sigma, st. Louis, MO, USA) prior to PCR 
reaction in a DNA thermal cycler (Biomed-60, Germany) under the following conditions. After a 5 min 
94"C denaturation step, samples were subjected to 40 cycles of denaturation at 94°C for 1 min, 
annealing at 60°C for 2 min, and extension at 72°C for 3 min. The last cycle was extended with 7 min 
at 72°C. Positive control samples were produced by stimulating 106 human spleen cells with 1% 
phytohemagglutinin (PHA)-M (Difco, Detroit, MI, USA) for 4 h at 37"'C. Messenger RNA from this 
positive control was extracted as described above. Negative controls consisted of omission of 
reverse transcriptase from the cDNA synthesis reaction for each EMS followed by amplification in 
PCR with the IL-2, IL-4 and keratin primers, and the use of and diethylpyrocarbonate-treated H20 as 
no-template reaction. After amplification, 16 j.J1 PCR product was electrophoresed through 2% 
agarose gel, transferred to a Hybond-N+ membrane (Amersham, Aylesbury, UK) by electroblotting 
and hybridized with y32P-labelied specific probes. Hybridization was detected by autoradiography. 
Semi-quantitative RT-PCR 
For semi-quantitative analYSis, cDNA samples were titrated (10-fold dilutions) and aliquots of ~ach 
dilution were amplified using the conditions as described above. The amount of target cDNA present 
was expressed as end-point of the titration. Corrections were made for the integrity of the mRNA 
isolated and the efficiency of cDNA synthesis, which both may vary from isolation to isolation by 
standardization witr :-·"ratin. It was expressed as arbitrary mRNA equivalents, defined as the highest 
dilution showing positive signal. To estimate the relative initial amount of functional mRNA in the GIL 
cultures, aliquots of titrated cDNA samples were amplified using specific primers for keratin to correct 
for the above mentioned variables. The results were expressed as a ratio calculated from the titre of 
IL~2 or IL-4 gene PCR product over the titre of amplified keratin product. To exclude inter- and intra-
assay variability, amplification of titrated cDNA of PHA-M activated spleen cells were included in each 
assay. These control celis expressed keratin, IL-2 and IL-4. 
Enzyme linked immunosorbent assay (ELISA) 
The concentration of cytokines in the supernatants of the GIL cultures was measured with the 
following ELISA kits: IL-2 (Immunotech, Marseille, France) detection range 15-1000 pg/ml IL-2; IL-4 
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(Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The 
Netherlands) detection range 10-450 pg/mIIL-4. 
Statistics 
As data regarding relative levels of mRNA expression and secreted IL~2 and IL~4 in supernatants 
were nonparametric, pairwise comparisons between groups were carried out using the Wilcoxon 
signed rank test. All P-values ~O.05 were considered to be statistically significant. 
Table 1 Oligonucleotides used to amplify target eDNA. Product sizes predicted, and the 
sequences of the internal oligonuleotides used for Southern blot analysis of the 
products. 
Target 
IL-2 sense 
lL-2 anti-sense 
IL-2 probe 
IL-4 sense 
IL-4 anti-sense 
IL-4 probe 
Keratin sense 
Keratin anti-sense 
Keratin probe 
Results 
Sequence 
5' ATG TAC AGG ATG CAA CTC CTG TCT T 3' 
5' GTC AGT GIT GAG ATG ATG CIT TGA C 3' 
5' ITC ITC TAG ACA CTG AAG ATG TIT CAG HC 3' 
5' ATG GGT CTC ACC TCC CAA CTG 3' 
5' TCA GCT CGA ACA CIT TGA ATA ITT CTC TCT CAT 3' 
5' GTC CIT CTC ATG GTG GCT GTA GAA CTG CCG 3' 
5' TGA AGA TCC GTG ACT GGT AC 3' 
5' ATG TCG GCT TCC ACA CTC AT 3' 
5' TCT CCT TCT GCA GAT TGA CAA TGC CCG TCT 3' 
Phenotypic analysis of GIL cultures 
Product 
size (bp) 
458 
462 
218 
Phenotypic characterization of the three GIL cultures showed that the majority of the 
cells 01 the GIL cultures were CD3' (95%,100%,100%) and expressed the al1 T-cell 
receptor. In these cultures 29%, 52%, 61% of the cells expressed CD4 and 39%, 
40%,70% COB. In culture I CD16 (5%) positive cells were present. 
mRNA expression of the housekeeping gene keratin 
This transcript was chosen as a marker for the total number of cells and for the total 
quantity of mRNA extracted. Keratin mRNA expression is found to be in the range of 
mRNA expression of the cytokines tested, which is an advantage above the 
frequently used house keeping genes l1-actin and glyceraldehyde 3-phosphate 
dehydrogenase."·20 Especially in muscle tissue glyceraldehyde 3-phosphate 
dehydrogenase levels are abundant and therefore not suitable lor analysis in heart 
samples." 
All samples obtained from one culture were isolated at the same time. After 
activation with either donor or third-party antigens, the keratin mRNA levels gradually 
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increased (Figure 1). Semi-quantitative analysis showed a maximum increase of the 
keratin mRNA levels of one-dilution step primary between 1 hand 72 h after 
stimulation. However, there was no statistically significant difference in the amount of 
mRNA for keratin after donor or third-party stimulation (P=0.50). 
Figure 1 
£l 
"1 c " ~ •." " cr • , « z 
'" E 
c 
~ 
e 
• ~
~ 
~ 
0,1 
0 2 4 8 12 20 48 72 
II1II Donor ~ Third party 
Time-course (in hours) of keratin mRNA expression in GIL cultures (n=3) after 
stimulation with either donor or third-party antigens. To estimate the relative initial 
amount of target eDNA, aJiquots of 10-fold diluted eDNA samples were amplified 
using specific primers for keratin. After amplification the amount of target eDNA was 
determined by the highest dilution showing a positive signal after hybridization. Each 
bar represents the relative mean value (± SD) for three GIL cultures. 
Relative IL-2 and IL-4 mRNA levels by GIL cultures 
In the present study, IL-2 and IL-4 mRNA expression was analysed only in GIL 
cultures and irradiated stimulator 8-LCL with keratin mRNA expression. 
Figure 2 depicts the time-course of keratin, IL-2 and IL-4 mRNA expression in culture 
III after stimulation with donor and third-party cells. 
Table 2 shows the kinetics of IL-2 and IL-4 mRNA expression of each individual GIL 
culture after stimulation with donor and third-party antigens, respectively. 
Unstimulated GIL cultures (0 h), and irradiated stimulator 8-LCL alone neither 
expressed mRNA nor secreted protein of IL-2 and IL-4 at detectable levels (Tables 2 
and 3), 
On stimulation by cells of donor or third-party origin an upregulation of cytokine 
mRNA production was observed. In general, IL-2 and IL-4 mRNA was apparent as 
early as 1 h after stimulation and reached maximal levels within 2-48 h after which it 
gradually decreased to prechallange base-line levels (20-72 h). This pattern was 
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seen after stimulation with both donor and third-party antigens. However, the relative. 
amount of IL-2 and IL-4 mRNA produced by GIL was higher after donor-specific 
stimulation than after stimulation with third-party cells (P=0.02). Moreover, the 
relative amount of donor-specific IL-2 or IL-4 mRNA by these GIL cultures was 
clearly different. GIL cultures grown from endomyocardial biopsies taken during 
acute rejection synthesized significantly more donor-specific IL-2 mRNA than IL-4 
mRNA (P=0.002). In two out of three cultures, we measured a 1 DO-fold IL-2/ILA 
mRNA ratio. 
IL-2 and IL-4 protein levels by GIL cultures 
After donor-specific stimulation, the upregulated IL-2 mRNA expression resulted in 
measurable IL-2 protein levels from 4-8 h and accumulating at least 20 and 48 h 
(Table 3). In contrast, after challenge by third-party antigens the significant levels of 
IL-2 mRNA did not, or only at very low levels, result in subsequent IL-2 protein 
release by GIL (P<0.001, Table 3). After antigen-specific stimulation the maximum 
IL-2 protein production ranged between 28-849 pg/ml versus 0-55 pg/ml after third-
party stimulation. 
IL-4 protein levels were only measured in GIL culture I. In the supernatant of this 
culture, we found comparable ILA protein levels within 20-48 h after stimulation with 
donor or third-party antigens (Table 3). 
Table 2 Ratio of IL-2 or lL-4/keratin mRNA expression in GIL cultures after stimulation with 
donor 8-LCL and third-party control B-LCL. 
donor stimulation 
I' 
time (h) IL-2 IL-4 
0 -, 
1 1" 0.1 
2 1 1 
4 
8 
12 0.1 
20 100 0.1 
48 100 
72 0.1 
2GIL culture number 
bnot detectable 
II 
IL-2 IL-4 
10 
10 10 
1 1 
10 
10 
10 
III 
IL-2 
10 
10 
1000 
10 
1 
0.1 
1 
third party stimulation 
II III 
IL-4 IL-2 IL-4 IL-2 IL-4 IL-2 IL-4 
10 0.1 1 
10 1 0.1 
10 1 0.1 1 0.1 
10 0.1 0.1 1 
10 0.1 0.1 
0.1 0.1 10 0.1 0.1 
1 1 
0.1 
"IL-2 and IL-4 are expressed as a ratio calculated from the titre of IL-2 Dr IL-4 mRNA product over the 
titre of amplified keratin mRNA product 
The amount of IL-2 mRNA and IL-4 mRNA were significantly higher after donor stimulation than after 
third-party stimulation (P=O.007 and P=O.02, respectively, Wilcoxon signed rank test). Donor-specific 
IL-2 mRNA titres were significantly higher than specific IL-4 mRNA titres (p<O.001). 
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Table 3 IL-2 and IL-4 protein production by GIL cultures after stimulation with donor 8-LCL and 
third-party control 8-LCL. 
donor stimulation 
I" 
time (h) IL-2' IL-4 
0 <15" <10 
1 <15 <10 
2 <15 <10 
4 62 <10 
8 115 <10 
12 161 <10 
20 849 16 
48 524 15 
72 164 <10 
aGIL culture number 
'pg/ml 
"Detection limit 
dN.A., not available 
II 
IL-2 IL-4 
<15 NA" 
<15 
<15 
<15 
28 
35 
24 
29 
20 
third party stimUlation 
III II III 
IL-2 IL-4 IL-2 IL-4 IL-2 IL-4 IL-2 IL-4 
<15 NA <15 <10 <15 NA <15 NA 
<15 <15 <10 <15 <15 
<15 <15 <10 <15 <15 
70 48 <10 <15 <15 
117 35 <10 <15 <15 
136 43 <10 <15 <15 
131 50 <10 <15 <15 
224 55 21 <15 <15 
125 35 <10 <15 <15 
The overall IL-2 protein was significantly higher after stimUlation with donor than after third-party 
stimulation (P=O.002, Wilcoxon signed rank test). 
Discussion 
In the present study, we have studied the kinetics of IL-2 and IL-4 mRNA and 
subsequent protein production by in vivo primed GIL, grown from rejection biopsies, 
after in vitro stimulation with donor and third-party cells. The relative level of IL-2 
mRNA transcription and subsequent IL-2 protein production was significantly higher 
after stimulation with donor antigens. This relative high level of IL-2 production by 
GIL cultures may reflect increased transcription in each cell or is the result of a 
higher frequency of donor-specific IL-2 producing T-cells in the graft during rejection. 
This explanation is in line with the results of Bishop et al. who showed a high 
frequency of IL-2 producing T-cells in sponge matrix allografts." The results for IL-4 
mRNA expression are in agreement with that of IL-2 mRNA. Also, at the mRNA level 
a donor-specific IL-4 signal was measured. However, during rejection, GIL cultures 
synthesized significantly more donor-specific IL-2 mRNA than IL-4 mRNA. 
Cells cultured from the transplanted graft are stimulated in vivo by donor antigen on 
antigen-presenting cells, and as a consequence they are differentiated into either 
Th 1 or Th2 cells and cannot be influenced by addition of cytokines as is the case for 
naive T-cells.23 Upon restimulation in vitro these cells maintain a similar pattern of 
cytokine production. Moreover, both IL-2 (Th1) and IL-4 (Th2) producing cells 
proliferate in response to the added IL-2 in vitro." Accordingly, it is likely that most of 
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the in vitro cytokine production is released by GIL that differentiated in vivo into either 
Th1 (IL-2) or Th2 (IL-4) producing lymphocytes. 
Also after transplantation, the Th1fTh2 paradigm is frequently used to explain 
different immunological phenomena. Abundant production of Th1 cytokines is often 
accompanied with low secretion of Th2 cytokines and visa versa. 6.7 
Our results obtained in human lymphocytes at time of cardiac rejection are 
consistent with the hypothesis of the balance between IL-2 and IL-4 in allogeneic 
processes. Much of today's knowledge about the kinetics of cytokine production by 
lymphocytes is based on studies of clonal cells and peripheral blood cells after 
stimulation with either mitogens or alloantigens25.29 These studies show that IL-2 and 
IL-4 mRNA expression is rapidly but transiently induced after stimulation in T-cells. 
Also, in our bulk GIL cultures IL-2 and IL-4 mRNA transcription was detectable as 
early as 1-2 h after stimulation reached maximum levels between 2 and 4S hand 
base-line levels were approached by 20-72 h. Subsequent IL-2 protein release was 
detectable from 4 h with cytokines accumulating at least 20 and 48 h. In contrast to 
the IL-2 mRNA expression by mitogen-activated human T-cells as described by 
Shaw and colleagues25 our mRNA profiles were definitely less spiking, which might 
be due to the composition of our bulk cultures. Phenotypic analysis showed that both 
CD4· and CDS· T-cells were present in the bulk GIL cultures. However, the time-
course patterns of IL-2 and IL-4 production on the mRNA and protein level by CD4· 
and CDS· T-cells are only marginally different. 26 In contrast, the kinetics of cytokine 
mRNA production by lymphocytes is dependent on their activation level. 30 
Accordingly, we assume that in the graft, during acute rejection, cytokines are 
produced by allospecific T-cells with different stages of activation. After the initial 
priming, alloreactive T-cells home in the graft but nevertheless, represent, less than 
1% of the total infiltrate."'" Severe local inflammation, perhaps triggered by cytokine 
release might not only recruit T-cells with allospecificity to the graft but also T-cells 
with broader or irrelevant specificity. This mechanism might also explain why 
considerable levels of IL-2 and IL-4 mRNA expression were also found after 
stimulation with third-party cells. 
In the present study, the time-course patterns of mRNA expression of IL-2 and IL-4 
were comparable between GIL stimulated with donor cells and those activated with 
third-party cells, suggesting that also infiltrating T-cells with more public specificities 
underwent some level of activation. Nevertheless, these third-party cytokine mRNA 
levels, in contrast to donor-specific cytokine mRNA levels, did not regularly result in 
measurable protein levels. 
A strong correlation has been shown between mRNA expression and protein 
production of various cytokines in GIL cultures isolated from rejected kidneys after 
activation with anti-CD3. 33 Anti-CD3 antibodies will activate all infiltrated T-cells 
including the donor-specific subpopulation. However, in vivo T-cell activation requires 
the interaction of antigen-presenting cells, peptide and a specific T-cell receptor. 
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Therefore, the results after in vitro stimulation with alloantigens is a better reflection 
of events within the allograft during acute rejection. 
The discrepancy we found between mRNA and protein production after third-party 
but not donor-specific stimulation could of course be a detection phenomenon. 
Another explanation is that donor-specific signals are involved at the post-
transcriptional level. GIL have T-cell receptors with low affinity for third-party 
antigens" and activation of these low affinity T-cell receptors might not lead to all the 
necessary signals required for translation of mRNA. 
In summary, analysis of the kinetics of cytokine production showed that each 
individual GIL culture had its own characteristic mRNA and protein profile 
presumably due to differences in activation level of the alloreactive T-cells. In biopsy 
derived T-cell cultures, we measured a donor-specific mRNA signal for IL-2 and IL-4 
but the relative IL-2 mRNA level was significantly higher resulting in abundant donor-
specific IL-2 protein levels. 
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Abstract 
Background: Cytokines play an important role in allograft rejection. The local 
production of cytokines by T-helper 1 and T-helper 2 cells within an allograft could 
influence the induction of graft rejection. 
Methods: Therefore we studied the in vitro production of cytokines by cells infiltrating 
the graft. Graft-infiltrating cell cultures derived from human endomyocardial biopsy 
specimens more often produced interleukin-2 (P<0.001), interferon-v (P<0.001), 
interleukinA (P=0.02) and interleukin-6 (P=0.04) after stimulation with a B-cell line 
obtained from the heart donor than after stimulation with a third-party B-cell line. 
Furthermore, the levels of these cytokines were significantly higher after donor 
stimulation than after third-party stimulation (P<0.001). 
Results: Within the first 90 days after heart transplantation, significantly higher levels 
of interleukin-2 (P=0.05) and interferon-v (P=0.02) were produced by donor-
stimulated lymphocyte cultures derived from biopsy specimens taken during a 
rejection episode compared with cultures from biopsy specimens taken during a 
period without rejection. After 90 days, the levels of T-helper 1 cytokine (interleukin-2 
and interferon-v) production were, irrespective of the rejection grade, comparable 
with those found in the cultures from rejection biopsy specimens taken early after 
transplantation. With regard to T-helper 2 cytokines (interleukinA and interleukin-6), 
no relation was found with the presence of rejection at any time after transplantation. 
Conclusions: These data suggest that in the first 3 months after heart 
transplantation, acute rejection is associated with the production of increased levels 
of T-helper 1 cytokines, but not of T-helper 2 cytokines by donor stimulated graft-
infiltrating lymphocytes. Thereafter, the T-helper 1 cytokine production of graft-
infiltrating cells remained high, suggesting a continuous state of immunologic activity 
even in the absence of rejection. 
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Introduction 
Cytokines playa key role in the generation of alloreactive effector cells and therefore 
are important in allograft rejection. Two distinct cytokine secretion patterns have 
been defined in mouse CD4' T-cell clones.' T-helper 1 (Th1) cells produce mainly 
interleukin (IL)-2, IL-3, interferon (IFN)-y, tumor necrosis factor-a and -l\, whereas T-
helper 2 (Th2) cells secrete IL-3, IL-4, IL-5, IL-6 and IL-10. Romagnani' presented 
evidence for the existence of similar Th1 and Th2 subsets in man. Th1 cytokines 
favor the activation of cytotoxic lymphocytes and natural killer cells, whereas Th2 
cytokines activate the humoral immune system and may be involved in the induction 
of non-responsiveness.' In efforts to monitor rejection, cytokines, their receptors or 
the corresponding mRNA were measured in peripheral blood or directly in 
endomyocardial biopsy specimens (EMSs). The levels of IL-2, IL-2 receptor and 
tumor necrosis factor-a in serum of peripheral blood'·5 or coronary sinus blood' from 
cardiac allograft recipients did not correlate with the histologic grade of rejection in 
EMSs. In several studies cytokine gene expression was determined in cardiac 
allografts by polymerase chain reaction. IL-2, IFN-y, tumor necrosis factor-l\ and ILA 
mRNA were specifically expressed in mouse cardiac allografts and not in isografts or 
native hearts.'·8 In EMSs from transplanted cynomolgus monkeys, IFN-y mRNA was 
already found to be present before histologic evidence of rejection, whereas IL-1 l\, 
IL-2 and IL-6 mRNA transcripts were expressed simultaneously with signs of 
moderate rejection.' After clinical heart transplantation (HTx), an increased 
expression of IL-2 mRNA was found during rejection,lO·11 whereas others reported a 
correlation of acute rejection with IL-6 and transforming growth factor-l\ expression in 
EMS"·13 Cytokines can also be detected with the use of monoclonal antibodies and 
immunohistochemical techniques. In this way, the presence of IL-2 and IFN-y located 
in lymphocytes of EMSs from cardiac allograft recipients were shown to be indicative 
for rejection, whereas IL-6 was rarely detected." 
However, with the previously mentioned techniques, it is impossible to show the 
exact cellular source of the cytokine expression or production or to quantify the levels 
of cytokines produced. In addition, when cytokine mRNA expression is present, 
protein production is not necessarily the result, whereas protein production of 
cytokines is always the consequence of mRNA expression.15 Lymphocytes from the 
recipient that infiltrate the allograft (g"'ft-infiltrating lymphocytes: GIL) and can be 
propagated from EMSs taken after HTx16,17 are the relevant cells to study cytokine 
production profiles in relation to cardiac allograft rejection. These GIL contain, 
amongst others, donor-specific cytotoxic T-cells, which play an important role in 
acute rejection. 18-20 The activation of these cells can be influenced by the local 
secretion of cytokines. Only two groups studied cytokine production by GIL. Kirk et 
al. 21 measured IL-2, IL-4, IFN-y, and tumor necrosis factor-a production in nine donor 
stimulated GIL cultures derived from renal biopsy specimens, and showed that only 
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I L -2 distinguished reversible from irreversible rejecting allografts. The second study 
described detectable frequencies of GIL secreting IFN-y, IL-6, and IL-10 in isolated 
cells again from irreversible rejected kidneys, whereas cells from non-transplanted 
kidneys showed either low or undetectable expression of these cytokines. 22 Both 
studies investigated small numbers of GIL, without mentioning differences between 
nonrejection and rejection biopsy specimens or between donor and third-party 
reactivity. In the present study, a large panel of GIL cultures (n=49) derived from 
EMBs taken after HTx were analyzed with respect to the presence of donor-specific 
Th1-like and Th2-like cells. In addition, we studied whether different levels in IL-2, 
IFN-y, IL-4 and IL-6 production were correlated with acute rejection at different time 
points after HTx. 
Patients and methods 
We studied 49 GIL cultures propagated from EMBs of 30 heart transplant recipients. Most acute 
rejections occurred during the first 90 days after HTx.23 GIL growth was positively correlated with 
increasing histologic rejection grade, and most successful growth was shown in the first 3 
postoperative months.17 Twenty EMBs were taken in the first 90 days after HTx, and 29 EMBs were 
taken more than 90 days after HTx. 
Grading of the EMS was according to the guidelines of the International Society of Heart and Lung 
Transplantation. 24 We divided the EMBs into two groups: (1) those without infiltrates or with infiltrates, 
but without myocyte damage: non rejection EMS (grades 0 and 1; n=26) and (2) those with infiltrates 
and myocyte damage: rejection EMS (grades 2 and 3; n=23). 
Cultures 
GIL were cultured from EMSs in 96-wells U-bottom tissue culture plates (Costar, Cambridge, Mass.) 
as described before17 in culture medium (Roswell Park Memorial Institute medium-1640 Dutch 
Modification; Gibco, Paisley, Scotland) supplemented with 10% pooled human heat-inactivated serum, 
4 mM L-glutamine, 100 IU/ml peniciJljn and 100 I-Ig/ml streptomycin) in the presence of approximately 
30 U/ml exogenous lL-2 (lectin-free Iymphocult T-LF, 8iotest AG, Oreieich, Germany) and 1x105 
irradiated (30 Gy) autologous peripheral blood mononuclear cells. Only if cell growth was slowing down 
or cell death was observed (27 cultures) were the cultures restimulated once with a third-party Epstein-
8arr virus-transformed 8-celJ line.25 This cell line shared no human leukocyte antigen (HLA) with the 
donor or with the third-party used in the stimulation experiments to be described. No differences in 
cytokine production pattern were found in cultures which were or were not restimulated (data not 
shown). The mean culture period before testing was 34±14 days. The majority of the GIL cultures 
consisted exclusively of T-cells carrying the T-cell receptor air.. (95% WT31 positive cells), the 
remaining 5% were NK-ceUs (C016 positive cells), and macrophages and S-cells were not detected. 
Cytokine production 
GIL cultures do not produce cytokines continuously after in vivo stimulation with donor antigen; 
therefore, they have to be restimulated with this antigen in vitro. This restimulation was done with an 
irradiated 8-ceff line (60 Gy) of donor origin. 
Before testing, the cultures were washed extensively and 5x104 cells per well were incubated in eight 
replicates in a 96-wells V-bottom plate (Sterilin Limited, Hounslow, United Kingdom) at 37°C in a 
humified atmosphere of 5% CO2 in air during 24 hours in the absence of exogenous IL-2. Thereafter 
5x104 irradiated and washed cells of a 8-cell line derived from the heart donor were added per well 
(total volume: 200 1-11 per wen culture medium). A third-party S-ceff line was used to test the donor 
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specificity of the response. After 20 hours of co-culture, 150 lJl supernatant per well was harvested and 
the concentrations of IL-2, IFN-y, IL-4 and IL-6 were determined with enzyme-linked immunosorbent 
assay (ELISA). Unstimulated cell cultures and the 8-celiline alone served as controls. 
Enzyme-linked immunosorbent assay 
The concentration of cytokines in the supernatants of the GIL cultures was measured with the following 
ELISA-kits: IL-2 (Immunotech, Marseille, France) detection range 15 to 1000 pglml IL-2; IFN-y (Life 
Technology, Breda, the Netherlands) detection range 80 to 5000 pg/ml IFN-y; IL-4 (Central Laboratory 
of the Netherlands Red Cross Blood Transfusion Service (CLB), Amsterdam, the Netherlands) 
detection range 10 to 450 pgfml IL-4; IL-S (CLB, Amsterdam, the Netherlands) detection range 7 to 
450 pg/ml IL-S. Values higher than three standard deviations above the lower detection limit were 
considered positive. 
Results 
Cytokine production in GIL cultures and donor specificity 
Cytokine production was measured in 49 GIL cultures derived from EMB of 30 heart 
transplant recipients. Unstimulated cells did not produce IL-2, IFN-y, IL-4, or IL-6. 
Also, stimulator cells alone did not produce IL-2, IFN-y, or IL-4. In a few cases (13%), 
stimulator cells alone produced IL-6 (median 24, range 7 to 290 pg/ml), and this 
production was subtracted from the IL-6 production of the stimulated GIL cultures. 
Approximately half (25 of 49; 51%) the GIL stimulated with donor cells produced Th1 
(IL-2, IFN-y, or both) as well as Th2-type (IL-4, IL6, or both) cytokines. Th1-like 
cytokines only were produced by 33% (16 of 49) of the cultures, whereas 6% (3 of 
49) produced Th2-like cytokines only. In some culture supernatants' no detectable 
cytokine levels could be measured (5 of 49; 10%). Thus, after stimulation with donor 
antigens Th1 cytokines were produced significantly more often than Th2 cytokines 
(41 of 49 versus 28 of 49; P=0.004, chi-squared test). 
IL-2 and IFN-y were found in 78% and 73% of the supernatants, respectively, 
whereas IL-4 and IL-6 were only detected in 35% and 43% of the cultures, 
respectively (Table 1). Significantly less GIL cultures produced cytokines after third-
party induction than after donor stimulation. Not only the number of cytokine-
producing cultures proved to be higher after donor than after third-party stimulation, 
but the cytokine production of the individual cell cultures also was higher after donor-
specific stimulation (Figure 1: A, IL-2; B, IFN-y; C, IL-4; D, IL-6). 
No correlation was found between Th 1 or Th2 profiles and the phenotypic 
composition (CD4, CD8, CD16 and WT31) of the cultures or the culture period (data 
not shown). 
Cytokine production in relation to acute rejection 
Most acute rejections occurred during the first 90 days after HTx.23 We tested 20 
GIL cultures derived from EMBs taken during this early posttransplant period: 8 from 
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Graft-infiltrating lymphocytes that produced detectable levels of cytokines after 
stimulation were compared after stimulation with donor B-cell lines (B-LCL) or with 
third-party B-LCL. More interleukin (IL)-2 (A, P<O.001), interferon (IFN)-y (8, P<O,001), 
IL-4 (C, P<O,001) and IL-6 (0, P<O,001) were produced after donor stimulation (both 
one-tailed paired sample t-test after logarithmic transformation and sign test). In cases 
of coinciding values the number of observations is indicated. 
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nonrejection and 12 from rejection EMBs, and 29 cultures from EMBs taken more 
than 90 days after transplantation, of which 18 were from nonrejection and 11 from 
rejection EMB. 
In the first 90 days after HTx significantly more IL-2 was produced after donor 
stimulation of the GIL cultures derived from EMBs with signs of rejection (median 
154 pg/ml IL-2, range 15 to 1000 pg/ml) compared with those from EMBs without 
signs of rejection (median 42 pg/ml IL-2, range 15 to 359) (P=0.05; Figure 2, A). 
Comparable results were obtained for IFN-y during this early period (Figure 2, 8). 
Cultures from rejection EMBs produced 659 pg/ml IFN-y (range 80 to 2898) which 
was significantly different from nonrejection EMBs (median 176 pg/ml IFN-y, range 
80 to 1787) (P=0.02). In contrast, both groups of EMBs produced comparable levels 
of IL-4 and IL-6 after donor-specific stimulation (Figure 3: A, ILA; 8, IL-6). In 
addition, no difference in cytokine production was found when we compared (within 
the group of cultures from nonrejection EMBs taken early after HTx) EMB without 
infiltrates (grade 0) with EMB with infiltrates but no myocyte damage (grade 1) (data 
not shown). 
For EMBs taken more than 90 days after HTx no differences in production for both 
Th1 cytokines (Figure 2: C, IL-2; 0, IFN-y) and Th2 cytokines (Figure 3: C, IL-4; 0, 
IL-6) were found between cultures from rejection and nonrejection EMBs. 
Table 1 
Stimulator 
donor 
3fd party 
Graft~infiltrating lymphocyte cultures (n=49) with detectable levels of cytokine 
production after stimulation either with a donor 8-ceJ! line (B-LCL) or with a third-party 
8-LCL. 
Cytokines produced 
IL-2 IFN-y IL-4 IL-6 
78% (38/49) 73% (36/49) 35% (17/49) 43% (21/49) 
38%' (18/48) 38%' (18/48) 14%0 (7/48) 22%' (11/48) 
fL, Interleukin; IFN, interferon. 
Statistical analysis (see footnotes) was donor response compared with third-party response for each 
cytokine (chi-square test) 
'P<O.001, 'P<O.001, °P=O.02, 'P=O.04 
Discussion 
In GIL cultures derived from EMBs, the relation of donor-specific cytotoxic T-cells 
and acute rejection has been studied extensively.17-20,26 Although the importance of 
cytokine production within the transplanted heart for the induction of rejection has 
been stressed by several investigators,'·14,27 only two clinical studies on this subject 
are available and both investigated kidney transplants with irreversible rejection."'" 
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Production of T -helper 1 cytokines after donor stimulation in graft-infiltrating 
lymphocyte cultures derived from rejection and non rejection endomyocardial biopsy 
specimens (EMBs) taken during the first 90 days after heart transplantation (A, n=12, 
rejection EMBs; B; n=8, non rejection EMBs) or more than 90 days after heart 
transplantation (C, n=11, rejection EMBs; D; n=18, non rejection EMBs). During the 
first 90 days after heart transplantation, more interleukin (lL)-2 (P=O.05) and 
interferon (fFN)-y (P=O.02) were produced by graft-infiltrating lymphocytes from 
rejection than from non rejection EMBs (Mann Whitney U test); later, after heart 
transplantation, the levels were comparable (IL-2, P=O.47; IFN-y, P=0.29). 
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Figure 3 Production of T-helper 2 cytokines after donor stimulation in the same cultures as 
Figure 2 during the first gO days after heart transplantation (A and B) and more than 
90 days after heart transplantation (C and DJ. No significant difference between 
rejection and non rejection endomyocardial biopsy specimens in interleukin (IL)-4 and 
lL-6 production up to 90 days after heart transplantation (P=O.08 and P=0.25, 
respectively) and more than 90 days (lL-4, P=0,41; IL-6, P=O.19) after heart 
transplantation. 
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The present study reports on the donor-specific cytokine production of GIL cultures 
and the relation with acute rejection. 
Both Th1 cytokines (IL-2 and IFN-y) and Th2 cytokines (IL-4 and IL-6) were 
produced significantly more often and at higher levels after donor stimulation than 
after third-party stimulation (Table 1 and Figure 1). Only a few cultures resulted in a 
higher cytokine response after third-party stimulation, which could be due to Epstein-
Barr virus-specific response or to the fact that patients could have received a 
pretransplant blood transfusion sharing HLA antigens with the third-party stimulator. 
The production of relative high levels of cytokines within a short time (20 hours) after 
stimulation with donor antigens indicates that the GIL were primed (memory) cells." 
The possibility of influencing the cytokine profile during a secondary immune 
response remains elusive (reviewed by O'Garra);" however, cytokines added in vitro 
during the development of Th1 and Th2 clones can determine their cytokine profile. 3D 
In contrast, cells which had already differentiated into Th1 or Th2 cells use IL-2 or IL-
4, respectively, as autocrine growth factor. In addition, because both Th1 and Th2 
cells proliferate in response to IL-2 added in vitro,31 it is likely that the cytokine 
production pattern of in vivo primed GIL cultures reflects the original situation in the 
graft. Although Th1 cells seemed to retain their responsiveness to IL-2 longer than 
Th2 cells,31 which might result in more cells secreting Th1 cytokines in the GIL 
cultures, a similar predominance of Th1 cytokines within the graft was found after 
murine heart transplantation." 
In our heart transplant program, as in other centers, most acute rejections occur in 
the first 90 days after HTx.23 Although an overlap in cytokine levels was detected 
between rejection and nonrejection samples, it is obvious that in this period more IL-
2 (Figure 2, A) and IFN-y (Figure 2, B) were produced by cultures derived from EMBs 
with signs of rejection compared with those without signs of rejection. Previously a 
positive strong correlation was also found after clinical HTx between IL-2 mRNA 
expression and rejection in EMB.1O·11 The present results on IL-2 protein production 
in GIL cultures are in agreement with these findings on the transcriptional level. The 
specific expression of IL-2 and increased expression of IFN-y mRNA and protein 
found in allogeneic compared with syngeneic mouse heart transplants"s,,, and the 
correlation of mRNA expression of these cytokines with the severity of acute 
rejection episodes in transplanted non-human primate' and human 14 hearts are in 
harmony with our results on cytokine protein production level. All these studies 
confirm the importance of Th1 cytokines in acute rejection. Apart from stimUlation of 
differentiation and proliferation of T-helper cells, IL-2 enhances the generation of 
cytotoxic T-cells,32 which can recognize and kill allogeneic target cells. The increment 
of IL-2 in rejection EMBs could enhance the maturation of donor-specific cytotoxic T-
cells in EMSs. The presence of a rather large amount of immature cytotoxic cells in 
GIL cultures from EMS" supports a role of locally produced cytokines in the final 
maturation step. 
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Furthermore, IFN-y can exert multiple effects on other cells, including an 
upregulation of surface class II antigen expression. 33 Under normal circumstances, 
human vascular endothelium expresses HLA class I antigens but little or no HLA 
class II antigens." However, the expression of the latter will increase during 
rejection35 and is probably induced by the IFN-y produced by GIL. 
Although We found a positive relation for Th1 cytokines and rejection early after HTx, 
comparable increased IL-2 and IFN-y levels were found both in GIL from early 
rejection EMBs and in GIL from EMBs taken late after transplantation. It is possible 
that, in the mean time, immunologic countermechanisms were induced, which would 
have resulted in nonresponsive ness despite the presence of Th1 cytokine-producing 
cells. 
With regard to the Th2 (ILA and IL-6) cytokines, no relation was found with the 
presence of rejection at any time after transplantation (Figure 3). Others also did not 
find a predictive value of IL-4 mRNA expression in EMBs for acute rejection of 
human cardiac allografts."·"·13 One group observed an increased gene expression of 
IL-6 in EMBs during rejection."·13 However, IL-6 mRNA expression is frequently 
found in human heart tissue both before and after transplantation" and in native 
murine hearts or isografts.' A reason may be that IL-6 is secreted not only by 
activated Th2 cells 1 but also by activated macrophages36 and endothelial cells,37 
suggesting a more overall expression of this cytokine in organs. In the present study 
only IL-6 production by GIL was determined, excluding the contribution of 
nonlymphoid cells; still, no relation with rejection was found. These results imply that 
Th2 cytokines may be less relevant in the early rejection process. Others suggested 
a role for both IL-2 and IL-4 during rejection, but this hypothesis was concluded from 
studies in nonimmunosuppressed mice bearing cardiac allografts.'" The differences 
in IL-4 may be the result of immunosuppressive therapy applied in human beings. 
In conclusion, the described study showed that in the first 3 months after HTx, the 
increased quantity of Th1 but not Th2 cytokines produced by GIL correlated with 
acute rejection. Thereafter, the Th1 cytokine production of GIL remained high, 
suggesting a continuous state of immunological activity even without histologic signs 
of rejection. 
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Abstract 
Graft vascular disease (GVD) is mediated, at least in part, by cellular processes. 
Therefore, we cultured graft-infiltrating lymphocytes (GIL) from endomyocardial 
biopsies (EMS) taken during the first year after transplantation, determined their 
phenotypic composition, and correlated it to GVD. No difference was found between 
patients with and without GVD one year after transplantation. CD4· cells were always 
predominant present to CD8· cells, and no difference in phenotypic composition was 
found between EMS derived from patients with or without signs of GVD. 
In conclusion, the development of GVD is not associated with AR, GIL growth from 
EMS or their phenotypic composition. 
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Introduction 
In several studies, we and others have shown that alloactivated graft-infiltrating 
lymphocytes (GIL) can be expanded in vitro from endomyocardial biopsies (EMB) in 
IL-2-containing medium.'-' This culture system is thought to promote growth from in 
vivo activated GIL only.' We also have suggested that the outgrowth of GIL from 
EMB and their phenotypic composition corresponded with histological findings of 
acute rejection (AR)' and graft vascular disease (GVD)2 In the present study, we 
applied the same method of culturing GIL and studied per patient the proportion of 
EMB from which GIL could be obtained and their phenotype in 3 periods during the 
first year after heart transplantation (HTx) in an attempt to show whether our 
previous findings in groups of patients could be applied for individual cardiac 
transplant recipients. We compared these parameters for patients with and without 
GVD in the first year after HTx. 
Patients and methods 
We studied 60 cardiac allograft recipients, who were transplanted between March 1991 and 
September 1993. EMS were taken at regular intervals after HTx and examined histologically. 
According to the criteria of the International Society of Heart and Lung Transplantation,4 AR was 
defined as cell infiltrate with myocyte necrosis, and anti-rejection therapy was prescribed. Because 
most AR episodes occur in the first 3 months after HTx,5 we focussed on this period. 
One year after HTx the diagnosis of GVD was assessed by coronary angiography and scored by one 
of us (AHMM 8). GVD was defined as clinically significant vascular changes including minimal wall 
irregularities.6 Twenty of the studied patients did have signs of GVD in their angiography one year after 
HTx, and 40 patients did not. 
Culture method and phenotypic analysis 
We received EMS from 49 out of 60 patients taken in the first year after HTx to obtain GIL. GIL were 
cultured from EMS in IL-2 containing medium as described before. 1.2 GIL were analyzed by two-colour 
flow cytometry on a FACScan for the expression of cell surface markers. Initial screening was 
performed with the combinations WT31 FITC-CD3 PE, CD4 FITC-CD8 PE, and CD16 FITC-CDS6 PE. 
When CD3+WT31- cells were found, the GIL cultures were stained for T-cells bearing TCR-yo. WT31 
(TCR-af1) and TCR-y15 were obtained from Secton Dickinson (San Jose, CA, USA) and the other 
monoclonal antibodies from Immunotech (Marseille, France). 
Statistics 
We determined from all individual patients the fraction of EMS in the first year post transplantation 
showing signs of AR, the GIL growth from EMS, and their phenotypic composition in fixed periods after 
HTx. The Mann-Whitney U test was used to evaluate the differences between the patient groups. 
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Results 
We found no correlation between the incidence of AR and GVD (Table 1). The 
development of GVD in the first year after HTx did not influence the cell growth from 
EMB (Table 2). No relation was detected in the mean percentage TCR-al1, TCR-yo, 
CD3, CD16, CD4 and CDS at any time after HTx (Table 3). More CD4' than CDS' 
cells were found and this proved to be independent of GVD development. 
Table 1 Percentage of endomyocardial biopsies with signs of rejection during different 
periods after transplantation in patients without (n=40) and patients with (n=20) signs 
of graft vascular disease (GVO) one year after heart transplantation (HTx). 
months after HTx without GVD with GVD P-value 
(mean %)a (mean %)a 
0-3 25 26 0.75 
3-6 20 17 0.68 
6-12 9 8 0.70 
amean value of all individual patients 
Table 2 Proportion of graft-infiltrating lymphocyte growth from endomyocardial biopsies 
during different periods after transplantation in patients without (n=30) and patients 
with (n=18) signs of graft vascular disease (GVO) one year after heart transplantation 
(HTx). 
months after HTx without GVD with GVD P-value 
(mean %}a (mean %)" 
0-3 43 50 0.30 
3-6 32 48 0.20 
6-12 28 30 0.67 
amean value of all individual patients 
Discussion 
In agreement with the previous study', in this report, we found CD4 to be the 
predominant phenotype in most cultures at any time after transplantation. 
Since GVD was diagnosed by annual angiography, the exact moment of onset of 
S2 
Table 3 
TCR-,,~ 
TCR-V~ 
CD3 
CD16 
CD4 
CD8 
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Mean phenotypic composition of cell growth from endomyocardial biopsies during 
different periods after transplantation in patients without and patients with signs of graft 
vascular disease (GVD) one year after heart transplantation (HTx). 
months after without GVD with GVD P-value 
HTx (mean %)2 (mean %)a 
0-3 90 93 0.54 
3-6 97 94 0.38 
6-12 79 88 0.47 
0-3 1.9 1.6 0.73 
3-6 0.1 0.7 0.66 
6-12 7.4 1.7 0.98 
0-3 93 94 0.68 
3-6 97 95 0.30 
6-12 88 90 0.77 
0-3 7.2 4.3 0.37 
3-6 1.5 4.0 0.60 
6-12 11.3 7.6 0.95 
0-3 54" 60' 0.46 
3-6 68' 66' 0.98 
6-12 63' 53" 0.45 
0-3 35" 31" 0.53 
3-6 31' 33' 1.0 
6-12 20' 29" 0.34 
aMean value of all individual patients 
b,c,d,e,f,gMean percentage CD4 versus COB in cultures derived from EMS of patients without signs of 
GVD taken 0-3 (P<0.001)", 3-6 (P=0.003)' and 6-12 (P<0.001)' months after HTx and from EMB of 
patients with signs of GVD taken 0-3 (P=0.002)', 3-6 (P=0.01)' and 6-12 (P=0.02)' months after HTx. 
GVD could not be determined. Therefore, we analyzed several parameters after 
different periods in the first year after HTx and their relationship with GVD. We could 
not detect any correlation with the development of GVD during the first year after 
HTx and the number of EMB with signs of AR, growth patterns of GIL or their 
phenotype. Recently, we published that in a different population of cardiac transplant 
recipients, patients with GVD had a higher percentage of CDS' T-Iymphocytes during 
the first year after transplantation.' The discrepancy between this and the previous 
S3 
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report is the difference in analysis: the present study per individual patient and the 
previous study per GIL culture. 
From the described study, we conclude that GVD is not related to AR, and also the 
GIL growth and their phenotype could not make a distinction between patients who 
did or did not develop GVD in the first year after transplantation. 
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Abstract 
8ackgroud: The development of graft vascular disease (GVD) in the allograft is a 
major impediment for long-term survival of hear! transplant recipients. GVD may be 
mediated by cellular processes, in response to the transplanted hear!, and regulated 
by cytokines. 
Methods: We studied donor-specific cytokine production patterns in graft-infiltrating 
lymphocyte cultures propagated from endomyocardial biopsies. The biopsies were 
derived from patients with and without signs of GVD, as diagnosed by angiography at 
one year after hear! transplantation. 
Results: In the first year after transplantation, significantly more T-helper (Th) 1 
cytokines (interleukin [ILJ-2: P=O.04; interferon-v: P=O.01), but not Th2 (IL-4 and IL-6) 
cytokines, were produced by cultures of patients with GVD compared with patients 
without GVD. Thereafter, the Th1 cytokine levels in patients with GVD normalized to 
the levels of patients without GVD. Detectable levels of IL-6 were produced 
significantly more often (P=O.009) by cultures obtained more than one year after 
transplantation from patients with GVD. 
Conclusions: The results suggest that high levels of Th1 cytokines produced by graft-
infiltrating lymphocytes early after transplantation may be responsible for activation 
of vascular endothelium, leading to migration and proliferation of smooth muscle 
cells that is characteristic of GVD. IL-6, produced later after transplantation, 
continues this process by promoting smooth muscle cell proliferation. 
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Introduction 
Graft vascular disease (GVD) is reported to be a major limiting factor for medium-and 
long-term human cardiac allograft survival.' In our transplant center, the incidence of 
GVD, as observed by coronary angiography, is 26% at one year after heart 
transplantation (HTx). 
GVD is characterized by accelerated, diffuse, and concentric intimal proliferation, 
involving both the microvasculature and epicardial vessels in the heart.' Arterial 
lesions develop in donor vessels and are absent in recipient vessels, which suggests 
that GVD results from an immune-mediated process, initiated at and located within 
the donor vasculature. However, the pathogenesis of GVD remains poorly 
understood and may be multifactorial. The number of acute rejection episodes, the 
presence of anti-HLA antibodies, disorders of lipoprotein metabolism, the influence 
of immunosuppressive drugs, and cytomegalovirus infection may all be involved 
(reviewed by Tullius).' In our transplant center, GVD could not be correlated to 
ischemic heart disease before transplantation, preoperative reactivity against a panel 
of lymphocytes, gender, age, acute rejection, hypertension, serum cholesterol and 
triglycerides, use of calcium antagonists, or cytomegalovirus infection' 
A leading hypotheSiS is that GVD arises from chronic immune stimulation of the 
donor endothelium.5,6 According to this view, local cytokine and growth factor 
production induces activation of the endothelium, which in turn results in neointimal 
thickening and vascular smooth muscular remodelling.'.7 However, there is little 
clinical evidence to support this explanation, which links GVD with specific cytokines 
affecting the endothelium. 
Recently, we have demonstrated that graft-infiltrating lymphocytes (GIL), propagated 
from endomyocardial biopsies (EMB) taken during acute rejection after HTx, can 
produce significant levels of T-helper (Th) 1-like cytokines (interleukin [IL]-2 and 
interferon [lFN]-y) after donor-specific stimulation of these GIL' To clarify the 
significance of cytokines produced by lymphocytes that infiltrate the allograft, we 
studied whether there is a relationship between Th1- and Th2-like (IL-4 and IL-6) 
cytokines produced by GIL and the development of GVD. GIL cultures derived from 
EMB taken after HTx were analyzed with respect to the presence of donor-specific 
Th1- and Th2-like cells. In addition, we studied whether the levels of IL-2, IFN-y, IL-4 
and IL-6 production were correlated with the development of GVD. Because the 
development of GVD in the first year after HTx seems crucial for the course of the 
disease in the subsequent years,' we determined the cytokine pattern of the GIL at 
different time points after HTx, focussing especially on the first postoperative year. 
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Materials and methods 
Patients 
All patients received one preoperative blood transfusion. Cyclosporine and low-dose prednisone 
were given only as maintenance immunosuppression. EMS were routinely taken at weekly intervals 
during the first 6 weeks after HTx, and once every 2 weeks during the following 4 weeks. Later, EMS 
were taken less frequently, declining to once every 4 months at one year. 
One year after HTx, GVD was visually assessed by coronary angiography and scored by one of the 
authors (AHMM 8). She was unaware of the cytokine data when she was analyzing the angiograms. 
GVD was defined as all vascular wall changes, including minimal wall irregularities. 4 
Before and after the diagnosis of GVD, 85 fresh (noncryopreserved) GIL cultures were propagated 
from EMS of 27 patients without GVD and of 15 patients with signs of GVD at one year after HTx. We 
arranged these cultures according to successive time intervals after HTx (Table 1). The group of 
patients without and with GVD did not differ significantly in the number of patients who did or did not 
reject their allograft in their first postoperative year (without GVD: 2 non rejectors, 25 rejectors; with 
GVD: 4 nonrejectors, 11 rejectors) nor in the number of acute rejections (without GVD: 3.4±3.0; with 
GVD: 3.9±2.8 [mean±SDD. Also, no differences in the number of acute rejection EMS was found 
between the cultures derived from patients without GVD and those with GVD in the different time 
periods (0-3 months after HTx: without GVD, 9 cultures were derived from EMS without acute 
rejection and 9 cultures were from EMS with acute rejection; with GVD, 5 and 7 cultures were 
derived, respectively; 3-6 months after HTx: without GVD, 8 and 4 were derived, respectively; with 
GVD, 4 and 5 cultures were derived, respectively; 6-12 months after HTx: without GVD, 5 and 1 
cultures were derived, respectively; with GVD, 4 and 2 cultures were derived, respectively; >12 
months after HTx: without GVD, 10 and 2 were derived, respectively; with GVD, 6 and 4 cultures 
were derived, respectively). When more than one GIL culture was determined for any patient, the 
mean cytokine production was calculated. 
Table 1 Number of graft-infiltrating lymphocyte cultures tested per number of patients without 
graft vascular disease (GVD) and with signs of GVD per period after heart 
transplantation (HTx). 
GVD- GVD+ 
Months after HTx No. of patients No. of cultures No. of patients No. of cultures 
0-3 11 18 7 12 
3-6 6 12 4 9 
6-12 5 6 5 6 
0-12 17 36 11 27 
>12 11 12 6 10 
Cultures 
GIL were cultured from EMS in 96-wel! U-bottom tissue culture plates (Costar, Cambridge, MA), as 
described previously,S in culture medium (RPMI-1640 Dutch Modification [Life Technologies, Paisley, 
Scotland], supplemented with 10% pooled hUman heat-inactivated serum, 4 mM L-glutamine, 100 
IU/ml penicillin and 100 ~g/m! streptomycin). Culture was performed in the presence of approximately 
30 U/ml exogenous IL-2 (lectin-free Iymphocult T-LF; Siotest AG, Dreieich, Germany) and 105 
irradiated (30 Gy) autologous peripheral blood mononuclear cells per well. If cell growth was slowing 
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down or cell death was observed (58% of the cultures), before sufficient cel! numbers were reached, 
the cultures were restimulated once with a third-party Epstein Barr virus-transformed 8-cell line (8-
LCL) (5x10 3/well).9 This eel! line shared no HLA antigens with the donor nor with the third-party cell 
line used in the stimulation experiments described below. The mean culture period before testing was 
33 days (SO: 13 days). The GIL cultures were analyzed by two- and three-color flow cytometry on a 
FACScan (Becton and Dickinson, San Jose, CAl for the expression of cell-surface markers. Sreening 
was performed with the combinations WT31/fluorescein isothiocyanate (T-cell receptor-a(1), 
CD4/phycoerythrin, CD8/PERCP, and CD3/fluorescein isothiocyanate, CD16+56/phycoerythrin 
(natural killer cells). 
Cytokine production 
Before testing, the cultures were washed extensively and 5x104 cells per well were incubated 8-fold 
in a 96-well V-bottom plate (Greiner, Alphen aan de Rijn, the Netherlands). Incubation was performed 
at 3rC in a humified atmosphere of 5% CO2 in air during 24 hours, in the absence of exogenous IL-
2. Thereafter, 5x104 irradiated (60 Gy), and subsequently washed, B-LCL derived from the heart 
donor were added per well (total volume: 200 1-11 per well culture medium in the absence of IL-2). A 
third-party B-LCL was used to test the donor-specificity of the response. After 20 hours of co-culture, 
150 1-11 of supernatant per well was harvested and the concentrations of IL-2, IFN-y, IL-4, and IL-6 
were determined by enzyme-linked immunosorbent assay (ELISA). Unstimulated cell cultures and B-
LCL alone served as controls. 
ELISA 
The concentration of cytokines in the supernatants of the GIL cultures was measured with the 
following ELISA kits: IL-2 (lmmunotech, Marseille, France), detection range 15-1000 pg/mIIL-2; IFN-y 
(kindly provided by Dr. P.H. van der Meide, Biomedical Primate Research Centre, Rijswijk, the 
Netherlands), detection range 80-5000 pg/ml IFN-y; IL-4 (Central Laboratory of the Netherlands Red 
Cross-Blood Transfusion Service (CLB), Amsterdam, the Netherlands), detection range 10-450 pg/ml 
IL-4; IL-6 (CLB, Amsterdam, the Netherlands), detection range 7-450 pglmIIL-6. 
Statistics 
For the statistical analysis of differences between patient groups, the two-sided Mann-Whitney U test 
was used (Tables 2 and 3; Figure 1). 
Results 
GIL cultures 
The majority of the cultures from patients without GVD (mean: 95±8%) and with GVD 
(mean: 93±12%) consisted of T-cells carrying the T-cell receptor alB, the remaining 
cells were natural killer cells (6±17% and 6±12%, respectively). We could also not 
differentiate for CD4- and CD8-positive cells and GVD (CD4: without GVD, 61±31%, 
with GVD, 53±28%; CD8: without GVD, 31±31%, with GVD, 39±29%). Macrophages 
and B-cells were not present in the cultures. 
Cytokine production in GIL cultures 
Unstimulated GIL cultures did not produce IL-2, IFN-y, IL-4, or IL-6. Stimulator B-LCL 
cells alone did not produce IL-2, IFN-y, or IL-4 either, whereas IL-6 was produced by 
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S-LCL alone in 28% of the cases (mean: 38±57 pg/ml). This base level production 
was subtracted from the IL-6 produced by the stimulated GIL cultures. 
Recently, we have demonstrated that a donor-specific cytokine production can be 
determined by stimulating the GIL cultures with donor S-LCL, because both Th1 
cytokines (IL-2 and IFN-y) and Th2 cytokines (IL-4 and IL-6) were produced 
significantly more often and at higher levels after donor stimulation than after third 
party stimulation.' 
Cytokines produced before and after the diagnosis of GVD 
We determined prospectively the cytokine production of donor-stimulated GIL 
cultures in the first year after HTx, before the diagnosis of GVD (Figure 1). During 
this period, significant more IL-2 (without GVD: median 140 pg/ml, range 15-469; 
with GVD: median 411 pg/ml, range 15-1000; P=0.04) and IFN-y (without GVD: 
median 386 pg/ml, range 80-2913; with GVD: median 1197 pg/ml, range 80-5000; 
P=O.01) was produced by the cultures derived from patients that had GVD at one 
year after HTx, compared with the cultures from patients without GVD. However, 
after the first preoperative year, no difference between the patient groups were found 
(IL-2: without GVD, median 156 pg/ml, range 15-1000; with GVD, median 136.5 
pg/ml, range 15-258; IFN-y: without GVD, median 502 pg/ml, range 80-1509; with 
GVD, median 365.5 pg/ml, range 80-2520). Comparing the first year after HTx with 
the period thereafter, comparable levels of cytokines were produced by the donor-
stimulated cultures from the patients without GVD. However, GIL cultures derived 
from patients with signs of GVD in their angiogram produced significantly more IL-2 
(P=0.05) and IFN-y (P=0.06) in the first year after HTx than in the period thereafter. 
The levels produced by GIL from EMS taken more than one year after HTx of the 
patients with signs of GVD were in the range of the group without GVD. 
No differences for the Th2 cytokines IL-4 and IL-6 were detected in the first year 
after HTx (Table 2). After the diagnosis of GVD at one year after HTx, more IL-6 was 
produced by the cultures derived from patients with GVD, compared with those 
without GVD (P=O.007). This was caused by the higher frequency of cultures from 
patients with GVD (6/6: 100%) than without GVD (3/11: 27%) that produced 
detectable levels of IL-6 (P=0.009: Fischer's exact test, two sided P-value). 
Cytokine production in the first year after transplantation 
To determine the cytokine profile of GIL obtained at different time periods in the first 
preoperative year after transplantation, we divided this year in three consecutive 
periods: 0-3, 3-6 and 6-12 months after HTx (Table 3). 
During the first 3 preoperative months, a trend (P=0.15) toward more IL-2 production 
by the cultures derived from patients with GVD compared with those without GVD 
was seen (Table 3A). This was accompanied by higher levels of IFN-y production by 
the cultures derived from patients with GVD (P=0.10; Table 3A). Over the next 3 
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IL-2 IFN-'Y 
Median levels of Th1 (IL-2, lFN-y) cytokine production after donor stimulation of graft-
infiltrating lymphocyte cultures derived from endomyocardial biopsies taken before 
(0-12 months) and after (>12 months after heart transplantation (HTx)) the diagnosis 
graft vascular disease (GVO). 
II, Cultures from patients without GVD; 2:J, cultures from patients with GVD. 
Median levels of Th2 (IL-4 and IL-6) cytokine production after donor stimulation of 
graft-infiltrating lymphocyte cultures derived from endomyocardial biopsies taken 
before (0-12 months) and after (>12 months after heart transplantation (HTx)) the 
diagnosis of graft vascular disease (GVD). 
IL-4 (pg/ml) IL-6 (pg/ml) 
Months after HTx GVD- GVD+ p' GVD- GVD+ P 
0-12' 10' 26 0.20 11 14 0.26 
10-160 10-149 7-110 7-138 
>123 10 50 0.35 7 14.5 0.007 
10-450 10-450 7-32 11-34 
p' 0.77 0.81 0.13 0.53 
lData are presented as the median cytokine production per group of patients, with their range 
(minimum-maximum). 
2Cytokine production from cultures of patients without GVD were compared with cultures of patients 
with GVD. 
3Seventeen patients without and 11 patients with GVD were tested in the first year after 
transplantation, and 11 patients without and 6 patients with GVD were tested after one year after 
transplantation. 
4Cytokines produced in the first year compared with more than one year after transplantation for 
patients without and with GVD. 
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months, this trend of increased IFN-y production continued, resulting in significant 
differences between the patient groups (P=O.01). Thereafter, in the period from 6 to 
12 months after HTx, comparable levels were produced by both groups. 
For IL-4, a slight increment (P=O.15) of cytokine production was seen only in the 
cultures derived from EM8 taken 6-12 months after HTx of patients with GVD, in 
comparison with the cultures derived from patients without GVD (Table 38). There 
was no differentiation in IL-6 levels between patients with and without GVD in any of 
the three periods of the first year after HTx (Table 38). 
Table 3 Median cytokine production levels of the Th1 (A: IL·2 and IFN·V) and Th2 cytokines 
(8: IL·4 and IL·6) after donor stimulation of GIL cultures derived from endomyocardial 
biopsies taken at different periods in the first year after heart transplantation (HTx) of 
patients without (GVD·) and with (GVD+) graft vascular disease. 
A 
B 
Months after HTx 
GVD- (n)/GVD+ (n) 
0-3 (11/7) 
3-6 (6/4) 
6-12 (5/5) 
Months after HTx 
GVD- (n)/GVD+ (n) 
0-3 (11/7) 
3-6 (6/4) 
6-12 (5/5) 
IL-2 (pg/ml) 
GVD- GVD+ 
82 266 
15-518' 15-552 
195.5 201.5 
33-877 100-1000 
149 257 
15-348 15-1000 
IL-4 (pg/ml) 
GVD- GVD+ 
10 20 
10-218' 10-149 
10 21.5 
10-125 
83 
10-450 
10-213 
10 
10-77 
p' 
0.15 
0.61 
0.42 
p' 
0.25 
0.35 
0.15 
IFN-y (pg/ml) 
GVD- GVD+ P 
271 926 0.10 
80-1899 80-5000 
238.5 1644 0.01 
80-895 1059-2224 
846 526 1.0 
164-2913 242-5000 
IL-6 (pg/ml) 
GVD- GVD+ 
7 9 
7-44 7-229 
16 15.5 
7-53 
57 
7-160 
12-31 
14 
7-59 
P 
0.43 
0.91 
0.55 
10ata are presented as the median cytokine production per group of patients, with their range 
(minimum-maximum). 
2Cytokine production from cultures of patients without GVD were compared with cultures of patients 
wilh GVD. 
92 
Intragraft monitoring of graft vascular disease 
Discussion 
The long-term success of organ transplantation is limited by the development of 
chronic rejection. The cause of GVD, or chronic rejection after HTx, may be 
endothelial cell activation, finally leading to intima proliferation, which is the 
characteristic of GVD. Tissue damage, e.g., by ischemia and reperfusion, induces 
early activation of endothelial cells, and causes expression of new adhesion 
molecules on surface of these cells. This is followed by macrophages infiltrating the 
graft and by secretion of monokines, which in turn results in another shift of adhesion 
molecules on endothelial cells. Such a process is an universal repair phenomenon in 
organ transplants. 1O•11 GVD is clearly not the result of nonspecific endothelial 
activation alone; other factors must also playa role. Unique to the allograft is the 
subsequent infiltration of the graft by activated T-Iymphocytes (GIL) and their 
production of cytokines when they encounter appropriate donor antigens. These 
allogeneic responses may be responsible for the characteristic vascular disease 
found after organ transplantation only. Therefore, we studied allogeneic immune 
processes within the transplanted heart in relation to the development of GVD. We 
have already demonstrated that neither growth frequency of GIL nor their phenotypic 
composition was differentiated between patients who developed GVD and those who 
remained free from GVD in the first year after HTx.12 In this report, we measured the 
donor-specific cytokine production of GIL cultures and studied their relation with 
GVD. 
An overlap in cytokine levels was detected between patients who did or did not have 
signs of GVD in their coronary angiogram at one year after HTx. However, it is 
obvious that more Th1 cytokines (IL-2 and IFN-y), and not the Th2 cytokines IL-4 
and IL-6, were produced by cultures derived from EMB with signs of GVD, compared 
with those without signs of GVD, in the first year after HTx. The overlap could be the 
result the method we used for detecting GVD. Rickenbacher and coworkers 13 already 
showed that 85% of cardiac transplant patients with normal angiograms had 
evidence of intima thickening by the intracoronary ultrasound method. Perhaps a 
clearer differentiation in cytokine production between the patient groups could be 
made by quantitatively determining the degree of intima thickening by such sensitive 
diagnostic techniques. 
In animal studies, the importance of the Th1 cytokines has also been indicated. 
Tilney et al. 14 and Hancock et al. 15 showed in renal rat allografts that at the time when 
arteritis and glomerulitis appeared, 10-20% of cellular infiltrates, consisting of T-
lymphocytes and macrophages, were positive for IL-2, IFN-y, and tumour necrosis 
factor (TN F)-a in immunohistology. Russell et al. 16 also found early and sustained 
up-regulation of IFN-y in mononuclear cells within the cardiac allograft in rats with 
chronic cardiac rejection. After human liver transplantation, Hayashi and coworkers 17 
demonstrated more IL-2 and IFN-y mRNA in explanted livers and biopsy samples 
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with the diagnosis of chronic rejection than in biopsies without evidence of rejection. 
However, Bishop et al." could not detect any difference between Th1 cytokine 
mRNA expression in biopsy tissue derived from human liver allografts recipients with 
chronic rejection and normal liver tissue. In human kidney transplant recipients, 
Noronha et al." could also not detect a correlation between chronic rejection and the 
expression of TNF-a and IFN-y measured by immunocytochemical studies. Merville 
et al. 20 studied GIL grown from removed kidney allografts and found no difference in 
the frequency of IFN-y-producing cells between patients with irreversible ongoing 
acute rejection and patients with chronic rejection complicated by superimposed 
acute rejection. So most clinical studies were not able to confirm the importance of 
Th1 cytokines in the development of GVD, which has been suggested by the studies 
in experimental animals. 
What about the Th2 cytokines? Parallel to our results, Hayashi et al. 17 found no 
difference in the expression of IL-4 and IL-10 in liver allografts, whereas the IL-5 
gene was significantly upregulated in the grafts with chronic rejection compared with 
stable grafts. In contrast, Bishop et al." found significantly less IL-10 mRNA 
expression in human liver biopsies derived from patients with chronic rejection after 
transplantation, compared with normal livers. Also, Merville et al. 20 showed a lower 
frequency of IL-10-producing cells in GIL of removed human kidney allografts from 
patients with chronic rejection compared with patients with irreversible acute 
rejection. 
It is difficult to compare the results mentioned above with our results. Although our 
results closely resemble of those found in the preclinical studies, they do differ from 
some of the clinical analyses. These differences could be the consequence of the 
organ transplanted, the immunosuppressive load, and the method used to diagnose 
GVD. Also, the methods used for detecting cytokines, and of course, the cellular 
source of the cytokines, can influence the results. Even more important could be the 
timing of the studies. In general, the investigators described only the cytokines found 
after the diagnosis of GVD was made. This is probably too late; the harm has already 
been done. Therefore, after our finding that Th lymphocytes playa role before the 
diagnosis of GVD, we longitudinally investigated in which period in the first 
postoperative year cytokines may playa crucial role in the development of GVD. A 
trend was detected toward more IL-2 and IFN-y production in the first 3 postoperative 
months for the GIL cultures derived from patients with compared with those without 
GVD at one year after HTx. In fact, early IL-2 production stimulates the activation 
and proliferation of lymphocytes," and IFN-y recruits macrophages23 into the graft 
and enhances cytotoxic T-Iymphocyte differentiation"-" and MHC expression of the 
vascular endothelium." The significance of IFN-y was intensified 3-6 months after 
transplantation in the donor-stimulated cultures derived from patients with GVD. In 
the second half of the year after HTx, no difference in Th1 cytokine production was 
seen anymore, whereas in this period only slightly higher levels of IL-4 were 
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produced by the cultures of patients without GVD compared with those patients with 
GVD. 
More than one year after HTx, no difference in Th1 cytokines between the patient 
groups was found by us, as the IL-2 and IFN-y levels of the patients with GVD had 
decreased to the concentrations observed in the patients without GVD. The results 
emphasize the importance of measuring cytokine levels during the first year after 
transplantation, before the diagnosis of GVD. 
The detectable production of IL-6 by the GIL cultures of patients with GVD was 
remarkable, in contrast to the non-detectable levels of the cultures from patients 
without GVD after the first year after HTx. Tilney and Hancock"·15 also described the 
importance of IL-6 after the diagnosis of chronic rejection in rats. When more then 
50% of the glomeruli were enlarged from mesangial proliferation, the glomeruli were 
stained positive for IL-2, IFN-y, TNF-a, and IL-6. Even when most glomeruli were 
sclerotic, little cytokine activity was noted, except for IL-6. Russel et al. 16 detected 
early and sustained expression of IL-6 by immunohistology in a rat model of chronic 
rejection after HTx. This increase in IL-6 was not only detected in the infiltrate, but 
also in the serum of the rats'" However, in the serum and urine of human renal 
allografts recipients, no relation between IL-6 and chronic rejection was seen." We 
suggest that the IL-6 produced by the GIL derived from patients with GVD will 
continue the process of intima thickening in the vessels of the donor heart. Because 
IL-6 promotes the proliferation of smooth muscle cells," this may be a co-factor in 
the accelerated process of coronairsclerosis. 
In summary, we presented evidence that GVD is an immune-mediated response to 
donor antigens and that the development of GVD is initiated by Th1 cytokines 
produced by GIL early after transplantation, whereas the IL-6 production of GIL 
maintains and accelerates GVD. 
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Abstract 
Background: Cellular immune processes may trigger the development of graft 
vascular disease (GVD). CD4 and CDS cytotoxic T-Iymphocytes that infiltrate the 
allograft could playa role in the development of GVD. 
Methods: We studied the presence of in vivo primed or committed cytotoxic T-
lymphocytes (cCTL) and their avidity for donor HLA class I and class II antigens in 
graft-infiltrating lymphocyte cultures propagated from endomyocardial biopsies 
derived from patients with and without signs of GVD. The fraction of cCTL with high 
avidity for HLA class I or class II antigens was estimated by the addition of anti-CDS 
or anti-CD4 monoclonal antibodies (MoAb) to the cytotoxic phase of the limiting 
dilution analysis. 
Results: In the first year after transplantation no difference in the frequency of donor-
specific class I cCTL between patients with and without GVD was found. Addition of 
anti-CDS mAb revealed that most cultures predominantly consisted of cCTL with low 
avidity for donor HLA class I antigens, irrespective of the development of GVD at one 
year after transplantation. However, in patients who did not develop GVD, the 
frequency of cCTL with donor HLA class II specificity was significantly higher than in 
patients who did develop GVD. The avidity for donor HLA class II antigens was 
comparable in both groups. 
Conclusions: A high frequency of donor-specific cCTL for HLA class II antigens 
seems to be a protective factor against the development of GVD. These cCTL might 
be cytotoxic for cells involved in GVD development, e.g. activated endothelium and 
smooth muscle cells of donor origin. 
9S 
Intragraft monitoring of graft vascular disease 
Introduction 
The long-term success of organ transplantation is limited by the development of 
chronic rejection. In the allograft, chronic rejection manifests itself as an occlusive 
disease of the donor vessels, which leads to ischemia and thereby to organ 
dysfunction. In human cardiac allografts, it is characterized by a process of 
accelerated coronary artery disease, which can be visualized by angiography or 
intravascular ultrasound. The vascular lesions develop in the donor vessels, while 
the recipient vessels remain free from lesions. Therefore an allogeneic immune 
process is probably involved in the pathogenesis of graft vascular disease (GVD). 
Cells obtained from affected coronary vessels are a likely source to study cellular 
immune processes in relation to GVD. Unfortunately, such an analysis is limited by 
the material available. However, GVD involves vessels of different sizes in the graft,l 
including the very small vessels that can be observed in endomyocardial biopsies 
(EM B). 2.3 After heart transplantation (HTx), EMB are regularly taken to diagnose 
acute rejection. Recently, we have demonstrated that during the first post-operative 
year graft-infiltrating lymphocytes (GIL) propagated from EMB derived from patients 
who developed GVD at one year after HTx produced significantly more T-helper 1 
cytokines than the cultures from patients who remained free from GVD 4 Not only the 
T-helper cells, but also cytotoxic T-Iymphocytes (CTL) could play a role in the 
development of GVD. During acute rejection, donor-specific CTL propagated from 
EMB had mainly a high avidity for donor HLA class I and class II antigens, whereas 
CTL from non-rejection EMB had a low avidity for donor antigens"-7 The CTL with 
high avidity for donor HLA class I or class II antigens are resistant to in vitro inhibition 
with CDS or CD4 monoclonal antibodies (MoAb), respectively, indicating that these 
cells do not need the CDS or CD4 molecule to stabilize their antigen binding.'" On 
the other hand, low-avidity CTL can easily be inhibited. 
In the present study, we analyzed the cytotoxic capacity of GIL to donor HLA class I 
and class II antigens during the first post-operative year and their relation with GVD 
as diagnosed at one year after HTx. To study the relevance of CDS· and CD4· CTL 
during the development of GVD, we investigated the frequency of in vivo primed or 
committed CTL (cCTL) present within the graft and their avidity for donor HLA class I 
and class II antigens in the first year after HTx, thus before the diagnosis of GVD. 
Patients and methods 
Patients 
We studied 89 cardiac allograft recipients transplanted consecutively between September 1987 and 
January 1991. Detection of acute rejection was performed by histological grading in EMB and defined 
as mononuclear cell infiltrates with myocyte damage. We refer to acute rejection when grade 3A or 
more is histologically diagnosed. 10 At one year after HTx, 18 patients had signs of GVD and 71 
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patients did not. GVD was visually assessed by coronary angiography taken at one year after HTx, 
and scored by one of us (AHMM B). GVD was defined as all vascular wall changes, including minimal 
wall irregularities. 
All patients received preoperative blood transfusion, maintenance immunosuppression consisted of 
cyclosporin A (GsA) and low dose of steroids. 
Culturing, phenotypic analysis and cel/-mediated Iympholysis of cultures 
GIL were established from EMS in 96-well U-bottomed tissue culture plates (Costar, Cambridge, MA) 
in medium (RPMI-1640 Dutch Modification; GibeD, Paisly, UK) supplemented with 10% pooled heat-
inactivated human serum, 4mM L-glutamine, 100 IU/ml penicillin and 100 1J9/ml streptomycin 
(=culture medium) in the presence of approximately 30 U/m! exogenous IL-2 (lectin-free Iymphocult 
T -LF; Biotest AG, Dreieich, Germany) and 1 x1 05 irradiated (30 Gy) autologous PBMC (peripheral 
blood mononuclear cells) per well. 11 GIL-cultures propagated under these conditions contain in vivo 
primed or cCTL. 6,12 The plates were incubated in a humidified atmosphere at 37 °C in 5% CO2, 
When sufficient cell numbers was reached, the cultures were analyzed by three-colour flow cytometry 
on a FACScan (Becton and Dickinson, San Jose, CAl for the expression of cell surface markers. 
Screening was performed with the combination wr31 FITC (T-cell receptor-a(1), C04 PE and COB 
PERCP. 
Subsequently, the cytotoxic capacity of GIL cultures was tested against donor cells or a panel of 
target cells sharing either HLA class I or class II antigens with the donor. Briefly, effector GIL were 
incubated with 2.5x103 51Cr-labelled target cells at different effector/target ratios in 200 1-11 culture 
medium. After 4 hours of incubation supernatants were harvested and the release of 51Cr-release 
was determined as described in the limiting dilution analysis (LOA). Cells not used for this test were 
stored at -140°C. 
AfJogeneic target cells 
T-cell blasts were obtained by culturing donor spleen cells for 7 days in culture medium 
supplemented with 1 % phytohaemagglutinin (PHA)-M (Oifco, Detroit, MI), after 3 days half of the 
medium was replaced by culture medium supplemented with 10% v/v Iymphocult-T (Biotest). These 
blasts served as target cells to determine donor class I-directed cytotoxicity. The T-cell blasts can not 
be used as HLA class II targets. 7 
Epstein-Barr virus (EBV)-transformed 8-cell lines (B-LCL) were obtained by infection of PBMC or 
spleen cells with the virus from the marmoset cell line B95-8 and addition of CsA as described by 
Moreau et al. 13 These cells were maintained in culture medium supplemented with 10% heat-
inactivated bovine calf serum (BCS; Hyclone, Logan, Utah). The B-LCL served as target cells to 
measure HLA class I and II antigens. Because we determined especially the avidity for donor HLA 
class II antigens, we used B-LCL that did not share donor HLA class I, but shared only donor HLA 
class II antigens with the donor.7 
Limiting Dilution Analysis 
We obtained outgrowth of GIL in approximately 42% of the non-rejection EMB14 and stored the 
cultures when enough cells were left after the standard cell-mediated Iympholysis test. Only cultures 
showing donor-specific class I and/or class II cytotoxicity were analysed in the present study. We 
studied 19 GIL cultures propagated from EMB of 8 patients without GVO and 10 patients with signs of 
GVD in their one-years angiogram. The donors of these patients had several mismatches for HLA 
class I (HLA-A and -8) andlor HLA class II (HLA-DR) antigens (Tables 1 and 2). The selected 
cultures had to exhibit donor HLA class I-directed cytotoxicity in 51Cr-release assays in order to be 
able to determine the percentage of celis with high avidity for donor HLA class I antigens, and donor 
HLA class II-directed cytotoxicity to determine the percentage of cells with high avidity for donor HLA 
class II antigens. The days after HTx, days in cultures, phenotYPIc composition and number of HLA 
mismatches (mm) between donor and acceptor were comparable between the patients with and 
without GVD (Tables 1 and 2). 
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The cultures were thawed in culture medium and irradiated (30 Gy) third-party B-LCL (5x10'/well) 
were added as feeder. These 8-LCL did not share HLA antigens with the donor and acceptor, to 
avoid de novo activation in Vitro of precursor CTL that can mature to cCTL by restimulating with 
donor antigens. Thus, only the activity of in vivo activated cCTL were quantified in the LDA. When 
sufficient cell numbers were reached, limiting dilution cultures were set up in 96-well U-bottomed 
tissue culture plates (Costar). 
Table 1 Characteristics of the graft-infiltrating lymphocyte cultures of which the fraction of 
cCTL and their avidity for donor HLA class I antigens were determined. 
patient pHTx culture WT31 CD3 CD4 CD8 CD16 y5 HLA-A HLA-B HLA-DR 
(days) (days) % % % % % % mm mm mm 
without GVD 
AN 163 60 97 97 40 53 0 0 2 2 
BE 215 60 79 81 9 65 19 0 2 
BN 216 29 88 89 5 76 10 2 2 2 
HO 133 24 99 99 4 95 0 0 
KU 196 23 74 95 15 77 4 20 2 2 
with GVD 
LI 212 37 99 99 49 50 0 0 2 2 
SA 334 32 97 98 4 96 0 
WI 141 30 90 90 29 58 2 0 
WL 131 27 88 95 8 80 5 7 2 
ZE 181 60 89 94 85 12 9 0 2 2 
Graded number of responder GIL were titrated in 8 double dilutions starting from 5000 to 39 cells per 
well in 24 replicates with 5x104 irradiated (30 Gy) autologous PBMC as feeder in 200 1-11 culture 
medium supplemented with 20 U recombinant ILw 2 (Biotest). After 7 days of culture, the microGuJtures 
were split in two. Half of the split wells were tested in the absence of MoAb and the other half were 
tested in the presence of CDB MoAb in case of determining the avidity for donor HLA class I antigens 
and CD4 MoAb for determining the avidity for donor HLA class II antigens. Each well was individually 
tested for cytolytic activity against 2.5x10 3 51Cr-labelled target cells. T-cell blasts of donor origin were 
used as targets when the avidity for donor HLA class I antigens was tested. B-LCL were used as 
targets when the avidity for donor HLA class II antigens was tested. 7 These B-LCL lacked donor HLA 
class I molecules. After 4 hours of incubation at 37 °C in 5% CO2 the supernatants were harvested 
(Skatron harvesting system: Skatron-AS, Lier, Norway) and the release of 51Cr was determined in a 
v-counter (Packard Instruments, Downers Grove, IL). Maximum and spontaneous release were 
determined in 4-fold and defined by incubation of target cells with culture medium in the presence 
and absence of Triton X-100 (5% vlv in TRIS buffer), respectively. 
The percentage of specific lysis was calculated according to the formula: 
experimental release - spontaneous release 
% lysis = 100% X ----------------------------------------------------------
maximal release - spontaneous release 
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The fraction of cCTL with high avidity for donor class I (CDS) or class II (CD4) HLA antigens was 
calculated using the formula: 
cCTLf with CD8 or CD4 MoAb 
% cCTL with high avidity = 100% x ------------------------------------------
cCTLf without CD8 or CD4 MoAb 
The microcultures were considered cytolytic when the percentage lysis exceeded 10%. 
As a control fOf specificity, 5000 cells per well were cultured in quadruple and the capacity to lyse 
third-party PHA blasts or B-LCL (these targets cells did not share HLA antigens of the donor) and the 
K562 cell line was tested. 
Table 2 
patient 
BN 
BR 
BU 
KU 
MO 
BO 
DA 
FR 
JA 
LI 
VE 
WI 
WL 
ZE 
pHTx 
(days) 
216 
251 
218 
196 
35 
128 
213 
122 
225 
212 
21 
141 
131 
224 
COB inhibition 
Characteristics of the graft-infiltrating lymphocyte cultures of which the fraction of 
cCTL and their avidity for donor HLA class II antigens were determined. 
culture WT31 
(days) % 
29 
40 
34 
23 
26 
55 
36 
25 
29 
37 
25 
30 
27 
79 
88 
99 
99 
74 
96 
97 
99 
87 
100 
99 
94 
90 
88 
98 
CD3 
% 
89 
98 
99 
95 
96 
97 
99 
87 
100 
99 
94 
90 
95 
91 
CD4 
% 
CD8 
% 
without GVD 
5 
74 
67 
15 
54 
76 
26 
33 
77 
46 
with GVD 
98 
64 
45 
13 
49 
42 
29 
8 
10 
o 
38 
42 
87 
50 
58 
58 
80 
91 
CD16 
% 
10 
o 
o 
4 
4 
2 
o 
15 
o 
o 
3 
2 
5 
o 
y~ 
% 
o 
56 
o 
o 
o 
o 
o 
o 
o 
o 
7 
o 
HLA-A 
mm 
2 
2 
o 
2 
2 
2 
2 
2 
HLA-B 
mm 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
HLA-DR 
mm 
2 
2 
2 
2 
2 
2 
2 
2 
FK18 (a kind gift of Dr F. Koning, Departmenl of Immunohematology and Bloodbank, Universily 
Hospital Leiden, The Netherlands), a mouse antibody of the IgG3 subclass, recognizes the gp32 
chain of the human CDB molecule. 15 A 1 :500 dilution of ascitic fluid totally inhibited the cytotoxic 
capacity of CD8~dependent CTL clones, but did not affect target cell lysis by COB-independent CTL 
clones. CDS clones were not affected by the CD4 MoAb RIV6. 7 Before addition of the target cells to 
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the microGultures, FK18 was added to half of the split well cultures and were incubated for 30 
minutes at 37 "C in a humidified atmosphere containing 5% CO2 , 
CD4 inhibition 
RIV6 (a kind gift of Dr M.F. Leerling, RIVM, Bilthoven, The Netherlands) is a mouse antibody of the 
19G2a subclass directed against the human CD4 molecule. At a concentration of 1 1J9/ml, RIV6 totally 
inhibited the cytotoxic capacity of CD4-dependent CTL clones, but did not affect target cell lysis by 
CD4-independent CTL clones. CD4 clones were not affected by FK18. 7 Before addition of the target 
cells to the microGultures, RIV6 was added to half of the split weI! cultures and were incubated for 30 
minutes at 37 "C in a humidified atmosphere containing 5% CO2 , 
Statistical analysis 
Data concerning the cytotoxicity against donor HLA class I and class II antigens were analyzed with 
the Fischer's Exact Test (Tables 3 and 4). The CTL frequency (CTLt; expressed as the number of 
CTL per 106 cells) and the 95% confidence interval (CI) were calculated by the Jackknife procedure 
for maximum likelihood. 16 The calculated frequencies were accepted when the goodness-of-fit did not 
exceeded 12. The significance of differences between the patient groups was analyzed with the 
Mann-Whitney U-test. 
Results 
GIL with donor-specific HLA class I and class /I cn 
We studied from 89 patients 531 GIL cultures propagated from acute rejection and 
non-rejection EMB, and analyzed per patient (Table 3) and per culture (Table 4) the 
cytotoxic reactivity for donor HLA class I and class II antigens. Moreover, we 
investigated whether this cytotoxicity was discriminating for GVD. There was no 
difference in non-donor-specific cytotoxicity, donor HLA class I or class II, or both 
donor HLA class I and II cytotoxicity of the GIL cultures between the patients with 
and without GVD, neither when the cytotoxic reactivity per patient was analyzed 
(Table 3A) nor when ali cultures together were analyzed (Table 4A). The cytotoxic 
capacity during acute rejection episodes was not discriminating for GVD 
development (Tables 3B and 4B). 
The frequency of ccn for donor HLA class I and their avidity for class I antigens 
We determined the frequency of cCTL and the fraction of high-avidity cCTL specific 
for donor class I antigens in 5 cultures from patients with GVD and 5 cultures from 
patients without GVD. Since we found previously that acute rejection correlated with 
an increased number of high-avidity CTL for donor HLA class I antigens,'·' we only 
analyzed cultures derived from non-rejection EMB. 
The cCTLf reactive to target celis expressing donor HLA class I antigens was not 
different between the two patient groups (Table 5). When anti-COB MoAb were 
added during the CML phase also no difference in cCTLf was found (Table 5). 
Looking at the avidity of the cCTL, we demonstrated that most cultures during the 
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first year after HTx predominantly consisted of cCTL with low avidity for donor HLA 
class I antigens, irrespective of GVD development at one year after transplantation 
(Figure 1A). 
The cCTL did not lyse third party PHA blasts or B-LCL and the K562 cell line. 
Therefore we conclude that the cytotoxic capacity was donor-specific. 
Table 3 Donor-specific cytotoxic characteristics analyzed per patient of graft-infiltrating 
lymphocyte cultures from patients with and without graft vascular disease (GVO) 
during the first year after transplantation. 
A. Non-rejection endomyocardial biopsies (EMS) 
no. of patients 
no. of patients of whom none of the cultures 
were cytotoxic for donor antigen 
donor HLA class I cytotoxicity 
donor HLA class II cytotoxicity 
both donor H LA class I and II cytotoxicity 
B. Acute rejection EMS 
no. of patients 
no. of patients of whom none of the cultures 
were cytotoxic for donor antigen 
donor HLA class I cytotoxicity 
donor HLA crass II cytotoxicity 
both donor HLA class I and II cytotoxicity 
without GVD 
71 
4 
65/67' 
57/67 
55/67 
without GVD 
37 
5 
31/32 
24/32 
23/32 
"number of patients with at least one culture with cytotoxicity 
with GVD 
18 
o 
18/18 
14/18 
14/18 
with GVD 
10 
919 
5/9 
4/9 
The cCTL frequency of donor HLA class" and their avidity for class" antigens 
The cCTLf and the fraction of high-avidity cCTL for donor class II antigens were 
measured in 9 patients with GVD and 5 patients without GVD. Acute rejection was 
already found to be associated with high-avidity CTL for donor HLA class II antigens 
in a previous stUdy.' Therefore we only determined GIL cultures derived from non-
rejection EMS. 
In patients who did not develop GVD at one year after transplantation the cCTLf with 
donor class II specificity was significantly higher than the frequency in the patients 
who had GVD (Table 6). Also, in the presence of anti-CD4 MoAb significant higher 
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frequencies were found in patients without GVD (Table 6). The percentage cells with 
high avidity in the cultures for donor HLA class II antigens was comparable between 
the patient groups (P=0.19) (Figure 1 B). 
Remarkable was the higher frequency of cCTl directed against donor HlA class II 
antigens compared with those cCTl directed against donor HlA class I antigens in 
patients who remained free from GVD (P=0.1 0) (Tables 5 and 6). 
Tahle 4 Donor-specific cytotoxicity analyzed per graft-infiltrating lymphocyte culture from 
patients with and without graft vascular disease (GVO) during the first year after 
transplantation. 
A. Non-rejection endomyocardial biopsies (EMS) 
no. of cultures tested 
no. of cultures which were not cytotoxic 
donor HLA class I cytotoxicity 
donor HLA class II cytotoxicity 
both donor HLA class I and II cytotoxicity 
B. Acute rejection EMS 
no. of cultures tested 
no. of cultures which were not cytotoxic 
donor HLA class I cytotoxicity 
donor HLA class II cytotoxicity 
both donor HLA class I and II Cytotoxicity 
Discussion 
without GVO 
365 
88 
250/277 
158/277 
128/277 
without GVD 
57 
5 
46/52 
34/52 
30/52 
with GVD 
94 
18 
70176 
43/76 
35/76 
with GVD 
15 
3 
11/12 
5112 
4/12 
Chronic rejection is a frequently encountered complication after organ 
transplantation. The pathogenesis of GVD is still unknown. However, as the vascular 
lesions develop in donor vessels and remain absent in recipient vessels, allogeneic 
immune processes may be involved in the pathogenesis of GVD. In the search for 
immunological parameters, we found no relation between GVD and the number of 
acute rejection periods, preoperative reactive antibodies against a panel of 
lymphocytes, number of HLA mismatches, in vitro growth or phenotypic composition 
of Gil derived from EMB.14,,, We found, however, that certain characteristics of 
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donor-specific T-helper cells are associated with the occurrence of GVD. Both IL-2 
mRNA expression in EMB" and production of high levels of T-helper 1 cytokines (IL-
2 and IFN-Yl by GIL derived from EMB' were especially found in patients with GVD. 
In the present report we investigated the possible link between GVD and the 
frequency or nature of CTL propagated from GIL. 
Table 5 Frequencies of donor-specific cCTL with their percentage of COB inhibition in graft-
infiltrating lymphocyte cultures from patients with or without graft vascular disease 
(GVD). 
patient without anti-COB with anti-CDS inhibition 
cCTLf 95% CI cCTLf 95% CI (%) 
without GVD 
AN 604 458-750 218 147-288 64 
BE 153 72-234 0.00 0-0 100 
BN 1671 1239-2104 721 540-901 57 
HO 200 130-270 58 24-92 71 
KU 130 78-181 88 46-130 32 
with GVD 
LI 8267 6338-10197 3277 2579-3976 60 
SA 630 437-823 600 418-783 5 
WI 222 156-287 80 40-120 64 
WL 1207 798-1616 382 280-484 68 
ZE 28 5-50 0,00 0-0 100 
First, we studied whether the presence of donor-directed CTL within the transplanted 
heart is associated with GVD. We found that the frequency of the GIL cultures lytic to 
donor HLA class I and class II antigens does not discriminate patients with GVD from 
patients who remain free from GVD in the first year after transplantation. 
Secondly, we analyzed 19 cultures from 10 patients with GVD and S patients without 
signs of GVD in more detail. We found no differences in phenotype of the GIL 
cultures between patients with and without GVD. This confirms our previous study, 
which also showed that the phenotypic composition of the cultures does not correlate 
with GVD." The EMB-derived cultures consisted of a mixture of CDS and/or CD4-
resistant and -susceptible donor-reactive CTL. During the first year after HTx, the 
frequency of donor-specific HLA class I cCTL did not differentiate the patients with 
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GVD from those without GVD. The same was true when the cytotoxicity was studied 
in the presence of CDB MoAb. The cultures contained predominantly cCTL with low 
avidity for donor HLA class I antigens, irrespective of the development of GVD at one 
year after HTx. During the first post-operative year, the frequency of cCTL to HLA 
class II donor antigens was found to be significantly higher in patients who remained 
free from GVD than in patients with angiographic signs of GVD at one year after 
transplantation. The fraction cCTL with high avidity for donor HLA class II antigens in 
the GIL cultures was comparable between these patient groups. 
Table 6 
patient 
BN 
BR 
BU 
KU 
MO 
BO 
DA 
FR 
JA 
LI 
VE 
WI 
WL 
ZE 
Frequencies of donor-specific ceTl with their percentage of CD4 inhibition in graft-
infiltrating lymphocyte cultures from patients with or without graft vascular disease 
(GVD). 
without anti-CD4 with anti-CD4 inhibition 
cCTLf 95% CI cCTLf 95% CI (%) 
without GVD 
335" 243-427 420b 318-523 0 
1519 1138-1901 649 436-862 43 
5266 3775-6756 731 527-934 86 
3928 3006-4849 5375 4149-6602 0 
818 563-1073 229 157-301 70 
with GVD 
174 115-233 56 25-87 68 
783 590-976 36 7-65 95 
208 138-279 134 80-187 36 
627 436-818 175 110-241 72 
138 84-192 30 4-56 78 
818 622-1014 422 319-524 48 
95 51-139 0 0-0 100 
941 709-1174 620 471-769 34 
320 218-423 19 0-39 94 
scCTLf obtained in the absence of CD4 of patients without GVD compared to those of with GVD 
(P=0.02) 
bcCTLf obtained in the presence of CD4 of patients without GVD compared to those of with GVD 
(P=0.01) 
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These data suggest that a high frequency of donor HLA class II-directed cCTL 
protects for GVD. As a possible explanation for this phenomenon, we suggest the 
following model. Shortly after transplantation, MHC class II antigens are 
predominantly expressed on the vascular wall of donor origin" due to tissue damage 
as the result of ischemia and reperfusion. 2O•21 Macrophages infiltrate the graft (GIL) 
and release cytokines to their microenvironment. These cytokines cause an 
upregulation on donor cells of donor HLA class I and class II antigens and 
expression of lymphocyte binding ligands (intercellular adhesion molecule (lCAM), 
vascular cell adhesion molecule (VCAM), etc.) in the graft. The permeability of the 
microvessels increases and donor-specific activated mononuclear cells 
(macrophages and lymphocytes) enter the graft. Subsequently, in patients who 
remain free from GVD, alia-activated cCTL specific for donor HLA class II antigens 
accumulate at sites with activated donor cells. Thereafter donor cells with HLA class 
II antigens on their surface, which are responsible for the development of GVD 
(endothelial cells and smooth muscle cells), are killed, thereby preventing the 
generation of GVD. At the same time the frequency of cCTL specific for donor HLA 
class I antigens is still too low to be cytotoxic. Previously, our research group 
demonstrated that cCTL from GIL are able to lyse donor endothelial cells." 
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Figure 1 The fraction of graft-infiltrating lymphocyte cultures propagated from endomyocardial 
biopsies taken during the first pre-operative year from patients with and without graft 
vascular disease (GVD) at one year after transplantation having a high avidity for 
donor HLA class I (A) and class II (8) antigens. 
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We have also reported a high production of l-helper 1 cytokines by Gil derived from 
patients with GVD in the first year after Hlx compared to those from patients without 
GVD' This consequently results in an up-regulation of HlA class I and class II 
antigens on vascular endothelial cells of patients with GVD.23 In case of GVD, the 
frequency of both the donor-directed HlA class I and class II cell is apparently too 
low to lyse the activated vascular wall cells and the characteristic process of GVD 
development continues: the activated endothelial cells and mononuclear cells 
secrete growth factors, which promote proliferation of smooth muscle cells, ultimately 
leading to intima thickening. 
Dong et al. 24 demonstrated that indeed endothelial cell damage was less evident in 
the vessels with greater intimal disease severity, probably by a decreased number of 
HlA class II specific elL. In future, our proposed model for GVD has to be 
confirmed by an investigation of growth factor production by vascular cells in the 
presence of ell from patients with and without GVD. 
In conclusion, cell that infiltrate the human cardiac allograft could playa role in the 
development of GVD. Especially the high frequency of donor-specific cell for HlA 
class II antigens seems to be a protective factor in the development of GVD. 
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Abstract 
Background: Monitoring for the responses to alloantigens presented either by the 
direct or the indirect presentation pathway have been reported to be of clinical value 
after kidney transplantation. Amongst others the level of these responses may be 
dependent on the immunosuppressive treatment. 
Methods: We studied these pathways in peripheral blood mononuclear cells (PBMC) 
of cardiac transplant patients in an attempt to find a correlation between these tests 
and the clinical status of the patients. 
Results: Both before and after transplantation, comparable proportions of PBMC 
samples reacted in MLC (mixed lymphocyte cultures) to nondepleted donor spleen 
cells (direct route), but never to donor cells depleted for antigen-presenting cells 
(indirect route). In contrast, the latter route could easily be activated by a nominal 
antigen (tetanus toxoid (TET)) and persisted after transplantation. After 
transplantation the proportion of PBMC samples responding to TET was significantly 
suppressed, irrespective of the occurrence of rejection. Nevertheless, analyzing the 
level of PBMC reactivity, both the immune responses via the direct and indirect 
presentation route increased when cyclosporine A (CsA) levels inadvertently 
decreased to inadequate concentrations and acute rejection was diagnosed. During 
immunological quiescence high and low responders could be detected to both the 
direct and indirect pathway, while graft vascular disease (GVD) was only positively 
correlated with a higher PBMC reactivity to indirect presented TET antigens. 
Conclusion: The level of PBMC reactivity via both the direct and indirect presentation 
pathway is correlated with acute rejection early after transplantation, while only the 
indirect pathway was associated with GVD. These tests might be used as a tool for 
selecting patients in which tapering of immunosuppresion can safely be performed. 
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Introduction 
Alloantigens can only stimulate T-cells via antigen-presenting cells (APC). T-cells 
require two signals of the APC to become activated. An antigen specific signal is 
provided by the antigen peptide in context with major histocompatibility complex 
(MHC) molecules present on the cell surface of the APC and interacting with the T-
cell receptor of the corresponding T-cell. A nonspecific second signal is given by 
interaction between adhesion and costimulatory molecules on the APC and on the 
responding T-cell. In order of potency dendritic cells, macrophages, B-cells, and in 
some circumstances activated endothelial cells, T-cells, keratinocytes, fibroblasts, 
and eosinophils do have antigen-presenting capacity.'·5 After transplantation, both 
donor APC (dAPC) and recipient APC (rAPC) are available to cause an immune 
response. dAPC differ from rAPC in MHC molecules expressed on their surface 
(donor or recipient MHC) and in proteins that were dissociated from foreign peptides 
derived from pathogens in the donor. T -helper cells of the transplant recipient may 
respond to dAPC via the direct presentation pathway or to rAPC via the indirect 
presentation pathway (reviewed by Sayegh).' In case of the direct pathway, T-cells 
recognize allogeneic MHC molecules on the surface of dAPC. For the indirect 
pathway donor MHC molecules are internalized by rAPC, subsequently processed 
into peptides which are bound by recipient's MHC class I and class II molecules, and 
finally presented at the cell surface of the rAPC to self-MHC-restricted allopeptide 
specific responder cells. This last pathway is identical to the presentation of nominal 
antigens, e.g. tetanus toxoid (TET). 
In vivo, the direct alloantigen presentation pathway is thought to be responsible for 
acute rejection and the indirect pathway for chronic rejection. As a consequence of 
the gradually replacement of dAPC by rAPC,' in time less dAPC are able to stimulate 
the recipient T-cells. However, the already activated T-cells become memory T-cells 
and may be susceptible to donor cells (endothelial cells) of the graft and do not need 
professional APC (dendritic cells, macrophages, activated B-cells). Others suggest 
that human endothelial cells, that constitutively express MHC class II antigens, have 
even the ability to provide all the signals necessary for direct stimulation of resting 
allogeneic T_cells 4 .5 Thus both pathways may remain present in the long term after 
transplantation. 
In vitro, both presentation pathways were found to be able to induce an alloresponse 
by peripheral blood mononuclear cells (PBMC) of healthy volunteers' In renal 
transplant recipients with stable graft function, the direct pathway was not different 
from that of healthy donors, whereas these patients showed no response to 
alloantigens presented via the indirect pathway. When the latter reactivity was 
detected, a correlation with acute or chronic rejection was reported.'·10 In addition, it 
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has been suggested that the indirect pathway is more sensitive to 
immunosuppression than the direct route of alloantigen presentation. 1O-" 
The present overview is mainly based on the manuscripts we published on 
presentation pathways,13-16 and some new results are added. We monitored the 
presence of both antigen presentation pathways in PBMC of human cardiac 
transplant recipients, by measuring the proliferative response of their cells to 
alloantigens in mixed lymphocyte cultures (MLC) and to TET. PBMC samples were 
collected longitudinally from the time of heart transplantation (HTx) to 2 years 
thereafter. In order to test whether the magnitude of the response of the PBMC to 
the different presentation pathways is dependent on the immunosuppressive load,'·" 
we also measured these responses before, during and after a moment that in vivo 
CsA (cyclosporine A) inadvertently decreased to inadequate plasma levels resulting 
in acute rejection. In addition, we wondered whether we could demonstrate 
differential PBMC reactivity to directly and indirectly presented antigens between 
patients with and without GVD (graft vascular disease). Finally, we determined the 
PBMC reactivity to the presentation routes in a period of immunological quiescence, 
in attempt to find a correlation with the immunological status of the patients and 
possibly to obtain a relevant tool to monitor the effect of tapering immunosuppression 
on the immune response. 
Materials and methods 
Patients 
All patients received one preoperative blood transfusion. Standard immunosuppressive therapy, 
consisting of GsA and low dose prednisone, was given as maintenance immunosuppression. 
Acute rejection was diagnosed histologically in endomyocardial biopsies and defined as cellular 
infiltrate with myocyte necrosis (ISHLT grade 3 or more)17 upon which anti-rejection therapy was 
instituted. 
One year after transplantation, GVD was visually assessed on coronary angiograms and defined as all 
vascular wall changes including minimal wall irregularities. 18 
PBMC sampling 
PBMC samples were isolated from heparinized blood by density gradient centrifugation using Ficoll-
Isopaque (~=1.077; Pharmacia Biotech AB, Uppsala, Sweden). The PBMC were collected from the 
interphase, washed twice with Hanks' Balanced Salt Solution (HBSS, Gibco BRl, Scotland, UK) and 
frozen at -140 cC until use. 
First, we determined the proportion of PBMC samples (n=68) from cardiac transplant recipients 
responding via the direct and indirect pathway before and after HTx. 
We selected 14 PBMC samples from 3 transplant recipients, who experienced one or more periods of 
acute rejection during the first 4 months after HTx at a moment that CsA inadvertently decreased to 
inadequate concentrations. In these samples we measured quantitatively the proliferative response to 
both presentation pathways. 
In addition, we measured the PBMC response to the presentation pathways of 5 patients with GVD 
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and 5 patients without GVD in the period 3 to 6 months, 1 year and 3 years after HTx. No histologic 
signs of acute rejection were seen in their endomyocardial biopsies taken at the same time of the 
PBMC samples. 
Finally, we determined the PBMC reactivity to the presentation routes from 5 patients at the day before 
HTx and in a period of immunological quiescence (PBMC samples (n=28) taken from approximately 4 
months tHI2 years after HTx when no acute rejection occurred). 
Donor cell sampling 
Spleen cells were obtained by mechanical dissociation of small pieces of donor spleen through a sieve 
of stainless steel in RPMI 1640-DM supplemented with 4 mM L~glutamine, 100 IUlml penicillin, 100 
!-191m I streptomycin (all from Gibco, Paisley, Scotland), and 10% pooled heat inactivated hUman AB 
serum (Le. culture medium). DNase (10 IJg/mf, Boehringer Mannheim GmbH, Germany) was added to 
prevent aggregation of cells. Subsequently the cell suspension was filtrated through a 70 fJm cell 
strainer (Falcon, Franklin Lakes, NJ) and washed. Thereafter the cells were centrifuged over a Ficoll-
Paque density gradient and stored at -140 ac. 
Proliferation tests 
To test the response to alloantigens presented via the direct or the indirect presentation route, we 
stimulated PBMC from the transplant recipient with spleen cells derived from the heart donor (direct 
route) or with donor spleen cells depleted for dAPC (indirect route). The response to TET (RIVM, 
Bilthoven, the Netherlands) served as positive control for the indirect presentation pathway. 
100 IJI of a PBMC suspension of 5x105 cells/ml in culture medium (RPM! 1640-DM supplemented with 
4 mM L-glutamine, 100 IU/ml penicillin and 10% heat inactivated human AB serum) was added in 
triplicate wells in a round-bottomed 96-well plate (Costar, Cambridge, MA) to 100 fJl (a) 5x104 irradiated 
(60 Gy) spleen cells derived from the donor; (b) 5x10' irradiated (60 Gy) dAPC depleted spleen cells; 
(c) TET at 7.5 Itlml final concentration; (d) phytohemagglutinin M (PHA, 1:100 final dilution; Difco 
Laboratories, Detroit, MI) to control the responsiveness of the cells; and (e) culture medium. To 
measure differences between patients with and without GVD, we stimulated the PBMC with Epstein 
Barr Virus transformed B-cell lines of donor origin (100 IJI 5x103 irradiated (30 Gy) donor B-cells) to 
determine the response of PBMC via the direct presentation pathway. After 6 days of incubation at 37 
°C in a humidified atmosphere of 5% CO2 in air, cell proliferation was measured by incorporation of 3H_ 
thymidine (0.5 fJCi/well) added during the last 8 hours of culture. The mean counts per minute (cpm) 
were determined and expressed as the stimulation index (SI). The SI is the ratio of the cpm obtained in 
the presence of antigen to the cpm obtained in the absence of antigen. Cell proliferation was 
considered significant when the SI was higher than 2. 
Ape-depletion 
To remove all dAPC, 107 donor spleen cells (in 3.5 ml) were incubated with 125 IJI of anti-CD14 
(monocytes/macrophages; MY4, Coulter Immunology, Hialeah, FL), 75 fJl of anti-CD19 (B-cells; Leu-
12, Becton Dickinson, San Jose, CAl and 75 fJl of anti-HLA-DR (dendritic cells; Becton Dickinson) in 
HBSS and 1 % pooled heat inactivated human AB serum. After an incubation period of gentle shaking 
for 30 minutes at 4 ac, the cells were washed in HBSS. Thereafter the cells were incubated with 210 1-11 
washed Dynabeads (M-450 sheep anti-mouse IgG, Dynal, Oslo, Norway) for 30 minutes of gentle 
shaking at 4°C. Subsequently, the dAPC were retained by a magnet and the nonadherent cells were 
transported to another tube. This depletion procedure was repeated twice before the non adherent cells 
were processed further. The APC-depleted cells were washed with HBSS and were counted with 
trypan blue to determine the vitality before testing. 
HTL-frequency 
The frequency of IL-2 producing T-helper lymphocytes (HTL) was determined using the limiting dilution 
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analysis assay (slightly modified) of Schanz et al. 19 In brief, 24 replicates of graded number PBMC 
responder cells were titrated in a four-step double dilutions starting from 5x104 to 6250 ceil/weI! and 
stimulated with 5x104 irradiated (30 Gy) spleen cells depleted or not depleted for APe. After 3 days of 
culture, 100 fJl of the culture supernatant were harvested to test for IL-2 in a bioassay using the IL-2 
dependent CTLL-2 eel! line as indicator system. 
GsA levels 
GsA trough levels were measured in plasma using a RIA with 1251_labeled GsA and esA-specific 
monoclonal antibodies (Cyclo-Trac SP; Incstar, Stillwater MN, USA). GsA plasma levels were 
maintained at therapeutic concentrations of 100-150 ng/ml after transplantation. Levels below 100 
ng/ml were considered inadequate. 
Results 
Efficiency of APC-depletion 
We have checked for the efficiency of APC-depletion by FACS-analysis and by 
performing two-way MLC with two depleted stimulator populations. After depletion 
0% CD14 positive, <1% CD19 positive and <1% HLA-DR positive cells were 
detected by analysis on FACS and in none of the cases a response was found in the 
two-way MLC (stimulation index (SI) $2). 
Discrepancy between stimulation of PBMC with APC depleted cells and TET 
The results of capability of 68 PBMC samples to react via the direct or the indirect 
pathway in MLC are shown in Table 1. Most PBMC samples taken before HTx 
reacted to both nondepleted donor spleen cells (88%) and TET (75%), but never to 
spleen cells depleted for dAPC. Similarly after HTx, 75% (45/60) of the PBMC 
samples did respond to spleen cells not depleted for dAPC, but not to the depleted 
population, independent of time after transplantation or occurrence of acute 
rejection. 
In contrast, the response to TET changed both after HTx compared with before HTx, 
and during the posttransplantation follow-up period. During the first year after HTx 
only 13% (6/47) of the PBMC samples reacted to TET, which is significantly less 
than before HTx (P<0.001). During rejection and nonrejection episodes, no 
significant difference in the TET response was observed (P=0.33). Also, no 
difference between the first and the second year after HTx was found with regard to 
the TET response of samples taken during rejection. In contrast, in periods without 
rejection, a trend was observed in time after HTx, i.e. the TET response was more 
frequently present during the second year (27%) compared with the first year (9%) 
after transplantation (P=0.15). 
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Frequencies of IL-2 producing helper T-Iymphocytes (HTL) 
We tested the frequency of HTL of 4 pre HTx samples, because the highest 
responses were expected at that point in time.' All PBMC reacted clearly to their 
nondepleted donor cell population (57, 33, 77, and 56 HTLl10' cells), while 
responses after APC depletion were nondetectable or very low (6, 0, 17, and 0 
HTL/10' cells, respectively). 
Table 1 Proliferative responses of PBMC samples pre and post heart transplantation (HTx) to 
directly and indirectly presented donor antigens and indirectly presented tetanus toxoid 
(TET) antigens.' 
pre-HTx First year post-HTx Second year post-HTx 
Stimulator' No rejection Rejection No rejection Rejection 
directly presented 71B 2S134 9/13 9/11 212 
donor antigens 
indirectly presented 0/8° O/34d 0113' 0111' 012 
donor antigens 
indirectly presented 61B 3/34e.l 3/13".1 3/11 e,f,Q 112' 
TET antigens 
aData are presented as number of samples responding (stimulation index >2) per number of samples 
tested. 
bThe mean response of spleen cells not depleted for APe: 7,320 cpm (range, 170-44,719). Mean cpm 
without stimulus: 130 (range, 26~497). Mean response of TET: 1,928 cpm (range, 142-6,870). 
c.dResponse to nondepleted versus depleted spleen cells before (P=O.001)C and after HTx (P<0.001)d 
(two sided p-value: Fisher's exact test with Yates' correction). 
"Response to nondepleted spleen cells versus TET during the first year after HTx in periods without 
(P<O.001) and with (P=O.05) rejection, and during the second year post HTx in periods without 
rejection (P=0.03). 
ITET response before HTx versus TET response in the first year after HTx in non rejection episodes 
(P<0.001) or in rejection episodes (P=O.03). 
QTET response in the first year after HTx versus the second year after HTx during non rejection 
(P=0.1S) and rejection (P=O.4B) episodes. 
Acute rejection due to inadequate GsA levels in relation to antigen presentation 
pathways 
Patient 1 (Figure 1A) experienced a rejection episode on day 75 after HTx. On this 
day a decrease in the level of CsA (86 ng/ml CsA) was found compared with the 
sample taken at day 40 (135 ng/ml CsA). At the same time the response to donor 
antigens mediated by the direct presentation pathway, increased from SI 1.4 (day 
40) to 13 (day 75). The response to the indirect presented TET antigens was 
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undetectable (SI<2), this in contrast to the situation before HTx (SI=11). After anti-
rejection therapy with steroids and increasing the dose of CsA, the response via the 
direct presentation route slowly decreased to a SI of 4.3 at day 97 when GsA 
reached the therapeutic level of 155 ng/ml. 
Patient 2 (Figure 18) had two successive biopsies with histological signs of acute 
rejection, on day 44 and day 51 after HTx. At both time points the GsA plasma levels, 
43 and 88 ng/ml GsA, respectively, proved to be inadequate low with respect to the 
level at day 37 (175 ng/ml GsA). After treatment with steroids and adjusting the GsA 
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dose on day 44, only a small increase in the GsA plasma level was detected on day 
51 (88 nglml GsA), while the PBMG strongly responded to directly (SI=39) but not to 
indirectly (SI=0.7) presented TET antigens. A second anti-rejection therapy with 
rabbit anti-thymocyte globulin and a higher dose of GsA proved to be necessary. 
Thereafter, at day 100, the GsA concentrations in plasma reached normal 
therapeutic levels (135 nglml GsA), the response via the direct pathway became 
undetectable (SI=1.6) and no histological signs of rejection were found anymore. 
Patient 3 (Figure 1 G) experienced the first rejection period 66 days after HT x, again 
during a drop in GsA concentration in plasma (89 nglml GsA), while 12 days before a 
high reactivity of PBMG to directly presented donor antigens had been found (SI=21) 
and the indirect pathway was undetectable (SI=0.6). After anti-rejection treatment 
with steroids and increasing the GsA dose to reach a plasma level of 180 nglml GsA 
at day 75, the response via the direct pathway decreased to a SI of 1.8. On day 117 
after transplantation a second rejection episode was observed, accompanied by 
another fall in the GsA level in plasma (64 nglml GsA) in combination with an 
increment of the response via the indirectly presented TET antigens (SI=6.9). In 
contrast to the fitst rejection episode, the response via the direct pathway remained 
low (SI=3.1). After anti-rejection therapy with steroids and an increased dose of GsA, 
the GsA levels normalized to therapeutic concentrations (145 nglml GsA) at day 124 
and a reduction of the response of PBMG to the indirect pathway was found (SI=1.4). 
Graft vascular disease and antigen-presentation routes 
All PBMG samples of both patients with and without GVD reacted via the direct 
presentation pathway. However, not all PBMG samples reacted in a significant way 
via the indirect presentation route: 3 to 6 months after HTx, 3/5 patients with GVD 
and 1/5 patient without GVD; 1 year after HTx, 2/5 with GVD and 2/5 without GVD, 
and at 3 years after HTx 5/5 with GVD and 2/5 without GVD reacted to TET. 
At 3 to 6 months, 1 year and 3 years after HTx, we neither found differences in the 
magnitude of the PBMG response to proliferate via direct presented donor antigens 
(Table 2A) between patients with and without GVD. In contrast, we found a relation 
with GVD and the indirect presentation pathway. Before (3 to 6 months after HTx) 
and after (3 years after HTx) the assessment of GVD at one year after HTx, the 
PBMG reactivity to TET was higher in patients with GVD compared to those who 
remained free from GVD (Table 2B). 
Antigen-presentation pathways during immunological quiescence 
During the second year after HTx, the PBMG response of patient 1 to both the direct 
presented donor antigens and indirect presented TET antigens increased compared 
to the PBMG reactivity before HTx (day 0) (Figure 2A). The PBMG reactivity of 
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patient 2 was only vigorous to the direct pathway (Figure 2B). The PBMC response 
of patient 3, 4 and 5 (Figure 2C, 20, 2E) remained stable or even decreased to both 
pathways compared to the response before HTx. 
Table 2 
A 
B 
GVD-
GVD+ 
GVD-
GVD+ 
Proliferative responses of PBMC samples from patients with (n=5) and without (n=5) 
graft vascular disease (GVO) to directly presented donor antigens (A) and to indirectly 
presented tetanus toxoid (TET) antigens (8). 
3-6 months 1 year 3 years 
post-HTx post-HTx post-HTx 
82 (18-128)" 172 (27-559) 149 (60-1510) 
36 (7-73) 141 (7-670) 58 (8-352) 
3-6 months 1 year 3 years 
post-HTx post-HTx post-HTx 
0.7 (0.4-2.8)' 1.3 (0.6-5.2) 1.6 (0.7-9.4) 
6.2 (1.3-39)' 1.0 (0.7-14) 24 (2.5-143)' 
"Data are presented as the median 81 with the range in parentheses. 
1,2TET response of patients with GVD compared to those without GVD (P=O.03 1, P=O.062; two-sided P-
value: Mann-Whitney U test) 
Discussion 
To investigate the clinical relevance of the allogeneic activation pathways after HTx, 
PBMC were stimulated with donor spleen cells not depleted for dAPC (direct 
pathway) or depleted for dAPC (indirect pathway) in MLC or were stimulated with 
TET antigens (indirect pathway). Most PBMC samples taken before HTx reacted to 
both nondepleted donor spleen cells and TET, but never to spleen cells depleted for 
dAPC. Similarly after HTx, only responses via the indirect presentation pathway to 
TET antigens were found and not to dAPC depleted spleen cells. In contrast to 
Shearer's group,'·" who found comparable positive responses both to indirectly 
presented nominal antigens and indirectly presented alloantigens in PBMC from 
kidney transplant recipients and healthy controls, we did not find any indirect 
response to alloantigens. Our results were confirmed by an unpublished study of 
PBMC from healthy persons, which did not react to an APC depleted stimulator 
population in MLC, while positive responses were found after stimulation with TET 
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tetanus toxoid (TET) antigens (III) in an immunological quiescence period after heart 
transplantation (HTx). 
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(F.H.J. Claas, Immunohematology and Blood 
communication, 1995). Although, the present study 
Bank, Leiden, personal 
was different from that of 
Shearer's group with respect to the organ transplanted and the immunosuppressive 
regimen, we think that the different results are due to the different methods used for 
APC depletion. Depletion of APC by plastic and nylon wool adherence'·11 may be 
incomplete, resulting in responses to suboptimal concentrations of dAPC, while the 
response was ascribed to alloantigens indirectly presented by rAPC. Dendritic cells 
are known as very potent APC, inducing MLC responses at low stimulator to 
responder ratios (1 dendritic cell to 1000 T-cells).20 Accordingly, a slight 
contamination of the stimulator population with dendritic cells can already induce T-
cell proliferation in a MLC. The reported correlation of dAPC depleted MLC 
responses with clinical events may rather be associated with the presence of a few 
remaining dAPC in the tests than with the measurement of the indirect presentation 
route. From the present study, it is clear that no responses to alloantigens in MLC 
can occur in the absence of dAPC. 
An explanation for the positive responses of PBMC to the nondepleted cells and the 
negative responses of PBMC to the dAPC depleted population, however, remains 
that the direct presentation pathway is responsible for the strong proliferative 
responses seen in vitro by a high frequency of T-cell precursors responding to 
allogeneic MHC molecules." The MLC used may not be sensitive enough for a 
detectable response to alloantigens presented via the indirect pathway to antigen 
specific T-cells. This was also reported by Watschinger et al.," who indicated that T-
cells primed in vivo by a vascularized cardiac allograft are able to proliferate in vitro 
to specific peptides but only when presented by APC, which were pre incubated with 
the allopeptide. Therefore, we used a limiting dilution analysis assay to determine the 
HTL frequencies. This assay is thought to be more sensitive than MLC to measure 
responses to directly and indirectly presented antigens. We tested pre HTx samples, 
because the highest responses were expected at that point in time.' All PBMC 
clearly reacted to their nondepleted donor cell population, while responses after APC 
depletion were nondetectable or very low. However, interference of backward 
stimulation (i.e. IL-2 production of stimulator spleen celis in response to PBMC), as 
described by Schanz et al. 19 could have played a role in case of low HTL responses. 
To avoid backward stimulation, in general B-celilines are used as stimulator cells in 
the HTL assay. However, these cell lines are not relevant for monitoring the indirect 
alioantigen presentation pathway, since they are excellent direct stimulators. 
Accordingly, as in the case with the MLC, the HTL assay with the APC-depleted cells 
as stimulator can not reliably be used to measure responses of PBMC to indirectly 
presented alloantigens. 
Before transplantation comparable proportions of PBMC samples reacted via the 
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direct and the indirect route of presentation. After transplantation qualitative 
responses via the direct pathway (75%) were more frequently found than via the 
indirect pathway (13%), suggesting that GsA mainly affects the indirect route. In 
order to test whether the magnitude of the response of the PBMG to the different 
presentation pathways is dependent on the immunosuppressive load,"" we 
measured these responses in a quantitative way before, during and after a moment 
that in vivo GsA inadvertently decreased to inadequate plasma levels resulting in 
acute rejection. During only one of these rejection episodes the indirect antigen 
presentation pathway was functional, while during the other 3 rejection periods only 
the direct pathway was found to be intact. This finding is consistent with data 
described by Muluk et ai., 10 who showed that the indirect presentation pathwa~ is 
more susceptible to GsA therapy than the direct pathway. In agreement with these 
results, Glerici et al." demonstrated that in vitro exposure of GsA to stimulated 
PBMG suppressed the indirect presentation pathway more strongly than the direct 
presentation pathway. Also Gallon et al. 12 confirmed that GsA inhibits proliferation of 
in vivo-primed T-cells to indirectly presented MHG peptides.While others suggested 
that only the indirect presentation pathway correlates with acute rejection, 
independently of the direct pathway,lO·11 we conclude from our data that acute 
rejection after clinical cardiac transplantation in the presence of inadequate GsA 
levels may be accompanied by an increase of the responses of PBMG both via 
directly and indirectly presented donor antigens. Therefore, we assume that after 
clinical heart transplantation GsA may prevent rejection by blocking both the direct 
and indirect presentation route. 
We found a relation with GVD and the indirect, but not the direct presentation 
pathway. Before (3 to 6 months after HTx) and after (3 years after HTx) the 
assessment of GVD at one year after HTx, the PBMG reactivity to TET was higher in 
patients with GVD compared to those who remained free from GVD. Our data are in 
conflict with those from Reinsmoen et al.,23 who found a relation between MLG 
donor-responsiveness (direct presentation) in the peripheral blood and chronic 
rejection in kidney, lung and heart transplant recipients. Others found a relation 
between the presence of the indirect presentation pathway and chronic rejection in 
kidney, lung and hearts aliografts. lO·24 We also conclude from our data that the direct 
presentation pathway does not predict GVD, while the indirect pathway appeared to 
correlate with GVD after HTx. 
In the second year after HTx, the PBMG reactivity to indirectly presented TET 
antigens tends to normalize, possibly as a consequence of the reduction in 
immunosuppressive load given to the patient. To investigate these late PBMG 
response in more detail, we studied the PBMG reactivity to both presentation routes 
in a period of immunological quiescence (4 months to 2 years after HTx). The 
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response of 3 out of 5 patients (60%) to donor antigens presented by the direct 
pathway or TET antigens presented by the indirect pathway decreased compared to 
the day of transplantation. This high percentages of hyporesponsiveness was also 
described one year after human cadaver kidney transplantation,25.26 while Reinsmoen 
et aL 27 demonstrated hyporeactivity in only 15% of cadaver kidney transplants and 
36% of the living related transplants. This low percentage may be explained by the 
usage of homozygous typing cells as stimulator instead of donor cells in MLC. We 
think it would be reasonable to postulate that patients whose PBMC showed a 
hyporeactivity against both direct presented donor antigens and indirect presented 
TET antigens could have their immunosuppression reduced or even withdrawn. In 
patients with high responses it is probably unwise to taper their immunosuppressive 
schedule. Efforts should be undertaken in these patients to suppress these 
responses by changing their immunosuppressive protocol in attempt to prevent 
chronic rejection. Therefore, the assessment of presentation routes may be useful to 
individualize the maintenance of immunosuppressive therapy. 
In conclusion, monitoring the direct and indirect presentation routes could be relevant 
tools to define the immunological status of transplant recipients. 
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Abstract 
Cellular mechanisms may playa role in the development of graft vascular disease 
(GVD). We previously demonstrated that GVD correlates with parameters measured 
in graft-infiltrating lymphocytes. 
In the present report, we investigated whether there is a correlation between the 
development of GVD and the frequency of donor-specific helper T-Iymphocyte 
precursors (pHTL) and cytotoxic T -lymphocyte precursors (pCTL) in peripheral blood 
mononuclear cells (PBMC). We tested PBMC samples of 5 patients with GVD and 5 
patients without GVD in the periods 3 to 6 months, 1 year and 3 years after heart 
transplantation (HTx). At all time points, GVD was not related to the number of pHTL 
and pCTL. 
In conclusion, donor-specific cellular tests in peripheral blood could not be related to 
GVD. Apparently, donor-specific reactions associated with the induction of GVD can 
only be monitored in the graft. 
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Introduction 
While the morphology of GVD (graft vascular disease) is well recognized, the 
mechanisms leading to GVD are still largely unknown. Both immunological and non-
immunological factors may playa role in the development of GVD. We focused on 
donor-specific cellular test systems both intragraft and in peripheral blood in an 
attempt to find associations with GVD. 
In a previous study, we demonstrated that increased T-helper 1 cytokine (lL-2 and 
IFN-y) production by donor-stimulated graft-infiltrating lymphocyte cultures derived 
from endomyocardial biopsies taken within the first postoperative year is associated 
with GVD diagnosed at one year after heart transplantation (HTx).' These T-helper 1 
cytokines give help to the differentiation and maturation of cytotoxic T-Iymphocytes 
(CTL). In the infiltrating cells, GVD could also be related to the frequency of CTL.' 
Because functional tests in the graft, necessitating culturing graft-infiltrating 
lymphocytes, are invasive and time-consuming, we performed experiments in 
peripheral blood. In heart transplant patients, high responses of increased numbers 
of helper T-Iymphocytes (HTL) have been reported in relation to acute rejection.' The 
relationship between HTL in peripheral blood and GVD is unknown. Several studies 
have demonstrated that a reduction in circulating HTL and/or CTL is associated with 
stable engraftment after kidney, liver and heart transplantation"6 Therefore, we 
wondered whether the frequency of HTL and CTL in PBMC (peripheral blood 
mononuclear cells) might also reflect an unstable situation as GVD. We stimUlated 
the PBMC with donor cells to determine the total pool of CTL in peripheral blood. 
Because circulating HTL and CTL are predominantly precursors cells and not their 
mature committed cells,' we considered the measured number of HTL and CTL as 
HTL precursors (pHTL) and CTL precursors (pCTL) and related their frequency to 
the development GVD. 
Materials and methods 
Patients 
We tested a total number of 15 PBMC samples from 5 patients with GVD and 5 patients without GVD 
in the period 3 to 6 months, 1 year and 3 years after HTx. All samples were taken at the day an 
endomyocardial biopsy was performed. To avoid bias of acute rejection, only those blood samples 
were analyzed that had no histological signs of myocytolysis in their accompanying biopsy. 
All patients received standard immunosuppressive therapy, conSisting of cyc!osporin A (GsA) and low 
dose prednisone. One year after HTx, GVD was visually assessed on coronary angiograms by one of 
us (A.H.M.M.B.) and defined as all vascular wall changes including minimal wall irregularities. s 
HTL- and CTL-assay 
Responder PBMC were isolated from heparinized blood by density gradient centrifugation using Ficoll-
Isopaque. PBMC were stimulated with phytohemagglutinin M (PHA; 1:100 final dilution; Difco 
Laboratories, Detroit, MI) to control the viability of the cells. 
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The frequency of IL-2 producing T-helper lymphocytes (HTL) was determined using the limiting dilution 
analysis assay described by Schanz et al.9 with minor modifications. 
Limiting dilution cultures were set up in 96-well U-bottom tissue culture plates (Costar, Cambridge, 
Mass.). 24 replicates of graded number PBMC responders were titrated in 7-step double dilutions 
starting from 2.Sx104 to 391 PBMC/weli and stimulated with an irradiated (30 Gy) and washed Epstein 
Barr transformed 8-cellline (B-LCL) of donor origin (5x103 cells/well) in 200 1-11 culture medium (RPMI-
1640 DM (Life Technology, Paisley, Scotland) supplemented with 10% pooled human heat-inactivated 
serum, 4 mM L-glutamine, 100 IU/ml penicillin and 100 I-Ig/ml streptomycin). 
After 3 days of culture, 1001-11 of the supernatant was harvested to test for IL-2 in a bio-assay using the 
lL-2-dependent CTLL-2 cel! line as indicator system. HTL-frequency (HTLf) was determined as 
described by Strijbosch et a1. 10 
The remaining cells were refreshed with 100 1-11 culture medium containing 40 U/ml recombinant Il-2 
(final concentration 20 U/ml IL-2) (Biotest AG, Dreieich, Germany). After another 7 days of culture, we 
performed a cell mediated Iympholysis. Each well was tested for cytolytic activity against 2.5x1 03 51Cr_ 
labelled T-cell blasts of donor origin. These T-cell blasts can only be used as HLA class I target, and 
not as HLA class II target. 11 After 4 hours of incubation at 37 DC in 5% CO2 the supernatants were 
harvested (Skatron harvesting system: Skatron-AS, Lierse, Norway) and the release of 51Cr was 
determined in a v-counter (Packard Instruments, Downers Grove, Il, USA). Maximum and 
spontaneous release were determined in 4-fold and defined by incubation of target cells with culture 
medium in the presence and absence of Triton X-1 00 (5%, vlv 4-fold in TRIS buffer), respectively. 
The percentage of lysis was calculated according to the formula: 
experimental release - spontaneous release 
%lysis = 100% x -----------------------------------------------.-----._._. 
maximal release - spontaneous release 
The microcultures were considered cytolytic when the percentage lysis exceeded 10%. 
Results 
All PBMC samples reacted to donor cells in the HTL-assay. The pHTLf fluctuated per 
patient in time after HTx. At 3 to 6 months, 1 year and 3 years after HTx, no 
differences were found in the pHTLf of the PBMC between patients with and without 
GVD (Table 1). 
Table 1 
GVD-
GVD+ 
Frequencies of precursor helper T-Iymphocytes (pHTLf) of peripheral blood 
mononuclear cells (PBMC) samples taken at different time points after heart 
transplantation (HTx) from patients with (n=5) and without (n=5) graft vascular disease 
(GVD). 
3-6 months after HTx 
128 (28-356)' 
106 (1-362) 
1 year after HTx 
290 (56-337) 
57 (5-359) 
3 years after HTx 
109 (16-981) 
206 (1-1105) 
#Data are presented as the median pHTLf per 106 PBMC with the range in parentheses. 
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Donor-specific pCTL for HLA class I antigens were detected in PBMC of both 
patients with and without GVD. The number of pCTL fluctuated per patient in time 
after HTx, too. At 3 to 6 months, 1 year and 3 years after HTx, we also found no 
differences in the frequency of donor-specific pCTL (pCTLf) between PBMC derived 
from patients with GVD and patients without GVD (Table 2). 
Analyzing the individual increase or decrease in pHTLf and pCTLf also did not result 
in differences between the patient groups. 
Table 2 
GVD-
GVD+ 
Frequencies of precursor cytotoxic T -lymphocytes (pCTLf) of PBMC samples taken at 
different time points after heart transplantation (HTx) from patients with (n=5) and 
without (n=5) graft vascular disease (GVD). 
3-6 months after HTx 
57 (11-302)' 
224 (0-1150) 
1 year after HTx 
142 (0-192) 
197 (11-1442)' 
3 years after HTx 
31 (0-199) 
126 (0-3079) 
#Data are presented as the median pCTLf per 106 PBMC with the range in parentheses. 
'one PBMC sample was inviable according to the PHA stimulation 
Discussion 
To elucidate whether a quantitative change of alloreactive pHTL andlor pCTL in 
PBMC is one of the mechanisms accounting for the development of GVD, we 
determined the frequency of pHTL and pCTL specific for donor HLA class I antigens 
of PBMC samples from patients with GVD and without GVD. 
Several studies have demonstrated that a reduction in circulating HTL and/or CTL is 
associated with stable engraftment4 .' Interestingly, our study suggests that in 
patients with stable engraftment, who remained free from GVD, no consistent 
reduction in circulating pHTL or pCTL numbers was observed in time. We also found 
that in an unstable situation, such as GVD development, both the number of pHTL 
and pCTL and the variability in time of frequencies were not different from the results 
of the patients without GVD. Apparently, the presence of a pool of pHTL or pCTL 
specific for donor HLA class I antigens in PBMC does not reflect GVD development. 
So, it seems that parameters of an activated immune system in peripheral blood do 
not parallel the pathogenesis of GVD. What about the immune reactivity in the graft? 
We found that graft-infiltrating lymphocytes derived from patients with GVD produced 
more IL-2 and IFN-y after donor-specific stimulation in the first year after HTx.' This 
increase of T-helper 1 cytokines in the graft from patients with GVD is not reflected in 
peripheral blood by an increment of IL-2 producing pHTL. We have investigated the 
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possible role of CTL in lymphocytes that infiltrate the transplanted heart. The 
frequency of in vivo primed or committed CTL with specificity for donor HLA class I in 
these graft-infiltrating cell cultures in our hands again did not discriminate between 
patients with and without GVD.' However, we found that a high frequency of CTL 
with specificity for donor HLA class II in the cultures may protect against the 
development of GVD.' We hypothesized that these particular CTL act by killing HLA 
class II bearing donor cells (endothelial cells and smooth muscle cells) responsible 
for GVD induction. In case of GVD development, the frequency of donor-directed 
HLA class II specific CTL is too low to lyse the donor cells. Activated donor 
endothelial cells secrete growth factors which promote donor smooth muscle cell 
proliferation leading to intima thickening. In other words, we think that GVD is an 
auto-reactive phenomenon of the donor tissue induced by acceptor derived 
cytokines. We have not yet measured the number of pCTL specific for donor HLA 
class II antigens in PBMC. Further studies on this hypothesis of donor auto-reactivity 
could be important for understanding the pathogenesis of GVD. 
In summary, the frequency of circulating donor-specific pHTL and pCTL with donor 
HLA class I specificity does not correlate with the development of GVD. Only donor-
specific T-helper 1 production and the frequency of CTL specific for donor HLA class 
II antigens in the graft are associated with the induction of GVD. 
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Summary and conclusions 

Summary and conclusions 
The efficacy of heart transplantation for end-stage cardiac disease has generally 
been accepted. The patient survival rates after the 1", 5'h and 7'h year are in the 
region of 92%, S4% and 77%, respectively.' However, despite these good results, 
many problems remain unsolved, e.g. the exact etiology of acute and chronic 
rejection processes. 
In chapter 1 a general introduction is given to possible cellular processes leading to 
the immune response directed to the allograft. Not only the difference of HLA 
antigens between allograft recipient and donor are important during rejection, but 
also the presentation pathway of donor HLA to recipient cells. Therefore, the direct 
and indirect antigen presentation pathways are described (chapter 1.4) and 
investigated (chapter 5.1). Cytokines and cytotoxic T-cells (CTLs) are also core 
topics in this thesis. Their role is discussed in the introduction in relation to clinical 
transplantation. In chapter 2 a brief overview of literature in relation to peripheral 
blood monitoring after transplantation and to monitoring of graft-infiltrating 
lymphocytes (GIL) propagated after clinical heart transplantation is provided. 
The major theme of the studies described in this thesis is: intragraft (chapter 3 and 4) 
and peripheral blood monitoring (chapter 5) in relation to both acute rejection 
(chapter 3 and 5) and graft vascular disease (GVD) (chapter 4 and 5). 
In the first part of chapter 3, it describes how GIL-cultures can be propagated from 
endomyocardial biopsies (EMBs) independent of acute rejection. It is also shown that 
no difference in phenotypic composition was found between acute rejection and non-
rejection EMBs (chapter 3.1). Additionally, this chapter shows that cell growth is 
significantly more often obtained from EMBs derived cell cultures with signs of acute 
rejection than those without rejection. In these cell cultures CD4· cells were always 
more numerous than CDS· cells. 
In chapter 3.2 a clear correlation between mRNA expression and the production of 
cytokines is demonstrated in the GIL-cultures. In chapter 3.3 the exact kinetic of one 
T-helper 1 (IL-2) and one T-helper 2 (ILA) cytokine is described. In this chapter, it is 
further shown that each individual GIL-culture has its own characteristic mRNA and 
protein profile. Stimulating the cultures for 20 hours with donor-antigens was a prime 
method to compare cytokine production patterns between different groups of 
cultures, e.g. cultures derived from acute rejection EMB versus non-rejection EMB 
and those cultures from patients who developed GVD versus who did not. Because 
significantly more cytokines were produced after donor stimulation than after third-
party stimulation, a donor-specific cytokine pattern can be determined (chapter 3.2, 
3.3 and 3.4). 
Cytokines play an important role in acute rejection. Therefore, the production of 
cytokines by cells infiltrating the allograft (GIL) was investigated during acute 
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rejection and in a rejection-free period (chapter 3.4). In the first 3 postoperative 
months significantly higher levels of T-helper 1 (IL-2 and IFN-y) cytokines were 
produced after donor-specific stimulation of GIL-cultures derived from rejection 
biopsies compared to those from non-rejection biopsies. These T-helper 1 cytokines 
enhance the generation of CTLs,' which can recognize and kill donor cells leading to 
histologic signs of acute rejection. In addition, the high levels of IFN-y produced by 
the GIL can upregulate HLA class II expression.' During an acute rejection episode 
HLA class II expression is increased,' probably induced by IFN-y produced by GIL, 
resulting in an infiltration of the graft with lymphocytes. 
After this period, the cytokine levels produced by the GIL were comparable. 
Interestingly, the high T-helper 1 cytokine levels produced in this later period after 
transplantation were in the range of the high levels of GIL taken from rejection 
biopsies in the first 3 postoperative months. Probably a higher dose of 
immunosuppression is necessary to prevent rejection in the first 3 months after 
transplantation than at any later stage, resulting in a suppressive effect on the T-
helper 1 cytokines produced by GIL. With regard to the T-helper 2 cytokines, IL-4 
and IL-6, no relation was found to the presence of acute rejection at any time after 
transplantation. Accordingly, these results demonstrated that in the first 3 months 
after transplantation, a high production of T-helper 1, and not T-helper 2 cytokines 
correlated with acute rejection. Thereafter, a continuous state of immunological 
activity is seen even in the absence of acute rejection, resulting in high T-helper 1 
cytokine production of the GIL. 
One year after transplantation, 26% of the patients had chronic rejection diagnosed 
in the coronary arteries by angiography. This finding increased proportionally to 
almost 80% 10 years after transplantation.' Chronic rejection is also called 
accelerated coronary atherosclerosis or graft vascular disease (GVD). 
Acute rejection cannot be associated with the development of GVD (chapter 4.1). 
Also no correlation was found between GVD and either GIL growth or the phenotypic 
composition of the GIL-cultures (chapter 4.1). 
Cytokines produced after stimulating the GIL-cultures with donor cells were 
investigated in relation to the development of GVD (chapter 4.2). A clear correlation 
was found between early cytokine production and GVD. Significantly higher levels of 
T-helper 1 cytokines (IL-2 and IFN-y) were produced by GIL-cultures from patients 
who developed GVD in the first year after transplantation, but there was no higher 
production of the T-helper 2 cytokines IL-4 and IL-6. Early IL-2 production stimulates 
the activation and proliferation of lymphocytes.5 IFN-y recruits macro phages' into the 
graft and enhances CTL differentiation'" along with the MHC expression of the 
vascular endothelium.' This endothelial cell activation by the T-helper 1 cytokines will 
finally lead to the characteristic manifestation of GVD: intima thickening. 
More than one year after transplantation, the T-helper 1 cytokine production no 
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longer discriminates between patients with and without GVD. These results 
emphasize the importance of measuring cytokine production levels during the first 
year after transplantation, which give an earlier warning of GVD before the 
angiogram routinely performed on the first anniversary of the transplant. However, 
after this first postoperative year, detectable IL-6 levels were produced more often by 
the GIL-cultures of patients with signs of GVD in their angiogram versus the cultures 
from patients who had no signs of GVD after one year. The IL-6 produced by the GIL 
probably continues the process of intima thickening in the vessels of the donor heart. 
Because IL-6 promotes the proliferation of smooth muscle cells,' this may be a co-
factor in the accelerated process of coronairsclerosis. Consequently, GVD is an 
immune-mediated response to donor antigens and the development of GVD is 
initiated by T-helper 1 cytokines produced by GIL early after transplantation, while 
the IL-6 production of GIL maintains and accelerates GVD. 
Because T -helper 1 cytokines enhance CTL differentiation,6-8 CTLs propagated from 
EMBs could also playa role in GVD development. The frequency of GIL-cultures lytic 
to donor HLA class I and class II antigens did not discriminate between the patients 
with and without GVD in the first year after transplantation (chapter 4.3). In addition, 
the frequency of in vivo primed or committed CTLs (cCTLs) specific for donor HLA 
class I antigens present within the graft did not differentiate between the patients with 
GVD and those without. The cultures contained predominantly cCTLs with low avidity 
for donor HLA class I antigens, which was also irrespective of the development of 
GVD one year after transplantation. However, in patients who did not develop GVD 
in the first postoperative year, the frequency of cCTLs with donor HLA class II 
specificity was significantly higher than in those patients who did. Apparently, a high 
frequency of donor HLA class II-directed cCTLs protects for GVD. 
As a possible explanation for this phenomenon, the following model was suggested. 
Nonspecific tissue damage shortly after transplantation results in macrophage 
infiltration and cytokine release followed by upregulation of HLA class I and class II 
and lymphocyte binding ligands on donor cells. 1O-12 Subsequently, donor-specific 
activated cells (GIL) enter the graft. GIL derived from patients with GVD in the first 
postoperative year produce high levels of T-helper 1 cytokines, resulting in an 
upregulation of HLA class II antigens on vascular wall cells. HLA class II directed 
cCTLs accumulate in the transplant at the site of the activated donor cells on the 
vascular wall. Thereafter, donor cells with HLA class II antigen on their surface, 
which are responsible for GVD (endothelial cells and smooth muscle cells), are killed 
and GVD is prevented. In case the donor-directed HLA class II cCTL frequency is too 
low to lyse the activated vascular wall cells, GVD will develop. 
Because the EMB-procedure is an invasive method and propagating GIL-cultures is 
time-consuming, relations with peripheral blood monitoring and acute rejection and 
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the development of GVD are investigated (chapter 5). 
In chapter 5.1 the relevance of measuring the direct and indirect presentation 
pathway was studied. The direct pathway was determined by the proliferative 
reactivity of peripheral blood mononuclear cells (PBMC) to donor cells. Complete 
removal of donor antigen-presenting cells from the stimulator population in a mixed 
lymphocyte culture is not a suitable tool for measuring indirect presentation of 
alloantigens. In contrast, this latter route could easily be activated by the nominal 
antigen tetanus toxoid. Analysing the level of PBMC reactivity showed that both the 
immune response via the direct and indirect presentation pathway increased, when 
cyclosporin A levels inadvertently decreased to inadequate concentrations and acute 
rejection was diagnosed. 
The direct presentation route does not predict GVD, while the indirect pathway 
appeared to correlate with GVD after transplantation. 
During immunological quiescence high and low responders were detected to both 
pathways. Therefore, the assessment of presentation routes in peripheral blood may 
be used as a tool for selecting patients in which the tapering of immunosuppression 
can safely be applied. 
In the graft T-helper 1 cytokines and CTLs playa role in the development of GVD 
(chapter 4.2 and 4.3). In chapter 5.2 the frequency of donor-specific helper T-
lymphocytes (HTLs) and CTLs in peripheral blood were related to GVD. Both the 
presence of a pool of HTLs and CTLs specific for donor HLA class I antigens did not 
reflec! GVD development. Currently, the role of CTL specific for donor HLA class II 
antigens in peripheral blood remains illusive. 
In conclusion, during acute rejection the response via directly presented donor 
antigens and indirectly presented tetanus toxoid antigens increased in peripheral 
blood. This latter presentation route is also associated with GVD. Donor-specific 
cellular tests such as the frequency of HTLs and CTLs could not be related to GVD 
in peripheral blood. In the graft, high levels of donor-specific T-helper 1 cytokine 
production not only correlated with acute rejection, but also with the development of 
GVD. The onset of GVD is prevented by high numbers of CTL specific for donor HLA 
class II antigens. 
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Samenvatting 
7.1. Samenvatting 
In dit proefschrift zijn T-cel funclies na klinische harttransplantatie beschreven. 
Aandacht is vooral besteed aan verschillen in T-cel funclies tussen episodes met en 
zonder acute afstotingsverschijnselen en verschillen tussen patienten die wei of 
geen versnelde coronairsclerose (VCS) ontwikkelen. VCS is een manifestatie van 
chronische afstoting in het getransplanleerde hart. 
Beide afstotingsprocessen zijn gerelateerd aan eigenschappen van zowel 
transplantaat-infiltrerende Iymfocyten (TIL) kweken als van perifeer bloed 
mononucleaire cellen (PBMC). Van de TIL-kweken werd het groeipatroon, het 
fenotype, de cytokinenproduktie en de cytotoxische capacileit geanalyseerd. In de 
PBMC werden de direkte en indirekte alloanligeen-presenlatie routes gemeten, en 
de hoeveelheid T-helper cellen en cytotoxische T-cellen bepaald. 
Acute afstoting in het transplantaat 
TIL kunnen zowel verkregen worden uit afstotingsbiopten als niet-afstotingsbiopten. 
Groei is echter vaker waargenomen in kweken die afkomstig zijn van 
afstotingsbiopten (hoafdstuk 3.1). Het fenotype van de TIL is onafhankelijk van 
afstoting (hoofdstuk 3.1). 
In de TIL-kweken is wat cytokinen betreft op gen- en eiwitniveau gedifferentieerd 
tussen donor en derde-partij reactiviteit (hoofdstuk 3.2 en 3.3). De gemeten 
cytokinenpatronen in de kweken zijn een afspiegeling van donor-specifieke 
processen in het getransplanteerde hart en niet van de algemene immuunreacliviteil. 
Na stimulatie met donorcellen, worden in de eerste 3 maanden na transplantatie 
meer T-helper 1 (IL-2 en IFN-y) cytokinen gemaakt door TIL-kweken afkomstig van 
afstotingsbiopten dan door de kweken van biopten zonder afstotingsverschijnselen 
(hoofdstuk 3.4). Vanaf 3 maanden is de produktie van de T-helper 1 cytokinen in de 
kweken van niet-afstotingsbiopten even hoog als in de kweken van de 
afstotingsbiopten. In deze periode is de produktie zelfs vergelijkbaar met de hoge 
produktie van de TIL-kweken afkomslig van de afstotingsbiopten afgenomen in de 
eerste 3 maanden na transplantatie. Voor de T-helper 2 cytokinen IL-4 en IL-6 is 
geen relalie met acute afstoting waargenomen. Deze resultaten suggereren dat T-
helper 1, en niet T-helper 2 cytokinen, in de eersle 3 maanden na de operatie 
geassocieerd zijn met acute afstoting. Hierna treedt een staat van continue 
immunologische activiteit op, zelfs in de afwezigheid van afstoting. 
Versnelde coronairsc/erose in het transplantaat 
Geen verschil is aantoonbaar tussen patienten met en zonder VCS voor wat betreft 
de groei van Iymfocyten uil endomyocardbiopten (hoofdstuk 4.1). Ongeacht de 
herkomst van de biopten worden er altijd meer CD4' dan CDS' T-cellen in de 
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kweken waargenomen. Het fenotype tussen de verschillende patientengroepen 
verschilt niet wat betreft het percentage cellen dat de T-cel receptor-af3 en -VB, CD3, 
CD4, CD8 of CD16 op hun oppervlak draagt (hoordsluk 4.1). 
Niet aileen werd een relatie tussen acute afstoting en cytokinenpatronen gevonden 
(hoordsluk 3.4), maar ook een verband tussen deze patronen en de ontwikkeling van 
VCS (hoordsluk 4.2). Na donor-specifieke stimulatie van Til-kweken, worden in het 
eerste jaar na transplantatie significant meer T-helper 1 (ll-2 en IFN-y), maar geen 
T-helper 2 (ll-4 en Il-6) cytokinen, gevonden bij patienten die tekenen van VCS 
vertonen in het een-jaars angiogram dan bij patienten die hiervan vrij blijven. Langer 
dan €len jaar na transplantatie, wordt deze relatie met T-helper 1 cytokinen niet meer 
gevonden, maar wordt significant meer van het T-helper 2 cytokine Il-6 gemaakt 
door de kweken afkomstig van patienten met VCS. Hieruit is te concluderen dat de 
verhoogde, maar voorbijgaande, T-helper 1 cytokinen produktie de aanzet kan zijn 
voor het ontstaan van VCS (activatie van endotheelcellen). Nadat de zichtbare 
tekenen van VCS in het een-jaars angiogram zijn ontstaan, kan Il-6, een mitogeen 
voor gladde spiercellen, het proces van gladde spiercelproliferatie in stand houden of 
verder versnellen. 
Omdat T-helper 1 cytokinen de activatie van cytotoxische T-cellen (CTls) 
bevorderen, zijn in de Til-kweken de frequentie en aviditeit van reeds in vivo 
geactiveerde CTls (cCTls) gericht tegen donor klasse I en II HlA antigenen 
bepaald en gerelateerd aan de ontwikkeling van VCS (hoofdsluk 4.3). In het eerste 
jaar na transplantatie kon de frequentie van cCTls gericht tegen HLA klasse I 
antigenen in de kweken niet differentieren tussen patienten met en zonder VCS. De 
frequentie van cCTls gericht tegen donor klasse II antigenen was echter hoger in de 
kweken afkomstig van patienten die eel'l jaar na transplantatie gave coronairvaten 
vertoonden. Bij de reactiviteit tegen klasse I antigenen overheersten in de kweken 
van beide patientengroepen de cCTls met een lage aviditeit. Uit deze resultaten 
wordt geconcludeerd dat een hoge frequentie van cCTls die gericht zijn tegen donor 
HlA klasse II antigenen de ontwikkeling van VCS tegengaan. Mogelijk zijn deze 
cellen cytotoxisch voor geactiveerde donor cellen, zoals endotheel en gladde 
spiercellen, die VCS mede kunnen veroorzaken. 
Acule afsloting en versnelde coronairsclerose in het perifeer bloed 
Zowel de direkte en indirekte route van alloantigeen-presentatie kunnen van be lang 
zijn bij acute afstoting en VCS (hoofdstuk 5.1). De direkte presentatie route is 
gemeten door ontvanger PBMC in een MlC ('mixed lymphocyte culture') met 
donorcellen te stimuleren. Indien er geen donor antigeen-presenterende cellen 
(APC) in een MlC aanwezig zijn, kan geen stimulatie via de direkte presentatie route 
plaatsvinden en moet de reactie dus via ontvanger APC verlopen (indirekte route). 
De indirekte route was niet detec!eerbaar na stimulatie met donorcellen waaruit de 
APC verwijderd zijn gemeten worden, maar werd bepaald door PBMC te stimuleren 
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met het nominaal antigeen tetanus toxoIde (TET), PBMC van patienten veer 
transplantatie kunnen zowel op antigeen gepresenteerd via de direkte als via de 
indirekte (TET) route reageren, Na transplantatie zijn nog maar weinig PBMC 
monsters hiertoe in staat en deze reageren dan voornamelijk op direkt 
gepresenteerde donor antigenen, Immunosuppressie beInvloedl dus de presentatie 
routes, Dit blijkt ook uit de hoogte van de reactiviteit op een lijdstip dat te lage, 
ineffectieve concentraties cyclosporine A in het plasma worden gevonden, waardoor 
acute alstoting optreedt. Op dat moment stijgt de PBMC reactiviteit na stimulatie met 
direkt gepresenteerde antigenen en wordt ook de indirekte route meetbaar. 
PBMC monsters alkomstig van patienten met VCS reageerden sterker tegen het 
indirekt gepresenteerde TET-antigeen, en niet tegen direkt gepresenteerde 
donorantigenen, dan PBMC monsters van palienten die geen VCS onlwikkelden 
waargenomen in het een-jaars angiogram, 
In een immunologische rustige periode reageerden sommige patienten heftig en 
andere patienten verminderd tegen direkt en indirekt gepresenteerde antigenen, Het 
monitoren van deze routes kan dan ook van be lang zijn bij het be palen van de 
immunologische status van de patient. 
In het transplantaat spelen T-helper 1 cytokinen en CTLs een rol bij het ontstaan van 
VCS (hoofds/uk 4,2 en 4,3), Daarom werd in hoards/uk 5,2 onderzocht of in perifere 
bloedcellen eveneens een relatie met de helper T-Iymphocyten (HTLs) en/of CTLs 
en VCS aantoonbaar is, V66r, noch na diagnose van VCS zijn in de frequentie van 
HTLs en CTLs verschillen te vinden tussen PBMC van patienten met en zonder 
tekenen van VCS in het een-jaars angiogram, 
Hieruit blijkt dat donor-specifieke immuunprocessen in relatie tot VCS aileen in het 
transplantaat (TIL-kweken) te meten zijn, 
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7.2. Populaire samenvatting 
Harttransplantatie is voor veel patienten in het eindstadium van hartlijden de enig 
mogelijke behandelvorm. Na transplantatie zijn zowel acute als chronische vormen 
van afstoting een groot probleem. Vroeg na transplantatie kan acute afstoting van 
het getransplanteerde hart voorkomen worden met medicijnen die het 
afweersysteem onderdrukken. Later na transplantatie kunnen, als gevolg van 
chronische afstoting, vaatafwijkingen in de kransslagaderen van het 
getransplanteerde hart (versnelde coronairsclerose: VCS) ontstaan, hetgeen op den 
duur een belangrijke doodsoorzaak is bij de transplantatie patienten. In het 
Academisch Ziekenhuis Rotterdam-Dijkzigt treedt bij 75% van de patienten een 
periode van acute afstoting op en vertoont 26% van de patienten een jaar na 
transplantatie tekenen van VCS. 
Acute afstoting en waarschijnlijk ook de afwijkingen in de vaten zijn het resultaat van 
cellulaire reacties. In Rotterdam worden regelmatig stukjes hartweefsel (biopten) na 
transplantatie afgenomen. Uit deze biopten kunnen infiltrerende cellen, aikomstig 
van de transplantaat-ontvanger, gekweekt worden. Deze cellen zijn verantwoordelijk 
voor de afstotingsprocessen. Ook met behulp van cellen die geYsoleerd zijn uit het 
bloed van de transplantatie patienten kunnen afstotingsprocessen bestudeerd 
worden. 
De vraagstellingen die in dit proefschrilt onderzocht werden zijn: 
Welke zichtbare verschillen (hoards/uk 3. 1) zijn er tussen de kweken van biopten 
met en zonder tekenen van acute afstoting en is het vermogen tot uitscheiden van 
regulerende stoffen (cytokinen) door de gekweekte cellen verschillend (hoordstuk 
3.2, 3.3 en 3.4)? 
Bevatlen kweken van biopten verkregen van patienten met en zonder VCS andere 
celtypen (hoards/uk 4.1), scheid en de kweken verschillende cytokinen uit 
(hoordstuk 4.2) en is hun vermogen om donorcellen te doden verschillend 
(hoordstuk 4.3)? 
Verschillen de patientengroepen (wel/geen acute afstoting, wel/geen VCS) in de 
manier waarop donor-eiwilten aan de cellen in het bloed van de transplantaat-
ontvanger worden gepresenteerd (hoordstuk 5.1)? Is in het bloed de hoeveelheid 
cellen die tegen donorcellen gericht zijn verschillend tussen patienten met en 
zonder VCS (hoords/uk 5.2)? 
Dit proefschrilt maakt duidelijk dat celgroei vaker optreedt uit biopten met 
afstotingsverschijnselen dan uit biopten zonder afstoting. Het al dan niet hebben van 
VCS heelt hier geen invloed op. Het celtype in de kweken is tussen de verschillende 
patientengroepen vergelijkbaar. 
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De cytokinen gemaakt door de celkweken van de biopten laten een relatie met acute 
afs!oting en met he! ontstaan van VCS zien. 
Cellen van afstotingsbiopten maken meer cytokinen (lL-2 en IFN-y) dan cellen 
alkomstig van biopten zonder tekenen van alstoting. Deze cytokinen zorgen onder 
andere voor de aanmaak van cellen die in staat zijn donorweelsel te doden. 
Cellen van patienten die een jaar na transplantatie tekenen van VCS vertonen 
produceren gedurende dat eerste jaar ook meer cytokinen (IL-2 en IFN-y) dan de 
patienten zonder VCS. Deze cytokinen kunnen eveneens cellen in de vaatwand van 
de kransslagaderen van het getransplanteerde hart beschadigen: he! eerste 
kenmerk van VCS. Een ander cytokine, IL-6, wordt later dan een jaar na 
transplantatie in hogere Irequentie gemaakt door de kweken van patienten die 
zichtbare coronaire vaatafwijkingen vertonen. Omdat onder invloed van het cytokine 
IL-6 spiercellen in de vaatwand van de kransslagaderen kunnen vermenigvuldigen, 
kan IL-6 het proces van VCS in stand houden en mogelijk versnellen. 
De gekweekte cellen verschillen ook in hun celdodende activiteit. In de celkweken 
van patienten zonder VCS bleken meer ontvangercellen gericht tegen donorcellen te 
zitten dan bij de kweken van patienten met VCS. De donorcellen in de vaatwand die 
betrokken zijn bij het ontstaan van VCS worden waarschijnlijk door deze cellen 
opgeruimd, zodat deze patienten vrij van VCS blijven. 
Indien de medicijnen, die het afweersysteem onderdrukken, per ongeluk te lage 
waarden in het bloed krijgen en acute alstoting wordt waargenomen worden donor-
eiwitten en ook andere eiwit!en, zoals tetanus-eiwit!en, makkelijker gepresenteerd 
aan bloedcellen van de transplantaat-ontvanger dan wanneer er geen alstoting is. 
Bij cellen uit het bloed van patienten met VCS wordt in vergelijking met de cellen van 
patienten zonder VCS aileen een verschil gemeten in de presentatie van tetanus-
eiwit!en, de presentatie van donor-eiwit!en is vergelijkbaar. 
In he! bloed van de getransplanteerde patienten is eveneens onderzocht 01 dezellde 
parameters, als in de celkweken van de biopten, gerelateerd zijn aan het ontstaan 
van VCS. De resultaien van deze testen zijn in het bloed echter niet diagnostisch 
voor he! optreden van VCS. 
Hierui! is te concluderen dat processen speciliek gericht tegen donorweelsel met 
be!rekking tot VCS aileen in het transplantaat (in de celkweken van biopten) 
voorkomen. 
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congressen waren erg gezellig. Onze nachtelijke uitstapjes naar het lab hebben 
uiteindelijk tot haafdsluk 3.3 geleid. Nicolet, vooral tijdens de beginperiode van het 
onderzoek hebben we boeiende discussies gehad. Lisette, je bleef enthousiast 
'cytotoxen', zodat hoafdsluk 4.3 gepubliceerd kon worden. Teun, jij hoort eigenlijk 
ook bij het lab. Bedankt voor de klinische informatie die jij vaak kan verstrekken en 
niet te vergeten het opzetten van de NSN-studie. Voor dit laatste wi! ik tevens de 
afdeling Nefrologie bedanken. Daarnaast waardeer ik hun interesse voor mijn 
promotie-onderzoek. 
Rene Daane en Franciska Hoekstra, jullie zijn niet voor niets mijn paranimfen 
geworden. Rene, zonder jou was beduidend minder 'T-help werk' verricht en zou dit 
proefschrift minder uitgebreid zijn geweest. Franciska, bij jou kunnen we 'in goede en 
slechte tijden' altijd terecht. Allebei bedankt voor de hulp op 17 februari. 
Nigel Chew, bedankt dat je in de avonduren de 'finishing touch' aan de engelse 
spelling en stijl hebt gegeven. 
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De belangslelling van Edwin, Liesl, Filip (de voorkanl is loch afgekomen), Ann en 
mijn schoonouders werkl moliverend. 
Mama en papa, jullie gaven mij niet aileen de gelegenheid te sluderen, maar zijn ook 
buitengewoon ge"interesseerd in het transplantatie-onderzoek. Bovendien zijn de 
maandagen bij 'oma en opa Tok-Tok' altijd bijzonder in trek. 
Jan en Casper, jullie staan onterechl op de laatste plaats, maar jullie weten 'er is 
meer dan wetenschap'. 
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1987 behaalde zij haar VWO-B diploma aan het Mencia de Mendoza Lyceum te 
Breda. Aansluitend begon zij met de studie Gezondheidswetenschappen (richting: 
Biologische Gezondheidskunde) aan de Rijksuniversiteit Limburg. Haar 
afstudeerstage op de Afdeling Klinische Immunologie van de Katholieke Universitei! 
Leuven (Belgie) werd besteed aan 'De technische diagnosestelling van 
voedingsmiddelenovergevoeligheid' onder leiding van dr E. Stevens. In augustus 
1991 behaalde zij he! doctoraal examen. Vervolgens heeft zij een aanvullende 
doctoraalfase Gezondheidswe!enschappen gevolgd, waarin zij twee 
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van autoimmuun-artritis onder leiding van dr N.P.M. Bakker en dr P.H. van der 
Meide. Tijdens de tweede stage (me i-november 1992) bepaalde zij onder leiding van 
dr R. Bontrop nucleotide sequenties van het HLA klasse II locus DM in verschillende 
niet-humane primaten. 
In december 1992 trad zij in dienst van de Erasmus Universiteit Rotterdam bij de 
Afdeling Interne Geneeskunde I van he! Academisch Ziekenhuis Rotterdam-Dijkzigt 
op he! door de Nederlandse Hartstichting gefinancierde projekt 'Pathogenese van 
versnelde coronairsclerose (chronische afstoting) na harttransplantatie'. Op de 
resultaten van dit projekt is, onder leiding van Prof.dr W. Weimar, dit proefschrift 
gebaseerd. Vanaf september 1996 werkt zij in dienst van het Academisch 
Ziekenhuis Rotterdam-Dijkzigt op deze afdeling (o.l.v. Prof.dr W. Weimar) aan het 
door de Nierstichting Nederland gesubsidieerde projekt 'Donor-specifieke T-cel 
reactiviteit als leidraad voor verantwoorde vermindering van immunosuppressieve 
druk'. 
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